<SEC-DOCUMENT>0001193125-24-077564.txt : 20240326
<SEC-HEADER>0001193125-24-077564.hdr.sgml : 20240326
<ACCEPTANCE-DATETIME>20240326153634
ACCESSION NUMBER:		0001193125-24-077564
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		16
CONFORMED PERIOD OF REPORT:	20240325
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20240326
DATE AS OF CHANGE:		20240326

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MAIA Biotechnology, Inc.
		CENTRAL INDEX KEY:			0001878313
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41455
		FILM NUMBER:		24783246

	BUSINESS ADDRESS:	
		STREET 1:		444 WEST LAKE STREET, SUITE 1700
		CITY:			CHICAGO
		STATE:			IL
		ZIP:			60606
		BUSINESS PHONE:		312-416-8592

	MAIL ADDRESS:	
		STREET 1:		444 WEST LAKE STREET, SUITE 1700
		CITY:			CHICAGO
		STATE:			IL
		ZIP:			60606
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d776139d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:maia="http://www.maiabiotechnology.com/20240325" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-278">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2024-03-25_to_2024-03-25">0001878313</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xlink:type="simple" xlink:href="maia-20240325.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase"/> </ix:references> <ix:resources> <xbrli:context id="duration_2024-03-25_to_2024-03-25"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001878313</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2024-03-25</xbrli:startDate> <xbrli:endDate>2024-03-25</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-289">8-K</ix:nonNumeric></span></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Current Report</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section 13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2024-03-25_to_2024-03-25" format="ixt:datemonthdayyearen" id="ixv-290">March 25, 2024</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-291">MAIA Biotechnology, Inc.</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2024-03-25_to_2024-03-25" format="ixt-sec:stateprovnameen" id="ixv-292">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-293">001-41455</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-294">83-1495913</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:50%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:48%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-295">444 West Lake Street</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-296">Suite 1700</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-297">Chicago</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-298">IL</ix:nonNumeric></p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:bottom"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-299">60606</ix:nonNumeric></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Address of principal executive offices)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Zip Code)</span></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-300">(312)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-301">416-8592</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2024-03-25_to_2024-03-25" format="ixt-sec:boolballotbox" id="ixv-302">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2024-03-25_to_2024-03-25" format="ixt-sec:boolballotbox" id="ixv-303">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2024-03-25_to_2024-03-25" format="ixt-sec:boolballotbox" id="ixv-304">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2024-03-25_to_2024-03-25" format="ixt-sec:boolballotbox" id="ixv-305">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section 12(b) of the Act:</p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"/>
<td style="vertical-align:bottom"/>
<td style="width:32%"/>
<td style="vertical-align:bottom;width:1%"/>
<td style="width:32%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br/>Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-306">Common Stock</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-307">MAIA</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2024-03-25_to_2024-03-25" format="ixt-sec:exchnameen" id="ixv-308">NYSE American</ix:nonNumeric></td></tr></table> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2024-03-25_to_2024-03-25" format="ixt-sec:boolballotbox" id="ixv-309">&#9746;</ix:nonNumeric></p> <p style="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2024-03-25_to_2024-03-25" format="ixt-sec:boolballotbox" id="ixv-310">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;1.01 Entry into a Material Definitive Agreement. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;25, 2024, MAIA Biotechnology, Inc. (the &#8220;<span style="text-decoration:underline">Company</span>&#8221;) entered into a Securities Purchase Agreement (the &#8220;<span style="text-decoration:underline">Purchase Agreement</span>&#8221;) with certain accredited investors (the &#8220;<span style="text-decoration:underline">Investors</span>&#8221;) for the issuance and sale in a private placement (the &#8220;<span style="text-decoration:underline">Private Placement</span>&#8221;) of (i) 578,643 shares (the &#8220;<span style="text-decoration:underline">Shares</span>&#8221;) of the Company&#8217;s common stock, par value $0.0001 per share (&#8220;<span style="text-decoration:underline">Common Stock</span>&#8221;), and (ii)&#160;warrants (the &#8220;<span style="text-decoration:underline">Warrants</span>&#8221;) to purchase up to 578,643 shares of Common Stock, at a price per share of $2.295, for an aggregate purchase price of approximately $1.33&#160;million.</p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Shares and the Warrants (and the shares of common stock underlying the Warrants) sold in the Private Placement are being issued as restricted securities as defined in Rule 144 of the Securities Act of 1933, as amended and do not contain any registration rights. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrants are exercisable at a price per Share of $2.55, which price represents the greater of the book or market value of the stock on the date the Purchase Agreement was executed (subject to customary adjustments as set forth in the Warrants, which do not include any provisions relating to price protection), are exercisable commencing six months following issuance and have a term of five years from the initial exercise date. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company intends to use the net proceeds from the offerings to fund research and development activities, such as to fund the first third of the pivotal accelerated approval Part C of the <span style="white-space:nowrap">THIO-101</span> trial in <span style="white-space:nowrap">non-small</span> cell lung cancer (NSCLC). The closing of the Private Placement is expected to occur on March&#160;28, 2024, subject to the satisfaction of customary closing conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The foregoing descriptions of terms and conditions of the Purchase Agreement, and the Warrants do not purport to be complete and are qualified in their entirety by the full text of the form of the Purchase Agreement and the form of the Warrant, which are attached hereto as Exhibits 10.1 and 4.1, respectively, to this Current Report on Form <span style="white-space:nowrap">8-K</span> and are incorporated by reference herein. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;3.02 Unregistered Sales of Equity Securities.</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Reference is made to the disclosure under Item 1.01 above which is hereby incorporated in this Item 3.02 by reference. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Shares, the Warrants and the shares issuable upon exercise of the Warrants have not been registered under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), or the securities laws of any state, and are being offered and sold in reliance on the exemption from registration under the Securities Act, afforded by Section&#160;4(a)(2) and/or Rule 506 promulgated thereunder. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on Form <span style="white-space:nowrap">8-K</span> shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;8.01 Other Events.</p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On March&#160;26, 2024, the Company issued a press release announcing the pricing of the Private Placement. A copy of the press releases is attached as Exhibit 99.1 and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Item&#8201;9.01 Financial Statements and Exhibits </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td/>

<td style="vertical-align:bottom;width:4%"/>
<td style="width:93%"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"><span style="font-weight:bold">Exhibit<br/>No.</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d776139dex41.htm">Form of Warrant </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1*</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d776139dex101.htm">Form of Securities Purchase Agreement </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d776139dex991.htm">Press Release dated March&#160;26, 2024 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"/>
<td style="height:6pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document).</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:2%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The schedules (and similar attachments) to this exhibit have been omitted from this filing pursuant to Item 601(b)(10) of <span style="white-space:nowrap">Regulation&#160;S-K.&#160;The</span> Company agrees to furnish a supplemental copy of any omitted schedule (or similar attachment) to the Securities and Exchange Commission upon request. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%"/>

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: March&#160;26, 2024 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p><div>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0;margin-left:auto">


<tr>

<td style="width:12%"/>

<td style="vertical-align:bottom;width:1%"/>
<td style="width:87%"/></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top" colspan="3"><span style="font-weight:bold">MAIA BIOTECHNOLOGY, INC.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"/>
<td style="height:12pt" colspan="2"/></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Vlad Vitoc</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Vlad Vitoc</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Title:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Chief Executive Officer</td></tr>
</table></div>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>d776139dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE
SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;SECURITIES ACT&#148;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE
REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS
SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK PURCHASE WARRANT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MAIA BIOTECHNOLOGY, INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Warrant Shares: _______</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Issue Date: March&nbsp;&#8195;, 2024</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initial Exercise Date: September&nbsp;&#8195;, 2024<SUP STYLE="font-size:75%; vertical-align:top">1</SUP></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">THIS COMMON STOCK PURCHASE WARRANT (the &#147;<U>Warrant</U>&#148;) certifies that, for value received,
_____________ or its assigns (the &#147;<U>Holder</U>&#148;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the &#147;<U>Initial
Exercise Date</U>&#148;) and on or prior to 5:00 p.m. (New York City time) on September&nbsp;&#8195;, 2029<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> (the &#147;<U>Termination Date</U>&#148;) but not thereafter, to subscribe for and
purchase from MAIA Biotechnology, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), up to ______ shares (as subject to adjustment hereunder, the &#147;<U>Warrant Shares</U>&#148;) of the Company&#146;s Common Stock. The purchase price
of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2(b). </P> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Insert the date that is the six (6) months anniversary of the Issue Date </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Insert the date that is the 5.5 year anniversary of the Issue Date, provided that, if such date is not a
Trading Day, insert the immediately following Trading Day. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;1</U>. <U>Definitions</U>.
Capitalized terms used and not otherwise defined herein shall have the meanings set forth in that certain Securities Purchase Agreement (the &#147;<U>Purchase Agreement</U>&#148;), dated March&nbsp;25, 2024, among the Company and the purchasers
signatory thereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;2</U>. <U>Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Exercise of Warrant</U>. Subject to Section&nbsp;2(e) herein, exercise of the purchase rights represented by this Warrant
may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by <FONT STYLE="white-space:nowrap">e-mail</FONT> (or
<FONT STYLE="white-space:nowrap">e-mail</FONT> attachment) of the Notice of Exercise in the form annexed hereto (the &#147;<U>Notice of Exercise</U>&#148;). Within the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading
Days comprising the Standard Settlement Period (as defined in Section&nbsp;2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice
of Exercise by wire transfer or cashier&#146;s check drawn on a United States bank unless the cashless exercise procedure specified in Section&nbsp;2(c) below is specified in the applicable Notice of Exercise.<B> </B>No <FONT
STYLE="white-space:nowrap">ink-original</FONT> Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the
contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation within three (3)&nbsp;Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company
shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1)&nbsp;Trading Day of receipt of such notice. <B>The Holder and any
assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at
any given time may be less than the amount stated on the face hereof.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Exercise Price</U>. The exercise price per
share of Common Stock under this Warrant shall be <B>$</B>2.55, subject to adjustment hereunder (the &#147;<U>Exercise Price</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Cashless Exercise</U>. If at the time of exercise hereof there is no
effective registration statement registering, or the prospectus contained therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a
&#147;cashless exercise&#148; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing <FONT STYLE="white-space:nowrap">[(A-B)</FONT> (X)] by (A), where: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)&#8201;=</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as applicable: (i)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of
Exercise if such Notice of Exercise is (1)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a) hereof on a day that is not a Trading Day or (2)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a) hereof on a Trading Day prior
to the opening of &#147;regular trading hours&#148; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;the VWAP on the Trading Day immediately preceding the date of the
applicable Notice of Exercise if such Notice of Exercise is executed during &#147;regular trading hours&#148; on a Trading Day and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after the close of &#147;regular
trading hours&#148; on a Trading Day) pursuant to Section&nbsp;2(a) hereof or (iii)&nbsp;the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed
and delivered pursuant to Section&nbsp;2(a) hereof after the close of &#147;regular trading hours&#148; on such Trading Day; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)&#8201;=</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Exercise Price of this Warrant, as adjusted hereunder; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(X)&#8201;=</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms
of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Bid Price</U>&#148; means, for any date, the price determined by the first of the following clauses that applies:
(a)&nbsp;if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as
reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp;if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or
the nearest preceding date) on OTCQB or OTCQX as applicable, or (c)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in
interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>VWAP</U>&#148; means, for any date, the price determined by the first of the following clauses that applies:
(a)&nbsp;if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or
quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Venture Market (&#147;<U>OTCQB</U>&#148;) or the OTCQX Best Market (&#147;<U>OTCQX</U>&#148;) is not a
Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, or (c)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an
independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with
Section&nbsp;3(a)(9) of the Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&nbsp;The Company agrees not to take any position contrary to this Section&nbsp;2(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Mechanics of Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i. <U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be
transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#147;<U>DWAC</U>&#148;) if
the Company is then a participant in such system and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B)&nbsp;the Warrant Shares are
eligible for resale by the Holder without volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by
physical delivery of a certificate, registered in the Company&#146;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the
Holder in the Notice of Exercise by the date that is the earliest of (i)&nbsp;two (2)&nbsp;Trading Days after the delivery to the Company of the Notice of Exercise, (ii)&nbsp;one (1)&nbsp;Trading Day after delivery of the aggregate Exercise Price to
the Company and (iii)&nbsp;the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#147;<U>Warrant Share Delivery Date</U>&#148;). Upon delivery of the Notice
of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided
that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of
Exercise by the Warrant Share Delivery Date, the Company shall </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the
applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third (3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP>) Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant
Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As
used herein, &#147;<U>Standard Settlement Period</U>&#148; means the standard settlement period, expressed in a number of Trading Days, on the Company&#146;s primary Trading Market with respect to the Common Stock as in effect on the date of
delivery of the Notice of Exercise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ii. <U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been
exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the
unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">iii. <U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares
pursuant to Section&nbsp;2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">iv. <U>Compensation for <FONT STYLE="white-space:nowrap">Buy-In</FONT> on Failure to Timely Deliver Warrant Shares Upon
Exercise</U>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;2(d)(i) above pursuant to an
exercise on or before the Warrant Share Delivery Date (other than any such failure that is solely due to any action or inaction by the Holder with respect to such exercise), and if after such date the Holder is required by its broker to purchase (in
an open market transaction or otherwise) or the Holder&#146;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &#147;<U><FONT STYLE="white-space:nowrap">Buy-In</FONT></U>&#148;), then the Company shall (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&#146;s total purchase price (including brokerage commissions,
if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying (1)&nbsp;the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times
(2)&nbsp;the price at which the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.
For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a <FONT STYLE="white-space:nowrap">Buy-In</FONT> with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving
rise to such purchase obligation of $10,000, under clause (A)&nbsp;of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to
the Holder in respect of the <FONT STYLE="white-space:nowrap">Buy-In</FONT> and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#146;s right to pursue any other remedies available to it
hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required
pursuant to the terms hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">v. <U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing
fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in
respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">vi. <U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or
transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as
may be directed by the Holder; <U>provided</U>, <U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment
Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for
<FONT STYLE="white-space:nowrap">same-day</FONT> processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for
<FONT STYLE="white-space:nowrap">same-day</FONT> electronic delivery of the Warrant Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">vii. <U>Closing of Books</U>. The Company will not close its stockholder
books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e)
<U>Holder&#146;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after
giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#146;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#146;s
Affiliates (such Persons, &#147;<U>Attribution Parties</U>&#148;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp;For purposes of the foregoing sentence, the number of shares of Common Stock
beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the
number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or
conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained
herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp;Except as set forth in the preceding sentence, for purposes of this Section&nbsp;2(e), beneficial ownership shall be calculated in accordance with
Section&nbsp;13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section&nbsp;13(d) of the
Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.&#8195;To the extent that the limitation contained in this Section&nbsp;2(e) applies, the determination of whether this Warrant is
exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice
of Exercise shall be deemed to be the Holder&#146;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant
is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.&#8195;In addition, a determination as to any group status as contemplated
above shall be determined in accordance with Section&nbsp;13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section&nbsp;2(e), in determining the number of outstanding shares of Common Stock, a
Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the Company&#146;s most recent periodic or annual report filed with the Commission, as the case may be, (B)&nbsp;a more recent public announcement by the
Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp;Upon the written or oral request of a Holder, the Company shall within one (1)&nbsp;Trading
Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp;In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of
securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#147;<U>Beneficial Ownership
Limitation</U>&#148; shall be [4.99%/9.99%] of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the
Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section&nbsp;2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section&nbsp;2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will
not be effective until the 61<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict
conformity with the terms of this Section&nbsp;2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;3</U>. <U>Certain Adjustments</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock
dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common
Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way of reverse stock split) outstanding shares of Common Stock into a
smaller number of shares, or (iv)&nbsp;issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the
number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a) shall become effective immediately
after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or
<FONT STYLE="white-space:nowrap">re-classification.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Subsequent Rights Offerings</U>. In addition to any adjustments
pursuant to Section&nbsp;3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common
Stock (the &#147;<U>Purchase Rights</U>&#148;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of
shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken
for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>,
<U>however</U>, that to the extent that the Holder&#146;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase
Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right
thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Pro Rata Distributions</U>.
During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise
(including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a
&#147;<U>Distribution</U>&#148;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the
Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that to the extent that the Holder&#146;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such
Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time,
if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person,
(ii)&nbsp;the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of the assets of the Company in one or a series of related
transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares
for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock or 50% or more of the voting power of the common equity of the Company, (iv)&nbsp;the Company, directly or indirectly, in one
or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities,
cash or property, or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">spin-off,</FONT> merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock or more than 50% of the voting
power of the common equity of the Company (each a &#147;<U>Fundamental Transaction</U>&#148;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon
such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section&nbsp;2(e) on the exercise of this Warrant), the number of shares of Common Stock of the
successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#147;<U>Alternate Consideration</U>&#148;) receivable as a result of such Fundamental Transaction by a holder of the
number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e) on the exercise of this Warrant). For purposes of any such exercise, the
determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.
Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
shall, at the Holder&#146;s option, exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public
announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the
date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is not within the Company&#146;s control, including not approved by the Company&#146;s Board of Directors, the Holder shall only be
entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of
Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among
alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common
Stock will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following such Fundamental Transaction) in such Fundamental Transaction. &#147;<U>Black Scholes Value</U>&#148; means the value of this
Warrant based on the Black-Scholes Option Pricing Model obtained from the &#147;OV&#148; function on Bloomberg determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A)&nbsp;a
risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B)&nbsp;an expected
volatility equal to the greater of (1)&nbsp;the 30 day volatility, (2)&nbsp;the 100 day volatility or (3)&nbsp;the 365 day volatility, each of clauses (1)-(3) as obtained from the HVT function on Bloomberg (determined utilizing a 365 day
annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction, (C)&nbsp;the underlying price per share used in such calculation shall be the highest VWAP during the
period beginning on the Trading Day immediately preceding the public announcement of the applicable contemplated Fundamental Transaction (or the consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the
Holder&#146;s request pursuant to this Section&nbsp;3(d) and (D)&nbsp;a remaining option time equal to the time between the date of the public announcement of the applicable contemplated Fundamental Transaction and the Termination Date and
(E)&nbsp;a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other consideration) within the later of (i)&nbsp;five Business Days of the Holder&#146;s election and
(ii)&nbsp;the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#147;Successor Entity&#148;) to assume in writing all of the
obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section&nbsp;3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by
the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable
upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price which applies the exercise price hereunder to such shares of capital stock (but
taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock and such exercise price being for the purpose of
protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any such Fundamental Transaction,
the Successor Entity shall be added to the term &#147;Company&#148; under this Warrant (so that from and after the occurrence or consummation of such Fundamental Transaction, each and every provision of this Warrant and the other Transaction
Documents referring to the &#147;Company&#148; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the Successor Entity or Successor Entities, jointly and severally with the Company,
may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior thereto under this Warrant and the other Transaction Documents with the same
effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the Holder shall be entitled to the benefits of the provisions of this
Section&nbsp;3(d) regardless of (i)&nbsp;whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii)&nbsp;whether a Fundamental Transaction occurs prior to the Initial Exercise Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Calculations</U>. All calculations under this Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of
a share, as the case may be. For purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding treasury shares, if
any) issued and outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <U>Notice to Holder</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i. <U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this
Section&nbsp;3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts
requiring such adjustment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ii. <U>Notice to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a
dividend (or any other distribution in whatever form) on the Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the Company shall authorize the granting to all
holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email
to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days prior to the applicable record or effective date hereinafter specified, a notice (unless such information is filed with
the Commission, in which case a notice shall not be required) stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date on which such reclassification, consolidation, merger, sale, transfer or
share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property
deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action
required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company or any of the Subsidiaries, the
Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of
such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;4</U>. <U>Transfer of Warrant</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in
Section&nbsp;4(d) hereof and to the provisions of Section&nbsp;4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of
this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to
pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the
denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three
(3)&nbsp;Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant
Shares without having a new Warrant issued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>New Warrants</U>. This Warrant may be divided or combined with other
Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to
compliance with Section&nbsp;4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that
purpose (the &#147;<U>Warrant Register</U>&#148;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or
any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Transfer
Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i)&nbsp;registered pursuant to an effective registration statement under the
Securities Act and under applicable state securities or blue sky laws or (ii)&nbsp;eligible for resale without volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions or current public
information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section&nbsp;5.7 of the Purchase
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Representation by the Holder</U>. The Holder, by the acceptance
hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant
Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;5</U>. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any
voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive Warrant
Shares on a &#147;cashless exercise&#148; pursuant to Section&nbsp;2(c) or to receive cash payments pursuant to Section&nbsp;2(d)(i) and Section&nbsp;2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this
Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the
Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably
satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock
certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised
on the next succeeding Trading Day. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Authorized Shares</U>. The Company covenants that, during the period the Warrant
is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants
that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such
reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed.
The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in
accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring
contemporaneously with such issue). Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization,
transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist
in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order
that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public
regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant. Before taking any action which would result in an adjustment in the number of Warrant Shares for which this
Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant
shall be determined in accordance with the provisions of the Purchase Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <U>Restrictions</U>. The Holder
acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <U>Nonwaiver and Expenses</U>. No course of dealing or any delay or
failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#146;s rights, powers or remedies, notwithstanding the fact that the right to exercise this Warrant terminates on
the Termination Date. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the
Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#146; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto
or in otherwise enforcing any of its rights, powers or remedies hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <U>Notices</U>. Any notice, request or other
document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this
Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such
liability is asserted by the Company or by creditors of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">j) <U>Remedies</U>. The Holder, in addition to being
entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">k) <U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced
hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from
time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">l) <U>Amendment</U>. This
Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">m) <U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be
effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the
remainder of such provisions or the remaining provisions of this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">n) <U>Headings</U>. The headings used in this
Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">********************
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Page Follows) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer
thereunto duly authorized as of the date first above indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MAIA BIOTECHNOLOGY, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXERCISE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO: <B>MAIA BIOTECHNOLOGY, INC.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(2) Payment shall take the form of (check applicable box): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[ ] in lawful money of the United States; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">[ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrant Shares shall be delivered to the following DWAC Account Number: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="15%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="42%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="41%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(4) <U>Accredited Investor</U>. The undersigned is an &#147;accredited investor&#148; as defined in Regulation
D promulgated under the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[SIGNATURE OF HOLDER] </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name&nbsp;of&nbsp;Investing&nbsp;Entity:&nbsp;
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8201;&#8195;&#8195;&#8195;&#8195;
</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><I>Signature&nbsp;of&nbsp;Authorized&nbsp;Signatory&nbsp;of&nbsp;Investing&nbsp;Entity:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8199;&#8201;&#8195;
</U></I></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name&nbsp;of&nbsp;Authorized&nbsp;Signatory:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title&nbsp;of&nbsp;Authorized&nbsp;Signatory:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;
</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8201;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8201;&#8195;&#8195;
</U></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ASSIGNMENT FORM </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.) </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="48%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(Please Print)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(Please Print)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Phone Number:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email Address:</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> <U>&#8195;</U>, <U>&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder&#146;s Signature: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder&#146;s Address: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>d776139dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES PURCHASE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This Securities Purchase Agreement (this &#147;<U>Agreement</U>&#148;) is dated as of March&nbsp;25, 2024, between MAIA Biotechnology, Inc., a
Delaware corporation (the &#147;<U>Company</U>&#148;), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a &#147;<U>Purchaser</U>&#148; and collectively the &#147;<U>Purchasers</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an exemption from the registration requirements of
Section&nbsp;5 of the Securities Act contained in Section&nbsp;4(a)(2) thereof and/or Regulation D promulgated thereunder, the Company desires to issue and sell to certain <FONT STYLE="white-space:nowrap">non-affiliated</FONT> Purchasers, and each <FONT
STYLE="white-space:nowrap">non-affiliated</FONT> Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">WHEREAS, in recognition of the past and continued future services provided by members of the Company&#146;s board of directors, the Company
desires to permit Director Purchasers (as defined below) to participate in the transactions contemplated hereunder, to align the interests of such Director Purchasers with those of the Company&#146;s stockholders, and to issue and sell the
securities described in this Agreement to such directors (each of which is a Purchaser hereunder) pursuant to the Company&#146;s 2021 Equity Incentive Plan (the &#147;Plan&#148;), and each director Purchaser (each, a &#147;Director Purchaser&#148;
and collectively, the &#147;Director Purchasers&#148;), severally and not jointly, desires to purchase from the Company, the securities of the Company as more fully described in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration the
receipt and adequacy of which are hereby acknowledged, the Company and each Purchaser agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE I. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">DEFINITIONS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.1
<U>Definitions</U>. In addition to the terms defined elsewhere in this Agreement, for all purposes of this Agreement, the following terms have the meanings set forth in this Section&nbsp;1.1: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Acquiring Person</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;4.5. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Action</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(j). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; means any Person that, directly or indirectly through one or more intermediaries, controls or is
controlled by or is under common control with a Person as such terms are used in and construed under Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Board of Directors</U>&#148; means the board of directors of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Day</U>&#148; means any day other than Saturday, Sunday or other day on which commercial banks in The City of
New York are authorized or required by law to remain closed; provided, however, for clarification, commercial banks shall not be deemed to be authorized or required by law to remain closed due to &#147;stay at home&#148;, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#147;shelter-in-place&#148;,</FONT></FONT> <FONT STYLE="white-space:nowrap">&#147;non-essential</FONT> employee&#148; or any other similar orders or restrictions or the closure of any
physical branch locations at the direction of any governmental authority so long as the electronic funds transfer systems (including for wire transfers) of commercial banks in The City of New York are generally open for use by customers on such day.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing</U>&#148; means the closing of the purchase and sale of the Securities pursuant to Section&nbsp;2.1. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Date</U>&#148; means the Trading Day on which all of the Transaction Documents have been executed and
delivered by the applicable parties thereto, and all conditions precedent to (i)&nbsp;the Purchasers&#146; obligations to pay the Subscription Amount and (ii)&nbsp;the Company&#146;s obligations to deliver the Securities, in each case, have been
satisfied or waived, but in no event later than the second (2nd) Trading Day following the date hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Commission</U>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common Stock</U>&#148; means the common stock of the Company, par value $0.0001 per share, and any other class of
securities into which such securities may hereafter be reclassified or changed. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common Stock
Equivalents</U>&#148; means any securities of the Company or the Subsidiaries which would entitle the holder thereof to acquire at any time Common Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other
instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company Counsel</U>&#148; means Sheppard Mullin Richter&nbsp;&amp;
Hampton LLP, with offices located at 30 Rockefeller Plaza, New York, NY 10112. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disclosure Schedules</U>&#148;
means the Disclosure Schedules of the Company delivered concurrently herewith. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disclosure Time</U>&#148; means,
(i)&nbsp;if this Agreement is signed on a day that is not a Trading Day or after 9:00 a.m. (New York City time) and before midnight (New York City time) on any Trading Day, 9:29 a.m. (New York City time) on the Trading Day immediately following the
date hereof, and (ii)&nbsp;if this Agreement is signed between midnight (New York City time) and 9:00 a.m. (New York City time) on any Trading Day, no later than 9:29 a.m. (New York City time) on the date hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Evaluation Date</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(s). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exchange Act</U>&#148; means the Securities Exchange Act of 1934, as amended, and the rules and regulations
promulgated thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Exempt Issuance</U>&#148; means the issuance of (a)&nbsp;shares of Common Stock or Common
Stock Equivalents to employees, consultants, officers or directors of the Company pursuant to any stock or option plan duly adopted for such purpose, by a majority of the <FONT STYLE="white-space:nowrap">non-employee</FONT> members of the Board of
Directors or a majority of the members of a committee of <FONT STYLE="white-space:nowrap">non-employee</FONT> directors established for such purpose for services rendered to the Company, provided that any securities issued to consultants shall be
issued as &#147;restricted securities&#148; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the prohibition period in Section&nbsp;4.12(a)
herein, (b)&nbsp;shares of Common Stock upon the exercise or exchange of or conversion of any Securities issued hereunder and/or other securities exercisable or exchangeable for or convertible into shares of Common Stock issued and outstanding on
the date of this Agreement, provided that such securities have not been amended since the date of this Agreement to increase the number of such securities or to decrease the exercise price, exchange price or conversion price of such securities
(other than in connection with stock splits or combinations) or to extend the term of such securities, and (c)&nbsp;securities issued pursuant to acquisitions or strategic transactions approved by a majority of the disinterested directors of the
Company, provided that such securities are issued as &#147;restricted securities&#148; (as defined in Rule 144) and carry no registration rights that require or permit the filing of any registration statement in connection therewith during the
prohibition period in Section&nbsp;4.12(a) herein, and provided that any such issuance shall only be to a Person (or to the equityholders of a Person) which is, itself or through its subsidiaries, an operating company or an owner of an asset in a
business synergistic with the business of the Company and shall provide to the Company additional benefits in addition to the investment of funds, but shall not include a transaction in which the Company is issuing securities primarily for the
purpose of raising capital or to an entity whose primary business is investing in securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>FCPA</U>&#148;
means the Foreign Corrupt Practices Act of 1977, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDA</U>&#148; shall have the meaning ascribed to
such term in Section&nbsp;3.1(hh). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>FDCA</U>&#148; shall have the meaning ascribed to such term in
Section&nbsp;3.1(hh). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(h). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Indebtedness</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(aa). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property Rights</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(p). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Legend Removal Date</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;4.1(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Liens</U>&#148; means a lien, charge, pledge, security interest, encumbrance, right of first refusal, preemptive right
or other restriction. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Material Adverse Effect</U>&#148; shall have the meaning assigned to such term in
Section&nbsp;3.1(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Material Permits</U>&#148; shall have the meaning ascribed to such term in
Section&nbsp;3.1(n). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Per Share Purchase Price</U>&#148; equals $2.295, subject to adjustment for reverse and
forward stock splits, stock dividends, stock combinations and other similar transactions of the Common Stock that occur after the date of this Agreement and prior to the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means an individual or corporation, partnership, trust, incorporated or unincorporated association,
joint venture, limited liability company, joint stock company, government (or an agency or subdivision thereof) or other entity of any kind. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Pharmaceutical Product</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(hh). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Proceeding</U>&#148; means an action, claim, suit, investigation or proceeding (including, without limitation, an
informal investigation or partial proceeding, such as a deposition), whether commenced or threatened. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Purchaser
Party</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;4.8. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Required Approvals</U>&#148; shall have the meaning ascribed to
such term in Section&nbsp;3.1(e). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Rule 144</U>&#148; means Rule 144 promulgated by the Commission pursuant to the
Securities Act, as such Rule may be amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Rule 424</U>&#148; means Rule 424 promulgated by the Commission pursuant to the Securities Act, as such Rule may be
amended or interpreted from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect as such Rule. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>SEC Reports</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;3.1(h). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities</U>&#148; means the Shares, the Warrants and the Warrant Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities Act</U>&#148; means the Securities Act of 1933, as amended, and the rules and regulations promulgated
thereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Shares</U>&#148; means the shares of Common Stock issued or issuable to each Purchaser pursuant to
this Agreement, but excluding the Warrant Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Short Sales</U>&#148; means all &#147;short sales&#148; as
defined in Rule 200 of Regulation SHO under the Exchange Act (but shall not be deemed to include locating and/or borrowing shares of Common Stock). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subscription Amount</U>&#148; means, as to each Purchaser, the aggregate amount to be paid for Shares and Warrants
purchased hereunder as specified below such Purchaser&#146;s name on the signature page of this Agreement and next to the heading &#147;Subscription Amount,&#148; in United States dollars and in immediately available funds. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Subsidiary</U>&#148; means any subsidiary of the Company as set forth on <U>Schedule 3.1(a)</U>, and shall, where
applicable, also include any direct or indirect subsidiary of the Company formed or acquired after the date hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trading Day</U>&#148; means a day on which the principal Trading Market is open for trading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trading Market</U>&#148; means any of the following markets or exchanges on which the Common Stock is listed or quoted
for trading on the date in question: the NYSE American, the Nasdaq Capital Market, the Nasdaq Global Market, the Nasdaq Global Select Market or the New York Stock Exchange (or any successors to any of the foregoing). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transaction Documents</U>&#148; means this Agreement, the Warrants, all exhibits and schedules thereto and hereto and
any other documents or agreements executed in connection with the transactions contemplated hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transfer
Agent</U>&#148; means Computershare Trust Company, N.A., the current transfer agent of the Company, with a mailing address of 6200 S. Quebec St. Greenwood Village, CO 80111, and any successor transfer agent of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Variable Rate Transaction</U>&#148; shall have the meaning ascribed to such term in Section&nbsp;4.12(b). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>VWAP</U>&#148; means, for any date, the price determined by the first of the following clauses that applies:
(a)&nbsp;if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or
quoted as reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp;if the OTCQB Venture Market (&#147;<U>OTCQB</U>&#148;) or the OTCQX Best Market (&#147;<U>OTCQX</U>&#148;)
is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, or (c)&nbsp;in all other cases, the fair market value of a share of Common Stock as
determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Warrants</U>&#148; means, collectively, the Common Stock purchase warrants delivered to the Purchasers at the Closing
in accordance with Section&nbsp;2.2(a) hereof, which Warrants shall be exercisable commencing six months following the date of issuance and have a term of exercise equal to five years, in the form of Exhibit
<FONT STYLE="white-space:nowrap">A-1</FONT> attached hereto (for <FONT STYLE="white-space:nowrap">non-affiliated</FONT> Purchasers) and Exhibit <FONT STYLE="white-space:nowrap">A-2</FONT> (for Director Purchasers). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Warrant Shares</U>&#148; means, the shares of Common Stock issuable upon exercise of the Warrants. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE II. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">PURCHASE AND
SALE </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.1 <U>Closing</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company agrees to sell,
and the Purchasers, severally and not jointly, agree to purchase, Shares and Warrants for an aggregate purchase price of up to $1,503,000. The Company shall deliver to each Purchaser its respective Shares and a Warrant as determined pursuant to
Section&nbsp;2.2(a), and the Company and each Purchaser shall deliver the other items set forth in Section&nbsp;2.2 deliverable at the Closing. Upon satisfaction of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
covenants and conditions set forth in Sections 2.2 and 2.3, the Closing shall occur at the offices of Company Counsel or such other location (including remotely by electronic transmission). The
Purchase and issuance of the Shares and Warrants to any of the Director Purchasers under this Agreement (which shall be deemed an Unrestricted Stock Agreement under the Plan) shall be deemed an Unrestricted Stock Award issuance and an Award of
Option granted (as such terms are defined in the Plan), respectively, to such Persons under the Plan and the Shares and Warrants issued to such Persons shall be deemed issued under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.2 <U>Deliveries</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) On or prior to the Closing Date, the Company shall deliver or cause to be delivered to each Purchaser the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) this Agreement duly executed by the Company; </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) the Company shall have provided each Purchaser with the Company&#146;s wire instructions, on Company letterhead and
executed by the Chief Executive Officer or Chief Financial Officer; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) a copy of the irrevocable instructions to the
Transfer Agent instructing the Transfer Agent to deliver, on an expedited basis, a certificate evidencing a number of Shares equal to such Purchaser&#146;s Subscription Amount divided by the Per Share Purchase Price, registered in the name of such
Purchaser, or, at the election of such Purchaser, evidence of the issuance of such Purchaser&#146;s Shares hereunder as held in DRS book-entry form by the Transfer Agent and registered in the name of such Purchaser, which evidence shall be
reasonably satisfactory to such Purchaser; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) a Warrant registered in the name of such Purchaser to purchase up to a
number of shares of Common Stock equal to 100% of such Purchaser&#146;s Shares, with an exercise price equal to $2.55 per share, subject to adjustment therein. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) On or prior to the Closing Date, each Purchaser shall deliver or cause to be delivered to the Company the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) this Agreement duly executed by such Purchaser; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) such Purchaser&#146;s Subscription Amount, by wire transfer to the account specified in writing by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.3 <U>Closing Conditions</U>.<U> </U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The obligations of the Company hereunder in connection with the Closing are subject to the following conditions being met:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the accuracy in all material respects (or, to the extent representations or warranties are qualified by materiality or
Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Purchasers contained herein (unless such representation or warranty is as of a specific date therein in which case they shall be
accurate in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) as of such date); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) all obligations, covenants and agreements of each Purchaser required to be performed at or prior to the Closing Date shall
have been performed; and </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the delivery by each Purchaser of the items set forth in Section&nbsp;2.2(b) of this
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The respective obligations of the Purchasers hereunder in connection with the Closing are subject to the
following conditions being met: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) the accuracy in all material respects (or, to the extent representations or warranties
are qualified by materiality or Material Adverse Effect, in all respects) when made and on the Closing Date of the representations and warranties of the Company contained herein (unless such representation or warranty is as of a specific date
therein in which case they shall be accurate in all material respects (or, to the extent representations or warranties are qualified by materiality or Material Adverse Effect, in all respects) as of such date); </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) all obligations, covenants and agreements of the Company required to be performed at or prior to the Closing Date shall
have been performed; </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) the delivery by the Company of the items set forth in Section&nbsp;2.2(a) of this Agreement;
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) there shall have been no Material Adverse Effect with respect to the Company since the date hereof; and </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) from the date hereof to the Closing Date, trading in the Common Stock shall not have been suspended by the Commission or
the Company&#146;s principal Trading Market, and, at any time prior to the Closing Date, trading in securities generally as reported by Bloomberg L.P. shall not have been suspended or limited, or minimum prices shall not have been established on
securities whose trades are reported by such service, or on any Trading Market, nor shall a banking moratorium have been declared either by the United States or New York State authorities nor shall there have occurred any material outbreak or
escalation of hostilities or other national or international calamity of such magnitude in its effect on, or any material adverse change in, any financial market which, in each case, in the reasonable judgment of such Purchaser, makes it
impracticable or inadvisable to purchase the Securities at the Closing. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE III. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">REPRESENTATIONS AND WARRANTIES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.1 <U>Representations and Warranties of the Company</U>. Except as set forth in the Disclosure Schedules, which Disclosure Schedules shall be
deemed a part hereof and shall qualify any representation or otherwise made herein to the extent of the disclosure contained in the corresponding section of the Disclosure Schedules, the Company hereby makes the following representations and
warranties to each Purchaser: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Subsidiaries</U>. All of the direct and indirect subsidiaries of the Company are set
forth on <U>Schedule 3.1(a)</U>. The Company owns, directly or indirectly, all of the capital stock or other equity interests of each Subsidiary free and clear of any Liens, and all of the issued and outstanding shares of capital stock of each
Subsidiary are validly issued and are fully paid, <FONT STYLE="white-space:nowrap">non-assessable</FONT> and free of preemptive and similar rights to subscribe for or purchase securities. If the Company has no subsidiaries, all other references to
the Subsidiaries or any of them in the Transaction Documents shall be disregarded. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Organization and
Qualification</U>. The Company and each of the Subsidiaries is an entity duly incorporated or otherwise organized, validly existing and in good standing under the laws of the jurisdiction of its incorporation or organization, with the requisite
power and authority to own and use its properties and assets and to carry on its business as currently conducted. Neither the Company nor any Subsidiary is in violation nor default of any of the provisions of its respective certificate or articles
of incorporation, bylaws or other organizational or charter documents. Each of the Company and the Subsidiaries is duly qualified to conduct business and is in good standing as a foreign corporation or other entity in each jurisdiction in which the
nature of the business conducted or property owned by it makes such qualification necessary, except where the failure to be so qualified or in good standing, as the case may be, could not have or reasonably be expected to result in: (i)&nbsp;a
material adverse effect on the legality, validity or enforceability of any Transaction Document, (ii)&nbsp;a material adverse effect on the results of operations, assets, business, prospects or condition (financial or otherwise) of the Company and
the Subsidiaries, taken as a whole, or (iii)&nbsp;a material adverse effect on the Company&#146;s ability to perform in any material respect on a timely basis its obligations under any Transaction Document (any of (i), (ii) or (iii), a
&#147;<U>Material Adverse Effect</U>&#148;) and no Proceeding has been instituted in any such jurisdiction revoking, limiting or curtailing or seeking to revoke, limit or curtail such power and authority or qualification. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Authorization; Enforcement</U>. The Company has the requisite corporate power and authority to enter into and to
consummate the transactions contemplated by this Agreement and each of the other Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of this Agreement and each of the other
Transaction Documents by the Company and the consummation by it of the transactions contemplated hereby and thereby have been duly authorized by all necessary action on the part of the Company and no further action is required by the Company, the
Board of Directors or the Company&#146;s stockholders in connection herewith or therewith other than in connection with the Required Approvals. This Agreement and each other Transaction Document to which it is a party has been (or upon delivery will
have been) duly executed by the Company and, when delivered in accordance with the terms hereof and thereof, will constitute the valid and binding obligation of the Company enforceable against the Company in accordance with its terms, except
(i)&nbsp;as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#146; rights generally, (ii)&nbsp;as limited by laws
relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>No Conflicts</U>. The execution, delivery and performance by the Company of this Agreement and the other Transaction
Documents to which it is a party, the issuance and sale of the Securities and the consummation by it of the transactions contemplated hereby and thereby do not and will not (i)&nbsp;conflict with or violate any provision of the Company&#146;s or any
Subsidiary&#146;s certificate or articles of incorporation, bylaws or other organizational or charter documents, or (ii)&nbsp;conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default)
under, result in the creation of any Lien upon any of the properties or assets of the Company or any Subsidiary, or give to others any rights of termination, amendment, anti-dilution or similar adjustments, acceleration or cancellation (with or
without notice, lapse of time or both) of, any agreement, credit facility, debt or other instrument (evidencing a Company or Subsidiary debt or otherwise) or other understanding to which the Company or any Subsidiary is a party or by which any
property or asset of the Company or any Subsidiary is bound or affected, except such conflicts or defaults as have been waived, or (iii)&nbsp;subject to the Required Approvals, conflict with or result in a violation of any law, rule, regulation,
order, judgment, injunction, decree or other restriction of any court or governmental authority to which the Company or a Subsidiary is subject (including federal and state securities laws and regulations), or by which any property or asset of the
Company or a Subsidiary is bound or affected; except in the case of each of clauses (ii)&nbsp;and (iii), such as could not, individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Filings, Consents and Approvals</U>. The Company is not required to
obtain any consent, waiver, authorization or order of, give any notice to, or make any filing or registration with, any court or other federal, state, local or other governmental authority or other Person in connection with the execution, delivery
and performance by the Company of the Transaction Documents, other than: (i)&nbsp;the filings required pursuant to Section&nbsp;4.4 of this Agreement, (ii)&nbsp;the notice and/or application(s) to each applicable Trading Market for the issuance and
sale of the Securities and the listing of the Shares and Warrant Shares for trading thereon in the time and manner required thereby, (iv)&nbsp;the filing of Form D with the Commission and (v)&nbsp;such filings as are required to be made under
applicable state securities laws (collectively, the &#147;<U>Required Approvals</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Issuance of the
Securities; Registration</U>. The Shares are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be duly and validly issued, fully paid and nonassessable, free and clear of all Liens imposed by
the Company. The Warrants are duly authorized and, when issued and paid for in accordance with the applicable Transaction Documents, will be a binding obligation of the Company under the law of the jurisdiction governing the Warrants. The Warrant
Shares, when issued in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable, free and clear of all Liens imposed by the Company. The Company has reserved from its duly authorized capital stock the maximum
number of shares of Common Stock issuable pursuant to this Agreement and the Warrants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Capitalization</U>. The
capitalization of the Company as of March&nbsp;11, 2024 is as set forth on <U>Schedule 3.1(g)</U>, which <U>Schedule 3.1(g)</U> shall also include the number of shares of Common Stock owned beneficially, and of record, by Affiliates of the Company
as of March&nbsp;11, 2024. The Company has not issued any capital stock since its most recently filed periodic report under the Exchange Act, other than pursuant to the exercise of employee stock options under the Company&#146;s equity incentive
plans, the issuance of shares of Common Stock to employees pursuant to the Company&#146;s employee stock purchase plans and pursuant to the conversion and/or exercise of Common Stock Equivalents outstanding as of the date of the most recently filed
periodic report under the Exchange Act. No Person has any right of first refusal, preemptive right, right of participation, or any similar right to participate in the transactions contemplated by the Transaction Documents. Except as a result of the
purchase and sale of the Securities and as set forth on <U>Schedule 3.1(g)</U>, there are no outstanding options, warrants, scrip rights to subscribe to, calls or commitments of any character whatsoever relating to, or securities, rights or
obligations convertible into or exercisable or exchangeable for, or giving any Person any right to subscribe for or acquire, any shares of Common Stock or the capital stock of any Subsidiary, or contracts, commitments, understandings or arrangements
by which the Company or any Subsidiary is or may become bound to issue additional shares of Common Stock or Common Stock Equivalents or capital stock of any Subsidiary. The issuance and sale of the Securities will not obligate the Company or any
Subsidiary to issue shares of Common Stock or other securities to any Person (other than the Purchasers). There are no outstanding securities or instruments of the Company or any Subsidiary with any provision that adjusts the exercise, conversion,
exchange or reset price of such security or instrument upon an issuance of securities by the Company or any Subsidiary. There are no outstanding securities or instruments of the Company or any Subsidiary that contain any redemption or similar
provisions, and there are no contracts, commitments, understandings or arrangements by which the Company or any Subsidiary is or may become bound to redeem a security of the Company or such Subsidiary. The Company does not have any stock
appreciation rights or &#147;phantom stock&#148; plans or agreements or any similar plan or agreement. All of the outstanding shares of capital stock of the Company are duly authorized, validly issued, fully paid and nonassessable, have been issued
in compliance with all federal and state securities laws, and none of such outstanding shares was issued in violation of any preemptive rights or similar rights to subscribe for or purchase securities. No further approval or authorization of any
stockholder, the Board of Directors or others is required for the issuance and sale of the Securities. There are no stockholders agreements, voting agreements or other similar agreements with respect to the Company&#146;s capital stock to which the
Company is a party or, to the knowledge of the Company, between or among any of the Company&#146;s stockholders. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)
<U>SEC Reports; Financial Statements</U>. The Company has filed all reports, schedules, forms, statements and other documents required to be filed by the Company under the Securities Act and the Exchange Act, including pursuant to Section&nbsp;13(a)
or 15(d) thereof, for the two (2)&nbsp;years preceding the date hereof (or such shorter period as the Company was required by law or regulation to file such material) (the foregoing materials, including the exhibits thereto and documents
incorporated by reference therein, being collectively referred to herein as the &#147;<U>SEC Reports</U>&#148;) on a timely basis or has received a valid extension of such time of filing and has filed any such SEC Reports prior to the expiration of
any such extension. As of their respective dates, the SEC Reports complied in all material respects with the requirements of the Securities Act and the Exchange Act, as applicable, and none of the SEC Reports, when filed, contained any untrue
statement of a material fact or omitted to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company has never
been an issuer subject to Rule 144(i) under the Securities Act. The financial statements of the Company included in the SEC Reports comply in all material respects with applicable accounting requirements and the rules and regulations of the
Commission with respect thereto as in effect at the time of filing. Such financial statements have been prepared in accordance with United States generally accepted accounting principles applied on a consistent basis during the periods involved
(&#147;<U>GAAP</U>&#148;), except as may be otherwise specified in such financial statements or the notes thereto and except that unaudited financial statements may not contain all footnotes required by GAAP, and fairly present in all material
respects the financial position of the Company and its consolidated Subsidiaries as of and for the dates thereof and the results of operations and cash flows for the periods then ended, subject, in the case of unaudited statements, to normal,
immaterial, <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) <U>Material Changes; Undisclosed Events, Liabilities or
Developments</U>. Since the date of the latest financial statements included within the SEC Reports, except as set forth on <U>Schedule 3.1(i)</U>, (i) there has been no event, occurrence or development that has had or that could reasonably be
expected to result in a Material Adverse Effect, (ii)&nbsp;the Company has not incurred any liabilities (contingent or otherwise) other than (A)&nbsp;trade payables and accrued expenses incurred in the ordinary course of business consistent with
past practice and (B)&nbsp;liabilities not required to be reflected in the Company&#146;s financial statements pursuant to GAAP or disclosed in filings made with the Commission, (iii)&nbsp;the Company has not altered its method of accounting,
(iv)&nbsp;the Company has not declared or made any dividend or distribution of cash or other property to its stockholders or purchased, redeemed or made any agreements to purchase or redeem any shares of its capital stock and (v)&nbsp;the Company
has not issued any equity securities to any officer, director or Affiliate, except pursuant to existing Company equity incentive plans. The Company does not have pending before the Commission any request for confidential treatment of information.
Except for the issuance of the Securities contemplated by this Agreement or as set forth on <U>Schedule 3.1(i)</U>, no event, liability, fact, circumstance, occurrence or development has occurred with respect to the Company or its Subsidiaries or
their respective businesses, prospects, properties, operations, assets or financial condition that would be required to be disclosed by the Company under applicable securities laws at the time this representation is made or deemed made that has not
been publicly disclosed at least one (1)&nbsp;Trading Day prior to the date that this representation is made. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)
<U>Litigation</U>. Except as set forth on <U>Schedule 3.1(j)</U>, there is no action, suit, inquiry, notice of violation, proceeding or investigation pending or, to the knowledge of the Company, threatened against or affecting the Company, any
Subsidiary or any of their respective properties before or by any court, arbitrator, governmental or administrative agency or regulatory authority (federal, state, county, local or foreign) (collectively, an &#147;<U>Action</U>&#148;). None of the
Actions set forth on <U>Schedule 3.1(j)</U>, (i) adversely affects or challenges the legality, validity or enforceability of any of the Transaction Documents or the Securities or (ii)&nbsp;could, if there were an unfavorable decision, have or
reasonably be expected to result in a Material Adverse Effect. Neither the Company nor any Subsidiary, nor, to the knowledge of the Company, any director or officer thereof, is or has been the subject of any Action involving a claim of violation of
or liability under federal or state securities laws or a claim of breach of fiduciary duty. There has not been, and to the knowledge of the Company, there is not pending or threatened, any investigation by the Commission of the Company or any
current or former director or officer of the Company. The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the
Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) <U>Labor Relations</U>. No labor dispute exists or, to the knowledge of the Company, is imminent with
respect to any of the employees of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company&#146;s or its Subsidiaries&#146; employees is a member of a union that relates to such employee&#146;s
relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are
good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information
agreement or <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject
the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and
employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) <U>Compliance</U>. Neither the Company nor any Subsidiary: (i)&nbsp;is in default under or in violation of (and no event
has occurred that has not been waived that, with notice or lapse of time or both, would result in a default by the Company or any Subsidiary under), nor has the Company or any Subsidiary received notice of a claim that it is in default under or that
it is in violation of, any indenture, loan or credit agreement or any other agreement or instrument to which it is a party or by which it or any of its properties is bound (whether or not such default or violation has been waived), (ii) is in
violation of any judgment, decree or order of any court, arbitrator or other governmental authority or (iii)&nbsp;is or has been in violation of any statute, rule, ordinance or regulation of any governmental authority, including without limitation
all foreign, federal, state and local laws relating to taxes, environmental protection, occupational health and safety, product quality and safety and employment and labor matters, except in each case as could not have or reasonably be expected to
result in a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) <U>Environmental Laws</U>. The Company and its Subsidiaries (i)&nbsp;are in
compliance with all federal, state, local and foreign laws relating to pollution or protection of human health or the environment (including ambient air, surface water, groundwater, land surface or subsurface strata), including laws relating to
emissions, discharges, releases or threatened releases of chemicals, pollutants, contaminants, or toxic or hazardous substances or wastes (collectively, &#147;<U>Hazardous Materials</U>&#148;) into the environment, or otherwise relating to the
manufacture, processing, distribution, use, treatment, storage, disposal, transport or handling of Hazardous Materials, as well as all authorizations, codes, decrees, demands, or demand letters, injunctions, judgments, licenses,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
notices or notice letters, orders, permits, plans or regulations, issued, entered, promulgated or approved thereunder (&#147;<U>Environmental Laws</U>&#148;); (ii) have received all permits
licenses or other approvals required of them under applicable Environmental Laws to conduct their respective businesses; and (iii)&nbsp;are in compliance with all terms and conditions of any such permit, license or approval where in each clause (i),
(ii) and (iii), the failure to so comply could be reasonably expected to have, individually or in the aggregate, a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n) <U>Regulatory Permits</U>. The Company and the Subsidiaries possess all certificates, authorizations and permits issued by
the appropriate federal, state, local or foreign regulatory authorities necessary to conduct their respective businesses as described in the SEC Reports, except where the failure to possess such permits could not reasonably be expected to result in
a Material Adverse Effect (&#147;<U>Material Permits</U>&#148;), and neither the Company nor any Subsidiary has received any notice of proceedings relating to the revocation or modification of any Material Permit. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o) <U>Title to Assets</U>. The Company and the Subsidiaries have good and marketable title in fee simple to all real property
owned by them and good and marketable title in all personal property owned by them that is material to the business of the Company and the Subsidiaries, in each case free and clear of all Liens, except for (i)&nbsp;Liens as do not materially affect
the value of such property and do not materially interfere with the use made and proposed to be made of such property by the Company and the Subsidiaries, and (ii)&nbsp;Liens for the payment of federal, state or other taxes, for which appropriate
reserves have been made therefor in accordance with GAAP and, the payment of which is neither delinquent nor subject to penalties. Any real property and facilities held under lease by the Company and the Subsidiaries are held by them under valid,
subsisting and enforceable leases with which the Company and the Subsidiaries are in compliance. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p) <U>Intellectual
Property</U>. The Company and the Subsidiaries have, or have rights to use, all patents, patent applications, trademarks, trademark applications, service marks, trade names, trade secrets, inventions, copyrights, licenses and other intellectual
property rights and similar rights necessary or required for use in connection with their respective businesses as described in the SEC Reports and which the failure to so have could have a Material Adverse Effect (collectively, the
&#147;<U>Intellectual Property Rights</U>&#148;). None of, and neither the Company nor any Subsidiary has received a notice (written or otherwise) that any of, the Intellectual Property Rights has expired, terminated or been abandoned, or is
expected to expire or terminate or be abandoned, within two (2)&nbsp;years from the date of this Agreement. Neither the Company nor any Subsidiary has received, since the date of the latest unaudited financial statements included within the SEC
Reports, a written notice of a claim or otherwise has any knowledge that the Intellectual Property Rights violate or infringe upon the rights of any Person, except as could not have or reasonably be expected to not have a Material Adverse Effect.
All such Intellectual Property Rights are enforceable and there is no existing infringement by another Person of any of the Intellectual Property Rights, except as could not have a reasonably be expected to result in a Material Adverse Effect. The
Company and its Subsidiaries have taken reasonable security measures to protect the secrecy, confidentiality and value of all of their intellectual properties, except where failure to do so could not, individually or in the aggregate, reasonably be
expected to have a Material Adverse Effect. The Company has no knowledge of any facts that would preclude it from having valid license rights or clear title to the Intellectual Property Rights. The Company has no knowledge that it lacks or will be
unable to obtain any rights or licenses to use all Intellectual Property Rights that are necessary to conduct its business. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q) <U>Insurance</U>. The Company and the Subsidiaries are insured by insurers of recognized financial responsibility against
such losses and risks and in such amounts as are prudent and customary in the businesses in which the Company and the Subsidiaries are engaged, including, but not limited to, directors and officers insurance coverage at least equal to the aggregate
Subscription Amount. Neither the Company nor any Subsidiary has any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar coverage from similar insurers as may be
necessary to continue its business without a significant increase in cost. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r) <U>Transactions With Affiliates and
Employees</U>. Except as set forth on <U>Schedule 3.1(r)</U>, none of the officers or directors of the Company or any Subsidiary and, to the knowledge of the Company, none of the employees of the Company or any Subsidiary is presently a party to any
transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or
personal property to or from, providing for the borrowing of money from or lending of money to or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge of the Company, any entity in which any officer,
director, or any such employee has a substantial interest or is an officer, director, trustee, stockholder, member or partner, in each case in excess of $120,000 other than for (i)&nbsp;payment of salary or consulting fees for services rendered,
(ii)&nbsp;reimbursement for expenses incurred on behalf of the Company and (iii)&nbsp;other employee benefits, including stock option agreements under any equity incentive plan of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s) <U>Sarbanes-Oxley; Internal Accounting Controls</U>. The Company and the Subsidiaries are in compliance with any and all
applicable requirements of the Sarbanes-Oxley Act of 2002, as amended, that are applicable to it as of the date hereof and as of the Closing Date, and any and all applicable rules and regulations promulgated by the Commission thereunder that are
effective as of the date hereof and as of the Closing Date. The Company and the Subsidiaries maintain a system of internal accounting controls sufficient to provide reasonable assurance that: (i)&nbsp;transactions are executed in accordance with
management&#146;s general </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
or specific authorizations, (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability,
(iii)&nbsp;access to assets is permitted only in accordance with management&#146;s general or specific authorization, and (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate
action is taken with respect to any differences. The Company and the Subsidiaries have established disclosure controls and procedures (as defined in Exchange Act Rules <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> and <FONT
STYLE="white-space:nowrap">15d-15(e))</FONT> for the Company and the Subsidiaries and designed such disclosure controls and procedures to ensure that information required to be disclosed by the Company in the reports it files or submits under the
Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission&#146;s rules and forms. The Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2022 does not include a report of management&#146;s assessment regarding&nbsp;internal control over financial reporting or an attestation report of the Company&#146;s independent registered public accounting firm due to a
transition period established by rules of the SEC for newly public companies. The Company&#146;s certifying officers have evaluated the effectiveness of the disclosure controls and procedures of the Company and the Subsidiaries as of the end of the
period covered by the most recently filed periodic report under the Exchange Act (such date, the &#147;<U>Evaluation Date</U>&#148;). The Company presented in its most recently filed periodic report under the Exchange Act the conclusions of the
certifying officers about the effectiveness of the disclosure controls and procedures based on their evaluations as of the Evaluation Date. Since the Evaluation Date, there have been no changes in the internal control over financial reporting (as
such term is defined in the Exchange Act) of the Company and its Subsidiaries that have materially affected, or is reasonably likely to materially affect, the internal control over financial reporting of the Company and its Subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t) <U>Certain Fees</U>. No brokerage or finder&#146;s fees or commissions are or will be payable by the Company or any
Subsidiary to any broker, financial advisor or consultant, finder, placement agent, investment banker, bank or other Person with respect to the transactions contemplated by the Transaction Documents. The Purchasers shall have no obligation with
respect to any fees or with respect to any claims made by or on behalf of other Persons for fees of a type contemplated in this Section that may be due in connection with the transactions contemplated by the Transaction Documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u) <U>Investment Company</U>. The Company is not, and is not an Affiliate of, and immediately after receipt of payment for the
Securities, will not be or be an Affiliate of, an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended. The Company shall conduct its business in a manner so that it will not become an &#147;investment
company&#148; subject to registration under the Investment Company Act of 1940, as amended. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v) <U>Registration
Rights</U>. Except as set forth on <U>Schedule 3.1(v)</U>, no Person has any right to cause the Company or any Subsidiary to effect the registration under the Securities Act of any securities of the Company or any Subsidiary. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w) <U>Listing and Maintenance Requirements</U>. The Common Stock is registered pursuant to Section&nbsp;12(b) or 12(g) of the
Exchange Act, and the Company has taken no action designed to, or which to its knowledge is likely to have the effect of, terminating the registration of the Common Stock under the Exchange Act nor has the Company received any notification that the
Commission is contemplating terminating such registration. Except as set forth on <U>Schedule 3.1(w)</U>, the Company has not, in the 12 months preceding the date hereof, received written notice from any Trading Market on which the Common Stock is
or has been listed or quoted to the effect that the Company is not in compliance with the listing or maintenance requirements of such Trading Market. Except as set forth on <U>Schedule 3.1(w)</U>, the Company is in compliance with all such listing
and maintenance requirements. The Common Stock is currently eligible for electronic transfer through the Depository Trust Company or another established clearing corporation and the Company is current in payment of the fees to the Depository Trust
Company (or such other established clearing corporation) in connection with such electronic transfer. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x) <U>Application
of Takeover Protections</U>. The Company and the Board of Directors have taken all necessary action, if any, in order to render inapplicable any control share acquisition, business combination, poison pill (including any distribution under a rights
agreement) or other similar anti-takeover provision under the Company&#146;s certificate of incorporation (or similar charter documents) or the laws of its state of incorporation that is or could become applicable to the Purchasers as a result of
the Purchasers and the Company fulfilling their obligations or exercising their rights under the Transaction Documents, including without limitation as a result of the Company&#146;s issuance of the Securities and the Purchasers&#146; ownership of
the Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y) <U>Disclosure</U>. Except with respect to the material terms and conditions of the transactions
contemplated by the Transaction Documents, the Company confirms that neither it nor any other Person acting on its behalf has provided any of the Purchasers or their agents or counsel with any information that it believes constitutes or might
constitute material, <FONT STYLE="white-space:nowrap">non-public</FONT> information which is not otherwise disclosed in the SEC Reports.&#8195;The Company understands and confirms that the Purchasers will rely on the foregoing representation in
effecting transactions in securities of the Company. All of the disclosure furnished by or on behalf of the Company to the Purchasers regarding the Company and its Subsidiaries, their respective businesses and the transactions contemplated hereby,
including the Disclosure Schedules to this Agreement, is true and correct and does not contain any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements made therein, in the light of the
circumstances under which they were made, not misleading. The press releases disseminated by the Company during the twelve months preceding the date of this Agreement taken as a whole do not contain any untrue statement of a material fact or omit to
state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made and when made, not misleading. The Company acknowledges and agrees that no
Purchaser makes or has made any representations or warranties with respect to the transactions contemplated hereby other than those specifically set forth in Section&nbsp;3.2 hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z) <U>No Integrated Offering</U>. Assuming the accuracy of the
Purchasers&#146; representations and warranties set forth in <U>Section</U><U></U><U>&nbsp;3.2</U>, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of
any security or solicited any offers to buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of (i)&nbsp;the Securities Act which would require the
registration of any such securities under the Securities Act, or (ii)&nbsp;any applicable shareholder approval provisions of any Trading Market on which any of the securities of the Company are listed or designated. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa) <U>Solvency</U>. Based on the consolidated financial condition of the Company as of the Closing Date, after giving effect
to the receipt by the Company of the proceeds from the sale of the Securities hereunder, (i)&nbsp;the fair saleable value of the Company&#146;s assets exceeds the amount that will be required to be paid on or in respect of the Company&#146;s
existing debts and other liabilities (including known contingent liabilities) as they mature, (ii)&nbsp;the Company&#146;s assets do not constitute unreasonably small capital to carry on its business as now conducted and as proposed to be conducted
including its capital needs taking into account the particular capital requirements of the business conducted by the Company, consolidated and projected capital requirements and capital availability thereof, and (iii)&nbsp;the current cash flow of
the Company, together with the proceeds the Company would receive, were it to liquidate all of its assets, after taking into account all anticipated uses of the cash, would be sufficient to pay all amounts on or in respect of its liabilities when
such amounts are required to be paid. The Company does not intend to incur debts beyond its ability to pay such debts as they mature (taking into account the timing and amounts of cash to be payable on or in respect of its debt). The Company has no
knowledge of any facts or circumstances which lead it to believe that it will file for reorganization or liquidation under the bankruptcy or reorganization laws of any jurisdiction within one year from the Closing Date. <U>Schedule 3.1(aa)</U> sets
forth as of September&nbsp;30, 2023 hereof all outstanding secured and unsecured Indebtedness of the Company or any Subsidiary, or for which the Company or any Subsidiary has commitments. For the purposes of this Agreement,
&#147;<U>Indebtedness</U>&#148; means (x)&nbsp;any liabilities for borrowed money or amounts owed in excess of $50,000 (other than trade accounts payable incurred in the ordinary course of business), (y) all guaranties, endorsements and other
contingent obligations in respect of indebtedness of others, whether or not the same are or should be reflected in the Company&#146;s consolidated balance sheet (or the notes thereto), except guaranties by endorsement of negotiable instruments for
deposit or collection or similar transactions in the ordinary course of business; and (z)&nbsp;the present value of any lease payments in excess of $50,000 due under leases required to be capitalized in accordance with GAAP. Neither the Company nor
any Subsidiary is in default with respect to any Indebtedness. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb) <U>Tax Status</U>. Except for matters that would not,
individually or in the aggregate, have or reasonably be expected to result in a Material Adverse Effect, the Company and its Subsidiaries each (i)&nbsp;has made or filed all United States federal, state and local income and all foreign income and
franchise tax returns, reports and declarations required by any jurisdiction to which it is subject, (ii)&nbsp;has paid all taxes and other governmental assessments and charges that are material in amount, shown or determined to be due on such
returns, reports and declarations and (iii)&nbsp;has set aside on its books provision reasonably adequate for the payment of all material taxes for periods subsequent to the periods to which such returns, reports or declarations apply. There are no
unpaid taxes in any material amount claimed to be due by the taxing authority of any jurisdiction, and the officers of the Company or of any Subsidiary know of no basis for any such claim. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc) <U>Foreign Corrupt Practices</U>. Neither the Company nor any Subsidiary, nor to the knowledge of the Company or any
Subsidiary, any agent or other person acting on behalf of the Company or any Subsidiary, has (i)&nbsp;directly or indirectly, used any funds for unlawful contributions, gifts, entertainment or other unlawful expenses related to foreign or domestic
political activity, (ii)&nbsp;made any unlawful payment to foreign or domestic government officials or employees or to any foreign or domestic political parties or campaigns from corporate funds, (iii)&nbsp;failed to disclose fully any contribution
made by the Company or any Subsidiary (or made by any person acting on its behalf of which the Company is aware) which is in violation of law, or (iv)&nbsp;violated in any material respect any provision of FCPA. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd) <U>Accountants</U>. The Company&#146;s independent registered public accounting firm is Grant Thornton LLP. To the
knowledge and belief of the Company, such accounting firm (i)&nbsp;is a registered public accounting firm as required by the Exchange Act and (ii)&nbsp;shall express its opinion with respect to the financial statements to be included in the
Company&#146;s Annual Report for the fiscal year ending December&nbsp;31, 2023. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee) <U>Acknowledgment Regarding
Purchasers&#146; Purchase of Securities</U>. The Company acknowledges and agrees that each of the Purchasers is acting solely in the capacity of an arm&#146;s length purchaser with respect to the Transaction Documents and the transactions
contemplated thereby. The Company further acknowledges that no Purchaser is acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated thereby
and any advice given by any Purchaser or any of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated thereby is merely incidental to the Purchasers&#146; purchase of the
Securities. The Company further represents to each Purchaser that the Company&#146;s decision to enter into this Agreement and the other Transaction Documents has been based solely on the independent evaluation of the transactions contemplated
hereby by the Company and its representatives. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff) <U>Acknowledgment Regarding Purchaser&#146;s Trading Activity</U>.
Anything in this Agreement or elsewhere herein to the contrary notwithstanding (except for <U>Sections 3.2(f)</U> and <U>4.14</U> hereof), it is understood and acknowledged by the Company that: (i)&nbsp;none of the Purchasers has been asked by the
Company to agree, nor has any Purchaser agreed, to desist from purchasing or selling, long and/or short, securities of the Company, or &#147;derivative&#148; securities based on securities issued by the Company or to hold the Securities for any
specified term; (ii)&nbsp;past or future open market or other transactions by any Purchaser, specifically including, without limitation, Short Sales or &#147;derivative&#148; transactions, before or after the closing of this or future private
placement transactions, may negatively impact the market price of the Company&#146;s publicly-traded securities; (iii)&nbsp;any Purchaser, and counter-parties in &#147;derivative&#148; transactions to which any such Purchaser is a party, directly or
indirectly, presently may have a &#147;short&#148; position in the Common Stock, and (iv)&nbsp;each Purchaser shall not be deemed to have any affiliation with or control over any arm&#146;s length counter-party in any &#147;derivative&#148;
transaction. The Company further understands and acknowledges that (y)&nbsp;one or more Purchasers may engage in hedging activities at various times during the period that the Securities are outstanding, including, without limitation, during the
periods that the value of the Warrant Shares deliverable with respect to Securities are being determined, and (z)&nbsp;such hedging activities (if any) could reduce the value of the existing stockholders&#146; equity interests in the Company at and
after the time that the hedging activities are being conducted.&nbsp;The Company acknowledges that such aforementioned hedging activities do not constitute a breach of any of the Transaction Documents. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg) <U>Regulation M Compliance</U>.&nbsp;The Company has not, and to its knowledge no one acting on its behalf has,
(i)&nbsp;taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of any of the Securities, (ii)&nbsp;sold, bid for,
purchased, or, paid any compensation for soliciting purchases of, any of the Securities, or (iii)&nbsp;paid or agreed to pay to any Person any compensation for soliciting another to purchase any other securities of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh) <U>FDA</U>. As to each product subject to the jurisdiction of the U.S. Food and Drug Administration
(&#147;<U>FDA</U>&#148;) under the Federal Food, Drug and Cosmetic Act, as amended, and the regulations thereunder (&#147;<U>FDCA</U>&#148;) that is manufactured, packaged, labeled, tested, distributed, sold, and/or marketed by the Company or any of
its Subsidiaries (each such product, a &#147;<U>Pharmaceutical Product</U>&#148;), such Pharmaceutical Product is being manufactured, packaged, labeled, tested, distributed, sold and/or marketed by the Company in compliance with all applicable
requirements under FDCA and similar laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good manufacturing practices, good laboratory practices, good clinical practices,
product listing, quotas, labeling, advertising, record keeping and filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. There is no pending, completed or, to the Company&#146;s knowledge,
threatened, action (including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against the Company or any of its Subsidiaries, and none of the Company or any of its Subsidiaries has
received any notice, warning letter or other communication from the FDA or any other governmental entity, which (i)&nbsp;contests the premarket clearance, licensure, registration, or approval of, the uses of, the distribution of, the manufacturing
or packaging of, the testing of, the sale of, or the labeling and promotion of any Pharmaceutical Product, (ii)&nbsp;withdraws its approval of, requests the recall, suspension, or seizure of, or withdraws or orders the withdrawal of advertising or
sales promotional materials relating to, any Pharmaceutical Product, (iii)&nbsp;imposes a clinical hold on any clinical investigation by the Company or any of its Subsidiaries, (iv)&nbsp;enjoins production at any facility of the Company or any of
its Subsidiaries, (v)&nbsp;enters or proposes to enter into a consent decree of permanent injunction with the Company or any of its Subsidiaries, or (vi)&nbsp;otherwise alleges any violation of any laws, rules or regulations by the Company or any of
its Subsidiaries, and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of the Company have been and are being conducted in all material respects in accordance with all
applicable laws, rules and regulations of the FDA.&nbsp;The Company has not been informed by the FDA that the FDA will prohibit the marketing, sale, license or use in the United States of any product proposed to be developed, produced or marketed by
the Company nor has the FDA expressed any concern as to approving or clearing for marketing any product being developed or proposed to be developed by the Company.<U> </U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) <U>Equity Incentive Plans</U>. Each stock option granted by the Company under the Company&#146;s equity incentive plans
was granted (i)&nbsp;in accordance with the terms of the Company&#146;s equity incentive plans and (ii)&nbsp;with an exercise price at least equal to the fair market value of the Common Stock on the date such stock option would be considered granted
under GAAP and applicable law. No stock option granted under the Company&#146;s equity incentive plans has been backdated. The Company has not knowingly granted, and there is no and has been no Company policy or practice to knowingly grant, stock
options prior to, or otherwise knowingly coordinate the grant of stock options with, the release or other public announcement of material information regarding the Company or its Subsidiaries or their financial results or prospects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj) <U>Cybersecurity</U>. (i)(x) There has been no security breach or other compromise of or relating to any of the
Company&#146;s or any Subsidiary&#146;s information technology and computer systems, networks, hardware, software, data (including the data of its respective customers, employees, suppliers, vendors and any third party data maintained by or on
behalf of it), equipment or technology (collectively, &#147;<U>IT Systems and Data</U>&#148;) and (y)&nbsp;the Company and the Subsidiaries have not been notified of, and has </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
no knowledge of any event or condition that would reasonably be expected to result in, any security breach or other compromise to its IT Systems and Data; (ii)&nbsp;the Company and the
Subsidiaries are presently in compliance with all applicable laws or statutes and all judgments, orders, rules and regulations of any court or arbitrator or governmental or regulatory authority, internal policies and contractual obligations relating
to the privacy and security of IT Systems and Data and to the protection of such IT Systems and Data from unauthorized use, access, misappropriation or modification, except as would not, individually or in the aggregate, have a Material Adverse
Effect; (iii)&nbsp;the Company and the Subsidiaries have implemented and maintained commercially reasonable safeguards to maintain and protect its material confidential information and the integrity, continuous operation, redundancy and security of
all IT Systems and Data; and (iv)&nbsp;the Company and the Subsidiaries have implemented backup and disaster recovery technology consistent with industry standards and practices. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk) <U>Office of Foreign Assets Control</U>. Neither the Company nor any Subsidiary nor, to the Company&#146;s knowledge, any
director, officer, agent, employee or affiliate of the Company or any Subsidiary is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control of the U.S. Treasury Department (&#147;<U>OFAC</U>&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll) <U>U.S. Real Property Holding Corporation</U>. The Company is not and has never been a U.S. real property holding
corporation within the meaning of Section&nbsp;897 of the Internal Revenue Code of 1986, as amended, and the Company shall so certify upon Purchaser&#146;s request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm) <U>Bank Holding Company Act</U>. Neither the Company nor any of its Subsidiaries or Affiliates is subject to the Bank
Holding Company Act of 1956, as amended (the &#147;<U>BHCA</U>&#148;) and to regulation by the Board of Governors of the Federal Reserve System (the &#147;<U>Federal Reserve</U>&#148;). Neither the Company nor any of its Subsidiaries or Affiliates
owns or controls, directly or indirectly, five percent (5%) or more of the outstanding shares of any class of voting securities or twenty-five percent (25%) or more of the total equity of a bank or any entity that is subject to the BHCA and to
regulation by the Federal Reserve. Neither the Company nor any of its Subsidiaries or Affiliates exercises a controlling influence over the management or policies of a bank or any entity that is subject to the BHCA and to regulation by the Federal
Reserve. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn) <U>Money Laundering</U>. The operations of the Company and its Subsidiaries are and have been conducted at
all times in compliance in all material respects with applicable financial record-keeping and reporting requirements of the Currency and Foreign Transactions Reporting Act of 1970, as amended, applicable money laundering statutes and applicable
rules and regulations thereunder (collectively, the &#147;<U>Money Laundering Laws</U>&#148;), and no Action or Proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any Subsidiary
with respect to the Money Laundering Laws is pending or, to the knowledge of the Company or any Subsidiary, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo) <U>Private Placement</U>. Assuming the accuracy of the Purchasers&#146; representations and warranties set forth in
<U>Section</U><U></U><U>&nbsp;3.2</U>, no registration under the Securities Act is required for the offer and sale of the Common Warrants or the Common Warrant Shares by the Company to the Purchasers as contemplated hereby. The issuance and sale of
the Securities hereunder does not contravene the rules and regulations of the Trading Market. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp) <U>No General
Solicitation</U>. Neither the Company nor any Person acting on behalf of the Company has offered or sold any of the Common Warrant or Common Warrant Shares by any form of general solicitation or general advertising. The Company has offered the
Common Warrants and Common Warrant Shares for sale only to the Purchasers and certain other &#147;accredited investors&#148; within the meaning of Rule 501 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq) <U>No Disqualification Events</U>. With respect to the Common Warrants and Common Warrant Shares to be offered and sold
hereunder in reliance on Rule 506 under the Securities Act, none of the Company, any of its predecessors, any affiliated issuer, any director, executive officer, other officer of the Company participating in the offering hereunder, any beneficial
owner of 20% or more of the Company&#146;s outstanding voting equity securities, calculated on the basis of voting power, nor any promoter (as that term is defined in Rule 405 under the Securities Act) connected with the Company in any capacity at
the time of sale (each, an &#147;<U>Issuer Covered Person</U>&#148;) is subject to any of the &#147;Bad Actor&#148; disqualifications described in Rule 506(d)(1)(i) to (viii)&nbsp;under the Securities Act (a &#147;<U>Disqualification
Event</U>&#148;), except for a Disqualification Event covered by Rule 506(d)(2) or (d)(3). The Company has exercised reasonable care to determine whether any Issuer Covered Person is subject to a Disqualification Event. The Company has complied, to
the extent applicable, with its disclosure obligations under Rule 506(e), and has furnished to the Purchasers a copy of any disclosures provided thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr) <U>Other Covered Persons</U>. The Company is not aware of any person (other than any Issuer Covered Person) that has been
or will be paid (directly or indirectly) remuneration for solicitation of purchasers in connection with the sale of any Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss) <U>Notice of Disqualification Events</U>. The Company will notify the Purchasers in writing, prior to the Closing Date of
(i)&nbsp;any Disqualification Event relating to any Issuer Covered Person and (ii)&nbsp;any event that would, with the passage of time, reasonably be expected to become a Disqualification Event relating to any Issuer Covered Person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.2 <U>Representations and Warranties of the Purchasers</U>. Each Purchaser, for itself and
for no other Purchaser, hereby represents and warrants as of the date hereof and as of the Closing Date to the Company as follows (unless as of a specific date therein, in which case they shall be accurate as of such date): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Organization; Authority</U>. Such Purchaser is either an individual or an entity duly incorporated or formed, validly
existing and in good standing under the laws of the jurisdiction of its incorporation or formation with full right, corporate, partnership, limited liability company or similar power and authority to enter into and to consummate the transactions
contemplated by the Transaction Documents and otherwise to carry out its obligations hereunder and thereunder. The execution and delivery of the Transaction Documents and performance by such Purchaser of the transactions contemplated by the
Transaction Documents have been duly authorized by all necessary corporate, partnership, limited liability company or similar action, as applicable, on the part of such Purchaser. Each Transaction Document to which it is a party has been duly
executed by such Purchaser, and when delivered by such Purchaser in accordance with the terms hereof, will constitute the valid and legally binding obligation of such Purchaser, enforceable against it in accordance with its terms, except:
(i)&nbsp;as limited by general equitable principles and applicable bankruptcy, insolvency, reorganization, moratorium and other laws of general application affecting enforcement of creditors&#146; rights generally, (ii)&nbsp;as limited by laws
relating to the availability of specific performance, injunctive relief or other equitable remedies and (iii)&nbsp;insofar as indemnification and contribution provisions may be limited by applicable law. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Understandings or Arrangements</U>. Such Purchaser is acquiring the Securities as principal for its own account and has
no direct or indirect arrangement or understandings with any other persons to distribute or regarding the distribution of such Securities or otherwise in compliance with applicable federal and state securities laws). Such Purchaser is acquiring the
Securities hereunder in the ordinary course of its business. Such Purchaser understands that the Common Warrants and the Common Warrant Shares are &#147;restricted securities&#148; and have not been registered under the Securities Act or any
applicable state securities law and is acquiring such Securities as principal for his, her or its own account and not with a view to or for distributing or reselling such Securities or any part thereof in violation of the Securities Act or any
applicable state securities law, has no present intention of distributing any of such Securities in violation of the Securities Act or any applicable state securities law and has no direct or indirect arrangement or understandings with any other
persons to distribute or regarding the distribution of such Securities in violation of the Securities Act or any applicable state securities law (this representation and warranty not limiting such Purchaser&#146;s right to sell such Securities
pursuant to a registration statement or otherwise in compliance with applicable federal and state securities laws). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
<U>Purchaser Status</U>. At the time such Purchaser was offered the Securities, it was, and as of the date hereof it is, and on each date on which it exercises any Warrants, it will be either: (i)&nbsp;an &#147;accredited investor&#148; as defined
in Rule 501(a)(1), (a)(2), (a)(3), (a)(7), (a)(8), (a)(9), (a)(12), or (a)(13) under the Securities Act or (ii)&nbsp;a &#147;qualified institutional buyer&#148; as defined in Rule 144A(a) under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Experience of Such Purchaser</U>. Such Purchaser, either alone or together with its representatives, has such knowledge,
sophistication and experience in business and financial matters so as to be capable of evaluating the merits and risks of the prospective investment in the Securities, and has so evaluated the merits and risks of such investment. Such Purchaser is
able to bear the economic risk of an investment in the Securities and, at the present time, is able to afford a complete loss of such investment. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Access to Information</U>. Such Purchaser acknowledges that it has had the opportunity to review the Transaction
Documents (including all exhibits and schedules thereto) and the SEC Reports and has been afforded, (i)&nbsp;the opportunity to ask such questions as it has deemed necessary of, and to receive answers from, representatives of the Company concerning
the terms and conditions of the offering of the Securities and the merits and risks of investing in the Securities; (ii)&nbsp;access to information about the Company and its financial condition, results of operations, business, properties,
management and prospects sufficient to enable it to evaluate its investment; and (iii)&nbsp;the opportunity to obtain such additional information that the Company possesses or can acquire without unreasonable effort or expense that is necessary to
make an informed investment decision with respect to the investment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Certain Transactions and Confidentiality</U>.
Other than consummating the transactions contemplated hereunder, such Purchaser has not, nor has any Person acting on behalf of or pursuant to any understanding with such Purchaser, directly or indirectly executed any purchases or sales, including
Short Sales,&nbsp;of the securities of the Company during the period commencing as of the time that such Purchaser first received a term sheet (written or oral) from the Company or any other Person representing the Company setting forth the material
terms of the transactions contemplated hereunder and ending immediately prior to the execution hereof. Notwithstanding the foregoing, in the case of a Purchaser that is a multi-managed investment vehicle whereby separate portfolio managers manage
separate portions of such Purchaser&#146;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing other portions of such Purchaser&#146;s assets, the representation set forth
above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this Agreement. Other than to other Persons party to this Agreement or to such
Purchaser&#146;s representatives, including, without limitation, its officers, directors, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
partners, legal and other advisors, employees, agents and Affiliates, such Purchaser has maintained the confidentiality of all disclosures made to it in connection with this transaction
(including the existence and terms of this transaction). Notwithstanding the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or
borrowing shares in order to effect Short Sales or similar transactions in the future. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>General Solicitation</U>.
Such Purchaser is not purchasing the Securities as a result of any advertisement, article, notice or other communication regarding the Securities published in any newspaper, magazine or similar media or broadcast over television or radio or
presented at any seminar or, to the knowledge of such Purchaser, any other general solicitation or general advertisement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company
acknowledges and agrees that the representations contained in this Section&nbsp;3.2 shall not modify, amend or affect such Purchaser&#146;s right to rely on the Company&#146;s representations and warranties contained in this Agreement or any
representations and warranties contained in any other Transaction Document or any other document or instrument executed and/or delivered in connection with this Agreement or the consummation of the transactions contemplated hereby. Notwithstanding
the foregoing, for the avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to locating or borrowing shares in order to effect Short Sales or similar transactions in the
future. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE IV. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">OTHER AGREEMENTS OF THE PARTIES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.1 <U>Removal of Legends.</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) The Securities may only be disposed of in compliance with state and federal securities laws. In connection with any
transfer of the Securities other than pursuant to an effective registration statement or Rule 144, to the Company or to an Affiliate of a Purchaser or in connection with a pledge as contemplated in Section&nbsp;4.1(b), the Company may require the
transferor thereof to provide to the Company an opinion of counsel selected by the transferor and reasonably acceptable to the Company, the form and substance of which opinion shall be reasonably satisfactory to the Company, to the effect that such
transfer does not require registration of such transferred Warrant under the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Purchasers agree to
the imprinting, so long as is required by this Section&nbsp;4.1, of a legend on any of the Securities in the following form: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">NEITHER THIS
SECURITY NOR THE SECURITIES INTO WHICH THIS SECURITY IS EXERCISABLE HAS BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF
1933, AS AMENDED (THE &#147;SECURITIES ACT&#148;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT
SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN
ACCOUNT WITH A REGISTERED BROKER-DEALER OR OTHER LOAN WITH A FINANCIAL INSTITUTION THAT IS AN &#147;ACCREDITED INVESTOR&#148; AS DEFINED IN RULE 501(a) UNDER THE SECURITIES ACT OR OTHER LOAN SECURED BY SUCH SECURITIES. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company acknowledges and agrees that a Purchaser may from time to time pledge pursuant to a bona fide margin agreement with
a registered broker-dealer or grant a security interest in some or all of the Securities to a financial institution that is an &#147;accredited investor&#148; as defined in Rule 501(a) under the Securities Act and, if required under the terms of
such arrangement, such Purchaser may transfer pledged or secured Warrants or Warrant Shares to the pledgees or secured parties. Such a pledge or transfer would not be subject to approval of the Company and no legal opinion of legal counsel of the
pledgee, secured party or pledgor shall be required in connection therewith. Further, no notice shall be required of such pledge. At the appropriate Purchaser&#146;s expense, the Company will execute and deliver such reasonable documentation as a
pledgee or secured party of the Securities may reasonably request in connection with a pledge or transfer of the Warrants or Warrant Shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) Certificates evidencing the Securities, if any, shall not contain any legend (including the legend set forth in
Section&nbsp;4.1(b) hereof): (i) while a registration statement covering the resale of such security is effective under the Securities Act, or (ii)&nbsp;following any sale of such Shares or Warrant Shares pursuant to Rule 144 (assuming cashless
exercise of the Warrants), or (iii)&nbsp;if such Shares or Warrant Shares are eligible for sale under Rule 144 (assuming cashless exercise of the Common Warrants), or (iv)&nbsp;if such legend is not required under applicable requirements of the
Securities Act (including judicial interpretations and pronouncements issued by the staff of the Commission). The Company shall cause its counsel to issue a legal opinion to the Transfer Agent or the Purchaser promptly if required by the Transfer
Agent to effect the removal of the legend </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
hereunder, or if requested by a Purchaser, respectively. If all or any portion of a Warrant is exercised at a time when there is an effective registration statement to cover the resale of the
Warrant Shares, or if such Shares or Warrant Shares may be sold under Rule 144 (assuming cashless exercise of the Warrants) or if such legend is not otherwise required under applicable requirements of the Securities Act (including judicial
interpretations and pronouncements issued by the staff of the Commission) then such Warrant Shares shall be issued free of all legends. The Company agrees that following such time as such legend is no longer required under this Section&nbsp;4.1(c),
the Company will, no later than the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period (as defined below) following the delivery by a Purchaser to the Company or the
Transfer Agent of a certificate representing Shares or Warrant Shares, as applicable, issued with a restrictive legend (such date, the &#147;<U>Legend Removal Date</U>&#148;), deliver or cause to be delivered to such Purchaser a certificate
representing such shares that is free from all restrictive and other legends. The Company may not make any notation on its records or give instructions to the Transfer Agent that enlarge the restrictions on transfer set forth in this Section&nbsp;4.
Securities subject to legend removal hereunder shall be transmitted by the Transfer Agent to the Purchaser by crediting the account of the Purchaser&#146;s prime broker with the Depository Trust Company System as directed by such Purchaser. As used
herein, &#147;Standard Settlement Period&#148; means the standard settlement period, expressed in a number of Trading Days, on the Company&#146;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of a
certificate representing Shares or Warrant Shares issued with a restrictive legend. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) In addition to such
Purchaser&#146;s other available remedies, the Company shall pay to a Purchaser, in cash, (i)&nbsp;as partial liquidated damages and not as a penalty, for each $1,000 of Shares or Warrant Shares (based on the VWAP of the Common Stock on the date
such Securities are submitted to the Transfer Agent) delivered for removal of the restrictive legend and subject to Section&nbsp;4.1(c), $10 per Trading Day (increasing to $20 per Trading Day three (3)&nbsp;Trading Days after the Legend Removal
Date) for each Trading Day after the Legend Removal Date until such certificate is delivered without a legend and (ii)&nbsp;if the Company fails to (a)&nbsp;issue and deliver (or cause to be delivered) to a Purchaser by the Legend Removal Date a
certificate representing the Securities so delivered to the Company by such Purchaser that is free from all restrictive and other legends and (b)&nbsp;if after the Legend Removal Date such Purchaser purchases (in an open market transaction or
otherwise) shares of Common Stock to deliver in satisfaction of a sale by such Purchaser of all or any portion of the number of shares of Common Stock, or a sale of a number of shares of Common Stock equal to all or any portion of the number of
shares of Common Stock, that such Purchaser anticipated receiving from the Company without any restrictive legend, then an amount equal to the excess of such Purchaser&#146;s total purchase price (including brokerage commissions and other <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, if any) for the shares of Common Stock so purchased (including brokerage commissions and other <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses, if any) (the &#147;<U><FONT STYLE="white-space:nowrap">Buy-In</FONT> Price</U>&#148;) over the product of (A)&nbsp;such number of Shares or Warrant Shares that the Company was required
to deliver to such Purchaser by the Legend Removal Date multiplied by (B)&nbsp;the lowest closing sale price of the Common Stock on any Trading Day during the period commencing on the date of the delivery by such Purchaser to the Company of the
applicable Shares or Warrant Shares (as the case may be) and ending on the date of such delivery and payment under this Section&nbsp;4.1(d). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) Each Purchaser, severally and not jointly with the other Purchasers, agrees with the Company that such Purchaser will sell
any Securities pursuant to either the registration requirements of the Securities Act, including any applicable prospectus delivery requirements, or an exemption therefrom, and that if Securities are sold pursuant to a registration statement, they
will be sold in compliance with the plan of distribution set forth therein, and acknowledges that the removal of the restrictive legend from certificates representing Securities as set forth in this Section&nbsp;4.1 is predicated upon the
Company&#146;s reliance upon this understanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.2 <U>Furnishing of Information</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Until the earlier of the time that (i)&nbsp;no Purchaser owns Securities and (ii)&nbsp;the Warrants have expired, the
Company covenants to use commercially reasonable efforts to timely file (or obtain extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the
Exchange Act even if the Company is not then subject to the reporting requirements of the Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) At any time
during the period commencing from the six (6)&nbsp;month anniversary of the date hereof and ending at such time that all of the Securities may be sold without the requirement for the Company to be in compliance with Rule 144(c)(1) and otherwise
without restriction or limitation pursuant to Rule 144, if the Company (i)&nbsp;shall fail for any reason to satisfy the current public information requirement under Rule 144(c) or (ii)&nbsp;has ever been an issuer described in Rule 144(i)(1)(i) or
becomes an issuer in the future, and the Company shall fail to satisfy any condition set forth in Rule 144(i)(2) (a &#147;<U>Public Information Failure</U>&#148;) then, in addition to such Purchaser&#146;s other available remedies, the Company shall
pay to a Purchaser, in cash, as partial liquidated damages and not as a penalty, by reason of any such delay in or reduction of its ability to sell the Common Warrant Shares, an amount in cash equal to two percent (2.0%) of the aggregate
Subscription Amount of such Purchaser&#146;s Securities on the day of a Public Information Failure and on every thirtieth (30th) day <FONT STYLE="white-space:nowrap">(pro-rated</FONT> for periods totaling less than thirty days) thereafter until the
earlier of (a)&nbsp;the date such Public Information Failure is cured and (b)&nbsp;such time that such public information is no longer required for the Purchasers to transfer the Shares or Warrant Shares pursuant to Rule 144. The payments to which a
Purchaser shall be entitled pursuant to this Section&nbsp;4.2(b) are referred to herein as &#147;Public Information Failure Payments.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Public Information Failure Payments shall be paid on the earlier of (i)&nbsp;the last day of the calendar month during which such Public Information Failure Payments are incurred and
(ii)&nbsp;the third (3rd) Business Day after the event or failure giving rise to the Public Information Failure Payments is cured. In the event the Company fails to make Public Information Failure Payments in a timely manner, such Public Information
Failure Payments shall bear interest at the rate of 1.5% per month (prorated for partial months) until paid in full. Nothing herein shall limit such Purchaser&#146;s right to pursue actual damages for the Public Information Failure, and such
Purchaser shall have the right to pursue all remedies available to it at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.3 <U>Integration</U>. The Company shall not sell, offer for sale or solicit offers to buy or otherwise negotiate in respect of any security
(as defined in Section&nbsp;2 of the Securities Act) that would be integrated with the offer or sale of the Securities in a manner that would require the registration under the Securities Act of the sale of the Common Warrants or Common Warrant
Shares or that would be integrated with the offer or sale of the Securities for purposes of the rules and regulations of any Trading Market such that it would require shareholder approval prior to the closing of such other transaction unless
shareholder approval is obtained before the closing of such subsequent transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.4 <U>Securities Laws Disclosure; Publicity</U>. The
Company shall (a)&nbsp;by the Disclosure Time, issue a press release disclosing the material terms of the transactions contemplated hereby, and (b)&nbsp;file a Current Report on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> including the
Transaction Documents as exhibits thereto, with the Commission within the time required by the Exchange Act. From and after the issuance of such press release, the Company represents to the Purchasers that it shall have publicly disclosed all
material, <FONT STYLE="white-space:nowrap">non-public</FONT> information delivered to any of the Purchasers by the Company or any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agents, in connection
with the transactions contemplated by the Transaction Documents. In addition, effective upon the issuance of such press release, the Company acknowledges and agrees that any and all confidentiality or similar obligations under any agreement, whether
written or oral, between the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents, on the one hand, and any of the Purchasers or any of their Affiliates on the other hand, shall terminate
and be of no further force or effect. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. The Company and each Purchaser shall consult with each
other in issuing any other press releases with respect to the transactions contemplated hereby, and neither the Company nor any Purchaser shall issue any such press release nor otherwise make any such public statement without the prior consent of
the Company, with respect to any press release of any Purchaser, or without the prior consent of each Purchaser, with respect to any press release of the Company, which consent shall not unreasonably be withheld or delayed, except if such disclosure
is required by law, in which case the disclosing party shall promptly provide the other party with prior notice of such public statement or communication. Notwithstanding the foregoing, the Company shall not publicly disclose the name of any
Purchaser, or include the name of any Purchaser in any filing with the Commission or any regulatory agency or Trading Market, without the prior written consent of such Purchaser, except (a)&nbsp;as required by federal securities law in connection
with the filing of final Transaction Documents with the Commission and (b)&nbsp;to the extent such disclosure is required by law or Trading Market regulations, in which case the Company shall provide the Purchasers with prior notice of such
disclosure permitted under this clause (b)&nbsp;and reasonably cooperate with such Purchaser regarding such disclosure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.5
<U>Shareholder Rights Plan</U>. No claim will be made or enforced by the Company or, with the consent of the Company, any other Person, that any Purchaser is an &#147;<U>Acquiring Person</U>&#148; under any control share acquisition, business
combination, poison pill (including any distribution under a rights agreement) or similar anti-takeover plan or arrangement in effect or hereafter adopted by the Company, or that any Purchaser could be deemed to trigger the provisions of any such
plan or arrangement, by virtue of receiving Securities under the Transaction Documents or under any other agreement between the Company and the Purchasers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.6 <U><FONT STYLE="white-space:nowrap">Non-Public</FONT> Information</U>. Except with respect to the material terms and conditions of the
transactions contemplated by the Transaction Documents, which shall be disclosed pursuant to Section&nbsp;4.4, the Company covenants and agrees that neither it, nor any other Person acting on its behalf will provide any Purchaser or its agents or
counsel with any information that constitutes, or the Company reasonably believes constitutes, material <FONT STYLE="white-space:nowrap">non-public</FONT> information, unless prior thereto such Purchaser shall have consented in writing to the
receipt of such information and agreed in writing with the Company to keep such information confidential. The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of
the Company. To the extent that the Company, any of its Subsidiaries, or any of their respective officers, directors, agents, employees or Affiliates delivers any material, <FONT STYLE="white-space:nowrap">non-public</FONT> information to a
Purchaser without such Purchaser&#146;s consent, the Company hereby covenants and agrees that such Purchaser shall not have any duty of confidentiality to the Company, any of its Subsidiaries, or any of their respective officers, directors,
employees, Affiliates or agents, or a duty to the Company, any of its Subsidiaries or any of their respective officers, directors, employees, Affiliates or agents, not to trade on the basis of, such material,
<FONT STYLE="white-space:nowrap">non-public</FONT> information, provided that the Purchaser shall remain subject to applicable law. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, <FONT
STYLE="white-space:nowrap">non-public</FONT> information regarding the Company or any Subsidiaries, the Company shall simultaneously with the delivery of such notice file such notice with the Commission pursuant to a Current Report on Form <FONT
STYLE="white-space:nowrap">8-K.</FONT> The Company understands and confirms that each Purchaser shall be relying on the foregoing covenant in effecting transactions in securities of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.7 <U>Use of Proceeds</U>. Except as set forth on <U>Schedule 4.7</U> attached hereto, the
Company shall use the net proceeds from the sale of the Securities hereunder for working capital purposes and shall not use such proceeds: (a)&nbsp;for the satisfaction of any portion of the Company&#146;s debt (other than payment of trade payables
in the ordinary course of the Company&#146;s business and prior practices), (b) for the redemption of any Common Stock or Common Stock Equivalents, (c)&nbsp;for the settlement of any outstanding litigation or (d)&nbsp;in violation of FCPA or OFAC
regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.8 <U>Indemnification of Purchasers</U>. Subject to the provisions of this Section&nbsp;4.8, the Company will indemnify and
hold each Purchaser and its directors, officers, shareholders, members, partners, employees and agents (and any other Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other
title), each Person who controls such Purchaser (within the meaning of Section&nbsp;15 of the Securities Act and Section&nbsp;20 of the Exchange Act), and the directors, officers, shareholders, agents, members, partners or employees (and any other
Persons with a functionally equivalent role of a Person holding such titles notwithstanding a lack of such title or any other title) of such controlling persons (each, a &#147;<U>Purchaser Party</U>&#148;) harmless from any and all losses,
liabilities, obligations, claims, contingencies, damages, costs and expenses, including all judgments, amounts paid in settlements, court costs and reasonable attorneys&#146; fees and costs of investigation that any such Purchaser Party may suffer
or incur as a result of or relating to (a)&nbsp;any breach of any of the representations, warranties, covenants or agreements made by the Company in this Agreement or in the other Transaction Documents or (b)&nbsp;any action instituted against the
Purchaser Parties in any capacity, or any of them or their respective Affiliates, by any stockholder of the Company who is not an Affiliate of such Purchaser Party, with respect to any of the transactions contemplated by the Transaction Documents
(unless such action is solely based upon a material breach of such Purchaser Party&#146;s representations, warranties or covenants under the Transaction Documents or any agreements or understandings such Purchaser Party may have with any such
stockholder or any violations by such Purchaser Party of state or federal securities laws or any conduct by such Purchaser Party which is finally judicially determined to constitute fraud, gross negligence or willful misconduct), or (c)&nbsp;in
connection with any registration statement of the Company providing for the resale by the Purchasers of the Common Warrant Shares issued and issuable upon exercise of the Common Warrants, the Company will indemnify each Purchaser Party, to the
fullest extent permitted by applicable law, from and against any and all losses, claims, damages, liabilities, costs (including, without limitation, reasonable attorneys&#146; fees) and expenses, as incurred, arising out of or relating to
(i)&nbsp;any untrue or alleged untrue statement of a material fact contained in such registration statement, any prospectus or any form of prospectus or in any amendment or supplement thereto or in any preliminary prospectus, or arising out of or
relating to any omission or alleged omission of a material fact required to be stated therein or necessary to make the statements therein (in the case of any prospectus or supplement thereto, in the light of the circumstances under which they were
made) not misleading, except to the extent, but only to the extent, that such untrue statements or omissions are based solely upon information regarding such Purchaser Party furnished in writing to the Company by such Purchaser Party expressly for
use therein, or (ii)&nbsp;any violation or alleged violation by the Company of the Securities Act, the Exchange Act or any state securities law, or any rule or regulation thereunder in connection therewith. If any action shall be brought against any
Purchaser Party in respect of which indemnity may be sought pursuant to this Agreement, such Purchaser Party shall promptly notify the Company in writing, and the Company shall have the right to assume the defense thereof with counsel of its own
choosing reasonably acceptable to the Purchaser Party. Any Purchaser Party shall have the right to employ separate counsel in any such action and participate in the defense thereof, but the fees and expenses of such counsel shall be at the expense
of such Purchaser Party except to the extent that (x)&nbsp;the employment thereof has been specifically authorized by the Company in writing, (y)&nbsp;the Company has failed after a reasonable period of time to assume such defense and to employ
counsel or (z)&nbsp;in such action there is, in the reasonable opinion of counsel, a material conflict on any material issue between the position of the Company and the position of such Purchaser Party, in which case the Company shall be responsible
for the reasonable fees and expenses of no more than one such separate counsel. The Company will not be liable to any Purchaser Party under this Agreement (1)&nbsp;for any settlement by a Purchaser Party effected without the Company&#146;s prior
written consent, which shall not be unreasonably withheld or delayed; or (2)&nbsp;to the extent, but only to the extent that a loss, claim, damage or liability is attributable to any Purchaser Party&#146;s breach of any of the representations,
warranties, covenants or agreements made by such Purchaser Party in this Agreement or in the other Transaction Documents. The indemnification required by this Section&nbsp;4.8 shall be made by periodic payments of the amount thereof during the
course of the investigation or defense, as and when bills are received or are incurred. The indemnity agreements contained herein shall be in addition to any cause of action or similar right of any Purchaser Party against the Company or others and
any liabilities the Company may be subject to pursuant to law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.9 <U>Reservation of Common Stock</U>. As of the date hereof, the Company
has reserved and the Company shall continue to reserve and keep available at all times, free of preemptive rights, a sufficient number of shares of Common Stock for the purpose of enabling the Company to issue Shares pursuant to this Agreement and
Warrant Shares pursuant to any exercise of the Warrants. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.10 <U>Listing of Common Stock</U>. The Company hereby agrees to use commercially
reasonable efforts to maintain the listing or quotation of the Common Stock on the Trading Market on which it is currently listed, and concurrently with the Closing, the Company shall apply to list or quote all of the Shares and Warrant Shares on
such Trading Market and promptly secure the listing of all of the Shares and Warrant Shares on such Trading Market. The Company further agrees, if the Company applies to have the Common Stock traded on any other Trading Market, it will then include
in such application all of the Shares and Warrant Shares, and will take such other action as is necessary to cause all of the Shares and Warrant Shares to be listed or quoted on such other Trading Market as promptly as possible. The Company will
then take all action reasonably necessary to continue the listing and trading of its Common Stock on a Trading Market and will comply in all respects with the Company&#146;s reporting, filing and other obligations under the bylaws or rules of the
Trading Market. The Company agrees to maintain the eligibility of the Common Stock for electronic transfer through the Depository Trust Company or another established clearing corporation, including, without limitation, by timely payment of fees to
the Depository Trust Company or such other established clearing corporation in connection with such electronic transfer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.11
<U>Reserved. </U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.12 <U>Reserved</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.13 <U>Equal Treatment of Purchasers</U>. No consideration (including any modification of this Agreement) shall be offered or paid to any
Person to amend or consent to a waiver or modification of any provision of this Agreement unless the same consideration is also offered to all of the parties to this Agreement. For clarification purposes, this provision constitutes a separate right
granted to each Purchaser by the Company and negotiated separately by each Purchaser, and is intended for the Company to treat the Purchasers as a class and shall not in any way be construed as the Purchasers acting in concert or as a group with
respect to the purchase, disposition or voting of Securities or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.14 <U>Certain Transactions and Confidentiality</U>. Each
Purchaser, severally and not jointly with the other Purchasers, covenants that neither it nor any Affiliate acting on its behalf or pursuant to any understanding with it will execute any purchases or sales, including Short Sales of any of the
Company&#146;s securities during the period commencing with the execution of this Agreement and ending at such time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described
in Section&nbsp;4.4.&nbsp;Each Purchaser, severally and not jointly with the other Purchasers, covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company pursuant to the initial press
release as described in Section&nbsp;4.4, such Purchaser will maintain the confidentiality of the existence and terms of this transaction and the information included in the Disclosure Schedules (other than as disclosed to its legal and other
representatives).&nbsp;Notwithstanding the foregoing, and notwithstanding anything contained in this Agreement to the contrary, the Company expressly acknowledges and agrees that (i)&nbsp;no Purchaser makes any representation, warranty or covenant
hereby that it will not engage in effecting transactions in any securities of the Company after the time that the transactions contemplated by this Agreement are first publicly announced pursuant to the initial press release as described in
Section&nbsp;4.4, (ii) no Purchaser shall be restricted or prohibited from effecting any transactions in any securities of the Company in accordance with applicable securities laws from and after the time that the transactions contemplated by this
Agreement are first publicly announced pursuant to the initial press release as described in Section&nbsp;4.4 and (iii)&nbsp;no Purchaser shall have any duty of confidentiality or duty not to trade in the securities of the Company to the Company,
any of its Subsidiaries, or any of their respective officers, directors, employees, Affiliates or agent, after the issuance of the initial press release as described in Section&nbsp;4.4.&nbsp;Notwithstanding the foregoing, in the case of a Purchaser
that is a multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Purchaser&#146;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers
managing other portions of such Purchaser&#146;s assets, the covenant set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by
this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.15 <U>Capital Changes</U>. Until the one year anniversary of the Closing Date, the Company shall not undertake a
reverse or forward stock split or reclassification of the Common Stock without the prior written consent of the Purchasers holding a majority in interest of the Shares other than a reverse stock split that is required, in the good faith
determination of the Board of Directors, to maintain the listing of the Common Stock on the Trading Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.16 <U>Exercise
Procedures</U>. The form of Notice of Exercise included in the Warrants set forth the totality of the procedures required of the Purchasers in order to exercise the Warrants. No additional legal opinion, other information or instructions shall be
required of the Purchasers to exercise their Warrants. Without limiting the preceding sentences, no <FONT STYLE="white-space:nowrap">ink-original</FONT> Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of
guarantee or notarization) of any Notice of Exercise form be required in order to exercise the Warrants. The Company shall honor exercises of the Warrants and shall deliver Warrant Shares in accordance with the terms, conditions and time periods set
forth in the Transaction Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.17 <U>Form D; Blue Sky Filings</U>. If applicable, the Company agrees to timely file a Form D with
respect to the Common Warrant and Common Warrant Shares as required under Regulation D and to provide a copy thereof, promptly upon request of any Purchaser. The Company shall take such action as the Company shall reasonably determine is necessary
in order to obtain an exemption for, or to qualify the Common Warrant and Common Warrant Shares for, sale to the Purchasers at the Closing under applicable securities or &#147;Blue Sky&#148; laws of the states of the United States, and shall provide
evidence of such actions promptly upon request of any Purchaser. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE V. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">MISCELLANEOUS </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.1
<U>Termination</U>.&nbsp;This Agreement may be terminated by any Purchaser, as to such Purchaser&#146;s obligations hereunder only and without any effect whatsoever on the obligations between the Company and the other Purchasers, by written notice
to the other parties, if the Closing has not been consummated on or before the fifth (5<SUP STYLE="font-size:75%; vertical-align:top">th</SUP>) Trading Day following the date hereof; <U>provided</U>, <U>however</U>, that no such termination will
affect the right of any party to sue for any breach by any other party (or parties). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.2 <U>Fees and Expenses</U>. Except as expressly
set forth in the Transaction Documents to the contrary, each party shall pay the fees and expenses of its advisers, counsel, accountants and other experts, if any, and all other expenses incurred by such party incident to the negotiation,
preparation, execution, delivery and performance of this Agreement. The Company shall pay all Transfer Agent fees (including, without limitation, any fees required for <FONT STYLE="white-space:nowrap">same-day</FONT> processing of any instruction
letter delivered by the Company and any exercise notice delivered by a Purchaser), stamp taxes and other taxes and duties levied in connection with the delivery of any Securities to the Purchasers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.3 <U>Entire Agreement</U>. The Transaction Documents, together with the exhibits and schedules thereto, contain the entire understanding of
the parties with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, oral or written, with respect to such matters, which the parties acknowledge have been merged into such documents, exhibits and
schedules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.4 <U>Notices</U>. Any and all notices or other communications or deliveries required or permitted to be provided hereunder
shall be in writing and shall be deemed given and effective on the earliest of: (a)&nbsp;the time of transmission, if such notice or communication is delivered via email attachment at the email address as set forth on the signature pages attached
hereto at or prior to 5:30 p.m. (New York City time) on a Trading Day, (b)&nbsp;the next Trading Day after the time of transmission, if such notice or communication is delivered via email attachment at the email address as set forth on the signature
pages attached hereto on a day that is not a Trading Day or later than 5:30 p.m. (New York City time) on any Trading Day, (c)&nbsp;the second (2<SUP STYLE="font-size:75%; vertical-align:top">nd</SUP>) Trading Day following the date of mailing, if
sent by U.S. nationally recognized overnight courier service or (d)&nbsp;upon actual receipt by the party to whom such notice is required to be given. The address for such notices and communications shall be as set forth on the signature pages
attached hereto. To the extent that any notice provided pursuant to any Transaction Document constitutes, or contains, material, <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company or any Subsidiaries, the Company
shall simultaneously file such notice with the Commission pursuant to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.5 <U>Amendments; Waivers</U>. No provision of this Agreement may be waived, modified, supplemented or amended except in a written instrument
signed, in the case of an amendment, by the Company and Purchasers which purchased at least 50.1% in interest of the Shares based on the initial Subscription Amounts hereunder (or, prior to the Closing, the Company and each Purchaser) or, in the
case of a waiver, by the party against whom enforcement of any such waived provision is sought, provided that if any amendment, modification or waiver disproportionately and adversely impacts a Purchaser (or group of Purchasers), the consent of at
least 50.1% in interest of such disproportionately impacted Purchaser (or group of Purchasers) shall also be required. No waiver of any default with respect to any provision, condition or requirement of this Agreement shall be deemed to be a
continuing waiver in the future or a waiver of any subsequent default or a waiver of any other provision, condition or requirement hereof, nor shall any delay or omission of any party to exercise any right hereunder in any manner impair the exercise
of any such right. Any proposed amendment or waiver that disproportionately, materially and adversely affects the rights and obligations of any Purchaser relative to the comparable rights and obligations of the other Purchasers shall require the
prior written consent of such adversely affected Purchaser. Any amendment effected in accordance with this Section&nbsp;5.5 shall be binding upon each Purchaser and holder of Securities and the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.6 <U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Agreement and shall not be deemed to limit
or affect any of the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.7 <U>Successors and Assigns</U>. This Agreement shall be binding upon and inure to the benefit
of the parties and their successors and permitted assigns. The Company may not assign this Agreement or any rights or obligations hereunder without the prior written consent of each Purchaser (other than by merger). Any Purchaser may assign any or
all of its rights under this Agreement to any Person to whom such Purchaser assigns or transfers any Securities, provided that such transferee agrees in writing to be bound, with respect to the transferred Securities, by the provisions of the
Transaction Documents that apply to the &#147;Purchasers.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.8 <U>No Third-Party Beneficiaries</U>. This Agreement is intended for the benefit of the
parties hereto and their respective successors and permitted assigns and is not for the benefit of, nor may any provision hereof be enforced by, any other Person, except as otherwise set forth in Section&nbsp;4.8 and this Section&nbsp;5.8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.9 <U>Governing Law</U>. All questions concerning the construction, validity, enforcement and interpretation of the Transaction Documents
shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal Proceedings concerning the interpretations,
enforcement and defense of the transactions contemplated by this Agreement and any other Transaction Documents (whether brought against a party hereto or its respective affiliates, directors, officers, shareholders, partners, members, employees or
agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of
Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein (including with respect to the enforcement of any of the Transaction Documents), and hereby irrevocably
waives, and agrees not to assert in any Action or Proceeding, any claim that it is not personally subject to the jurisdiction of any such court, that such Action or Proceeding is improper or is an inconvenient venue for such Proceeding. Each party
hereby irrevocably waives personal service of process and consents to process being served in any such Action or Proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at
the address in effect for notices to it under this Agreement and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve
process in any other manner permitted by law.&#8195;If any party shall commence an Action or Proceeding to enforce any provisions of the Transaction Documents, then, in addition to the obligations of the Company under Section&nbsp;4.8, the
prevailing party in such Action or Proceeding shall be reimbursed by the <FONT STYLE="white-space:nowrap">non-prevailing</FONT> party for its reasonable attorneys&#146; fees and other costs and expenses incurred with the investigation, preparation
and prosecution of such Action or Proceeding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.10 <U>Survival</U>. The representations and warranties contained herein shall survive the
Closing and the delivery of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.11 <U>Execution</U>. This Agreement may be executed in two or more counterparts, all of
which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to each other party, it being understood that the parties need not sign the same
counterpart. In the event that any signature is delivered by <FONT STYLE="white-space:nowrap">e-mail</FONT> delivery (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the
Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method, such signature shall be deemed to have been duly and validly delivered and shall create a valid and binding obligation of the party
executing (or on whose behalf such signature is executed) with the same force and effect as if such &#147;.pdf&#148; signature page were an original thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.12 <U>Severability</U>. If any term, provision, covenant or restriction of this Agreement is held by a court of competent jurisdiction to be
invalid, illegal, void or unenforceable, the remainder of the terms, provisions, covenants and restrictions set forth herein shall remain in full force and effect and shall in no way be affected, impaired or invalidated, and the parties hereto shall
use their commercially reasonable efforts to find and employ an alternative means to achieve the same or substantially the same result as that contemplated by such term, provision, covenant or restriction. It is hereby stipulated and declared to be
the intention of the parties that they would have executed the remaining terms, provisions, covenants and restrictions without including any of such that may be hereafter declared invalid, illegal, void or unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.13 <U>Rescission and Withdrawal Right</U>. Notwithstanding anything to the contrary contained in (and without limiting any similar
provisions of) any of the other Transaction Documents, whenever any Purchaser exercises a right, election, demand or option under a Transaction Document and the Company does not timely perform its related obligations within the periods therein
provided, then such Purchaser may rescind or withdraw, in its sole discretion from time to time upon written notice to the Company, any relevant notice, demand or election in whole or in part without prejudice to its future actions and rights;
<U>provided</U>, <U>however</U>, that in the case of a rescission of an exercise of a Warrant, the applicable Purchaser shall be required to return any shares of Common Stock subject to any such rescinded exercise notice concurrently with the return
to such Purchaser of the aggregate exercise price paid to the Company for such shares and the restoration of such Purchaser&#146;s right to acquire such shares pursuant to such Purchaser&#146;s Warrant (including, issuance of a replacement warrant
certificate evidencing such restored right). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.14 <U>Replacement of Securities</U>. If any certificate or instrument evidencing any
Securities is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation thereof (in the case of mutilation), or in lieu of and substitution therefor, a new certificate
or instrument, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft or destruction. The applicant for a new certificate or instrument under such circumstances shall also pay any reasonable third-party costs
(including customary indemnity) associated with the issuance of such replacement Securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.15 <U>Remedies</U>. In addition to being entitled to exercise all rights provided herein
or granted by law, including recovery of damages, each of the Purchasers and the Company will be entitled to specific performance under the Transaction Documents. The parties agree that monetary damages may not be adequate compensation for any loss
incurred by reason of any breach of obligations contained in the Transaction Documents and hereby agree to waive and not to assert in any Action for specific performance of any such obligation the defense that a remedy at law would be adequate. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.16 <U>Payment Set Aside</U>. To the extent that the Company makes a payment or payments to any Purchaser pursuant to any Transaction
Document or a Purchaser enforces or exercises its rights thereunder, and such payment or payments or the proceeds of such enforcement or exercise or any part thereof are subsequently invalidated, declared to be fraudulent or preferential, set aside,
recovered from, disgorged by or are required to be refunded, repaid or otherwise restored to the Company, a trustee, receiver or any other Person under any law (including, without limitation, any bankruptcy law, state or federal law, common law or
equitable cause of action), then to the extent of any such restoration the obligation or part thereof originally intended to be satisfied shall be revived and continued in full force and effect as if such payment had not been made or such
enforcement or setoff had not occurred. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.17 <U>Independent Nature of Purchasers&#146; Obligations and Rights</U>. The obligations of
each Purchaser under any Transaction Document are several and not joint with the obligations of any other Purchaser, and no Purchaser shall be responsible in any way for the performance or <FONT STYLE="white-space:nowrap">non-performance</FONT> of
the obligations of any other Purchaser under any Transaction Document. Nothing contained herein or in any other Transaction Document, and no action taken by any Purchaser pursuant hereto or thereto, shall be deemed to constitute the Purchasers as a
partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Purchasers are in any way acting in concert or as a group with respect to such obligations or the transactions contemplated by the Transaction
Documents. Each Purchaser shall be entitled to independently protect and enforce its rights including, without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any
other Purchaser to be joined as an additional party in any Proceeding for such purpose. Each Purchaser has been represented by its own separate legal counsel in its review and negotiation of the Transaction Documents. The Company has elected to
provide all Purchasers with the same terms and Transaction Documents for the convenience of the Company and not because it was required or requested to do so by any of the Purchasers. It is expressly understood and agreed that each provision
contained in this Agreement and in each other Transaction Document is between the Company and a Purchaser, solely, and not between the Company and the Purchasers collectively and not between and among the Purchasers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.18 <U>Liquidated Damages</U>. The Company&#146;s obligations to pay any partial liquidated damages or other amounts owing under the
Transaction Documents is a continuing obligation of the Company and shall not terminate until all unpaid partial liquidated damages and other amounts have been paid notwithstanding the fact that the instrument or security pursuant to which such
partial liquidated damages or other amounts are due and payable shall have been canceled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.19 <U>Saturdays, Sundays, Holidays, etc.</U>
If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Business Day, then such action may be taken or such right may be exercised on the next succeeding Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.20 <U>Construction</U>. The parties agree that each of them and/or their respective counsel have reviewed and had an opportunity to revise
the Transaction Documents and, therefore, the normal rule of construction to the effect that any ambiguities are to be resolved against the drafting party shall not be employed in the interpretation of the Transaction Documents or any amendments
thereto. In addition, each and every reference to share prices and shares of Common Stock in any Transaction Document shall be subject to adjustment for reverse and forward stock splits, stock dividends, stock combinations and other similar
transactions of the Common Stock that occur after the date of this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.21 <B><U>WAIVER OF JURY TRIAL</U></B><B>. </B><B><U>IN
ANY ACTION, SUIT, OR PROCEEDING IN ANY JURISDICTION BROUGHT BY ANY PARTY AGAINST ANY OTHER PARTY, THE PARTIES EACH KNOWINGLY AND INTENTIONALLY, TO THE GREATEST EXTENT PERMITTED BY APPLICABLE LAW, HEREBY ABSOLUTELY, UNCONDITIONALLY, IRREVOCABLY AND
EXPRESSLY WAIVES FOREVER TRIAL BY JURY. </U></B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Pages Follow) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have caused this Securities Purchase Agreement to be
duly executed by their respective authorized signatories as of the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MAIA BIOTECHNOLOGY, INC. </B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><U>Address for Notice:</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><FONT STYLE="white-space:nowrap">E-Mail:</FONT></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With a copy to (which shall not constitute notice): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sheppard Mullin Richter&nbsp;&amp; Hampton LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">30 Rockefeller
Plaza </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New York, NY 10112 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Attn: Richard Friedman, Esq.
(rafriedman@sheppardmullin.com) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">SIGNATURE PAGE FOR PURCHASER FOLLOWS] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[PURCHASER SIGNATURE PAGES TO MAIA SECURITIES PURCHASE AGREEMENT] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the undersigned have caused this Securities Purchase Agreement to be duly executed by their respective authorized
signatories as of the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Purchaser: ______________________________________________________</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Signature of Authorized Signatory of Purchaser: _________________________________</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Authorized Signatory: _______________________________________________</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title of Authorized Signatory:</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email Address of Authorized Signatory:_________________________________________</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Director of the Company &#9744; Yes or &#9744; No</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Address for Notice to Purchaser:</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Address for Delivery of Warrants to Purchaser (if not same as address for notice): </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subscription Amount: $_________________ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares:
_________________ </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Warrant Shares: __________________ Beneficial Ownership Blocker &#9744; 4.99% or &#9744; 9.99% (for
<FONT STYLE="white-space:nowrap">non-Directors)</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EIN Number: ____________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#9744; Notwithstanding anything contained in this Agreement to the contrary, by checking this box (i)&nbsp;the obligations of the above-signed to purchase
the securities set forth in this Agreement to be purchased from the Company by the above-signed, and the obligations of the Company to sell such securities to the above-signed, shall be unconditional and all conditions to Closing shall be
disregarded, (ii)&nbsp;the Closing shall occur by the second (2nd) Trading Day following the date of this Agreement and (iii)&nbsp;any condition to Closing contemplated by this Agreement (but prior to being disregarded by clause (i)&nbsp;above) that
required delivery by the Company or the above-signed of any agreement, instrument, certificate or the like or purchase price (as applicable) shall no longer be a condition and shall instead be an unconditional obligation of the Company or the
above-signed (as applicable) to deliver such agreement, instrument, certificate or the like or purchase price (as applicable) to such other party on the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[SIGNATURE PAGES CONTINUE] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Exhibit <FONT STYLE="white-space:nowrap">A-1</FONT> </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form of Warrant <FONT STYLE="white-space:nowrap">(non-affiliated</FONT> purchasers) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See attached </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH
THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;SECURITIES ACT&#148;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR
SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK PURCHASE WARRANT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MAIA BIOTECHNOLOGY, INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Warrant Shares: _______</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Issue Date:______, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initial Exercise Date: _______, 2024<SUP STYLE="font-size:75%; vertical-align:top">1</SUP></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">THIS COMMON STOCK PURCHASE WARRANT (the &#147;<U>Warrant</U>&#148;) certifies that, for value received,
_____________ or its assigns (the &#147;<U>Holder</U>&#148;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the &#147;<U>Initial
Exercise Date</U>&#148;) and on or prior to 5:00 p.m. (New York City time) on ______________<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> (the &#147;<U>Termination Date</U>&#148;) but not thereafter, to subscribe for and purchase from MAIA
Biotechnology, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), up to ______ shares (as subject to adjustment hereunder, the &#147;<U>Warrant Shares</U>&#148;) of the Company&#146;s Common Stock. The purchase price of one share of
Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2(b). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set
forth in that certain Securities Purchase Agreement (the &#147;<U>Purchase Agreement</U>&#148;), dated _______, 2024, among the Company and the purchasers signatory thereto. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Insert the date that is the six (6)&nbsp;months anniversary of the Issue Date </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Insert the date that is the 5.5 year anniversary of the Issue Date, provided that, if such date is not a
Trading Day, insert the immediately following Trading Day. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;2</U>. <U>Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Exercise of Warrant</U>. Subject to Section&nbsp;2(e) herein, exercise of the purchase rights represented by this Warrant
may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by <FONT STYLE="white-space:nowrap">e-mail</FONT> (or
<FONT STYLE="white-space:nowrap">e-mail</FONT> attachment) of the Notice of Exercise in the form annexed hereto (the &#147;<U>Notice of Exercise</U>&#148;). Within the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading
Days comprising the Standard Settlement Period (as defined in Section&nbsp;2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice
of Exercise by wire transfer or cashier&#146;s check drawn on a United States bank unless the cashless exercise procedure specified in Section&nbsp;2(c) below is specified in the applicable Notice of Exercise.<B> </B>No <FONT
STYLE="white-space:nowrap">ink-original</FONT> Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the
contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation within three (3)&nbsp;Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company
shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1)&nbsp;Trading Day of receipt of such notice. <B>The Holder and any
assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at
any given time may be less than the amount stated on the face hereof.</B> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Exercise Price</U>. The exercise price per
share of Common Stock under this Warrant shall be <B>$</B>_____, subject to adjustment hereunder (the &#147;<U>Exercise Price</U>&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Cashless Exercise</U>. If at the time of exercise hereof there is no
effective registration statement registering, or the prospectus contained therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in part, at such time by means of a
&#147;cashless exercise&#148; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing <FONT STYLE="white-space:nowrap">[(A-B)</FONT> (X)] by (A), where: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)&#8201;=</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as applicable: (i)&nbsp;the VWAP on the Trading Day immediately preceding the date of the applicable Notice of
Exercise if such Notice of Exercise is (1)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a) hereof on a day that is not a Trading Day or (2)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a) hereof on a Trading Day prior
to the opening of &#147;regular trading hours&#148; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;the VWAP on the Trading Day immediately preceding the date of the
applicable Notice of Exercise if such Notice of Exercise is executed during &#147;regular trading hours&#148; on a Trading Day and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after the close of &#147;regular
trading hours&#148; on a Trading Day) pursuant to Section&nbsp;2(a) hereof or (iii)&nbsp;the VWAP on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed
and delivered pursuant to Section&nbsp;2(a) hereof after the close of &#147;regular trading hours&#148; on such Trading Day; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)&#8201;=</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Exercise Price of this Warrant, as adjusted hereunder; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(X)&#8201;=</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms
of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Bid Price</U>&#148; means, for any date, the price determined by the first of the following clauses that applies:
(a)&nbsp;if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as
reported by Bloomberg L.P. (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp;if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or
the nearest preceding date) on OTCQB or OTCQX as applicable, or (c)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in
interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>VWAP</U>&#148; means, for any date, the price determined by the first of the following clauses that applies:
(a)&nbsp;if the Common Stock is then listed or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or
quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if the OTCQB Venture Market (&#147;<U>OTCQB</U>&#148;) or the OTCQX Best Market (&#147;<U>OTCQX</U>&#148;) is not a
Trading Market, the volume weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, or (c)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an
independent appraiser selected in good faith by the Holders of a majority in interest of the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with
Section&nbsp;3(a)(9) of the Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&nbsp;The Company agrees not to take any position contrary to this Section&nbsp;2(c). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Mechanics of Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i. <U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be
transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#147;<U>DWAC</U>&#148;) if
the Company is then a participant in such system and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B)&nbsp;the Warrant Shares are
eligible for resale by the Holder without volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by
physical delivery of a certificate, registered in the Company&#146;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the
Holder in the Notice of Exercise by the date that is the earliest of (i)&nbsp;two (2)&nbsp;Trading Days after the delivery to the Company of the Notice of Exercise, (ii)&nbsp;one (1)&nbsp;Trading Day after delivery of the aggregate Exercise Price to
the Company and (iii)&nbsp;the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#147;<U>Warrant Share Delivery Date</U>&#148;). Upon delivery of the Notice
of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than
in the case of a cashless exercise) is received by the Warrant Share Delivery Date. If the Company fails for any reason to deliver to the Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall
pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day
(increasing to $20 per Trading Day on the third (3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP>) Trading Day after the Warrant Share Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are
delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &#147;<U>Standard Settlement
Period</U>&#148; means the standard settlement period, expressed in a number of Trading Days, on the Company&#146;s primary Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ii. <U>Delivery of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at
the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by
this Warrant, which new Warrant shall in all other respects be identical with this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section&nbsp;2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">iv. <U>Compensation for <FONT STYLE="white-space:nowrap">Buy-In</FONT> on Failure to Timely Deliver Warrant Shares Upon
Exercise</U>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;2(d)(i) above pursuant to an
exercise on or before the Warrant Share Delivery Date (other than any such failure that is solely due to any action or inaction by the Holder with respect to such exercise), and if after such date the Holder is required by its broker to purchase (in
an open market transaction or otherwise) or the Holder&#146;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &#147;<U><FONT STYLE="white-space:nowrap">Buy-In</FONT></U>&#148;), then the Company shall (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&#146;s total purchase price (including brokerage commissions,
if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying (1)&nbsp;the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times
(2)&nbsp;the price at which the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.
For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a <FONT STYLE="white-space:nowrap">Buy-In</FONT> with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving
rise to such purchase obligation of $10,000, under clause (A)&nbsp;of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to
the Holder in respect of the <FONT STYLE="white-space:nowrap">Buy-In</FONT> and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#146;s right to pursue any other remedies available to it
hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required
pursuant to the terms hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">v. <U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing
fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in
respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">vi. <U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or
transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as
may be directed by the Holder; <U>provided</U>, <U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment
Form attached hereto duly executed by the Holder and the Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for
<FONT STYLE="white-space:nowrap">same-day</FONT> processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for
<FONT STYLE="white-space:nowrap">same-day</FONT> electronic delivery of the Warrant Shares. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">vii. <U>Closing of Books</U>. The Company will not close its stockholder
books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e)
<U>Holder&#146;s Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this Warrant, pursuant to Section&nbsp;2 or otherwise, to the extent that after
giving effect to such issuance after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&#146;s Affiliates, and any other Persons acting as a group together with the Holder or any of the Holder&#146;s
Affiliates (such Persons, &#147;<U>Attribution Parties</U>&#148;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined below).&nbsp;For purposes of the foregoing sentence, the number of shares of Common Stock
beneficially owned by the Holder and its Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the
number of shares of Common Stock which would be issuable upon (i)&nbsp;exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates or Attribution Parties and (ii)&nbsp;exercise or
conversion of the unexercised or nonconverted portion of any other securities of the Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise analogous to the limitation contained
herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.&nbsp;Except as set forth in the preceding sentence, for purposes of this Section&nbsp;2(e), beneficial ownership shall be calculated in accordance with
Section&nbsp;13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is in compliance with Section&nbsp;13(d) of the
Exchange Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith.&#8195;To the extent that the limitation contained in this Section&nbsp;2(e) applies, the determination of whether this Warrant is
exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice
of Exercise shall be deemed to be the Holder&#146;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant
is exercisable, in each case subject to the Beneficial Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.&#8195;In addition, a determination as to any group status as contemplated
above shall be determined in accordance with Section&nbsp;13(d) of the Exchange Act and the rules and regulations promulgated thereunder. For purposes of this Section&nbsp;2(e), in determining the number of outstanding shares of Common Stock, a
Holder may rely on the number of outstanding shares of Common Stock as reflected in (A)&nbsp;the Company&#146;s most recent periodic or annual report filed with the Commission, as the case may be, (B)&nbsp;a more recent public announcement by the
Company or (C)&nbsp;a more recent written notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding.&nbsp;Upon the written or oral request of a Holder, the Company shall within one (1)&nbsp;Trading
Day confirm orally and in writing to the Holder the number of shares of Common Stock then outstanding.&nbsp;In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion or exercise of
securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the date as of which such number of outstanding shares of Common Stock was reported. The &#147;<U>Beneficial Ownership
Limitation</U>&#148; shall be [4.99%/9.99%] of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the
Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section&nbsp;2(e), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding
immediately after giving effect to the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section&nbsp;2(e) shall continue to apply. Any increase in the Beneficial Ownership Limitation will
not be effective until the 61<SUP STYLE="font-size:75%; vertical-align:top">st</SUP> day after such notice is delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict
conformity with the terms of this Section&nbsp;2(e) to correct this paragraph (or any portion hereof) which may be defective or inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements
necessary or desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder of this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;3</U>. <U>Certain Adjustments</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock
dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common
Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way of reverse stock split) outstanding shares of Common Stock into a
smaller number of shares, or (iv)&nbsp;issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the
number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a) shall become effective immediately
after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or
<FONT STYLE="white-space:nowrap">re-classification.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Subsequent Rights Offerings</U>. In addition to any adjustments
pursuant to Section&nbsp;3(a) above, if at any time the Company grants, issues or sells any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares of Common
Stock (the &#147;<U>Purchase Rights</U>&#148;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number of
shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken
for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>,
<U>however</U>, that to the extent that the Holder&#146;s right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such Purchase
Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until such time, if ever, as its right
thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Pro Rata Distributions</U>.
During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise
(including, without limitation, any distribution of cash, stock or other securities, property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a
&#147;<U>Distribution</U>&#148;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the
Holder had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the
date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (<U>provided</U>,
<U>however</U>, that to the extent that the Holder&#146;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder shall not be entitled to participate in such
Distribution to such extent (or in the beneficial ownership of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time,
if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d)
<U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company, directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person,
(ii)&nbsp;the Company (or any Subsidiary), directly or indirectly, effects any sale, lease, license, assignment, transfer, conveyance or other disposition of all or substantially all of the assets of the Company in one or a series of related
transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares
for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock or 50% or more of the voting power of the common equity of the Company, (iv)&nbsp;the Company, directly or indirectly, in one
or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities,
cash or property, or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">spin-off,</FONT> merger or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock or more than 50% of the voting
power of the common equity of the Company (each a &#147;<U>Fundamental Transaction</U>&#148;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon
such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section&nbsp;2(e) on the exercise of this Warrant), the number of shares of Common Stock of the
successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#147;<U>Alternate Consideration</U>&#148;) receivable as a result of such Fundamental Transaction by a holder of the
number of shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to any limitation in Section&nbsp;2(e) on the exercise of this Warrant). For purposes of any such exercise, the
determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the
Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice as to the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this
Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity (as defined below) shall, at the Holder&#146;s option, exercisable at any time
concurrently with, or within 30 days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder
an amount of cash equal to the Black Scholes Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental Transaction; provided, however, that, if the Fundamental Transaction is
not within the Company&#146;s control, including not approved by the Company&#146;s Board of Directors, the Holder shall only be entitled to receive from the Company or any Successor Entity the same type or form of consideration (and in the same
proportion), at the Black Scholes Value of the unexercised portion of this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental Transaction, whether that consideration be in the
form of cash, stock or any combination thereof, or whether the holders of Common Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction; provided, further, that if holders
of Common Stock of the Company are not offered or paid any consideration in such Fundamental Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Entity may be the Company following
such Fundamental Transaction) in such Fundamental Transaction. &#147;<U>Black Scholes Value</U>&#148; means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &#147;OV&#148; function on Bloomberg determined
as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (A)&nbsp;a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public
announcement of the applicable contemplated Fundamental Transaction and the Termination Date, (B)&nbsp;an expected volatility equal to the greater of (1)&nbsp;the 30 day volatility, (2)&nbsp;the 100 day volatility or (3)&nbsp;the 365 day volatility,
each of clauses (1)-(3) as obtained from the HVT function on Bloomberg (determined utilizing a 365 day annualization factor) as of the Trading Day immediately following the public announcement of the applicable contemplated Fundamental Transaction,
(C)&nbsp;the underlying price per share used in such calculation shall be the highest VWAP during the period beginning on the Trading Day immediately preceding the public announcement of the applicable contemplated Fundamental Transaction (or the
consummation of the applicable Fundamental Transaction, if earlier) and ending on the Trading Day of the Holder&#146;s request pursuant to this Section&nbsp;3(d) and (D)&nbsp;a remaining option time equal to the time between the date of the public
announcement of the applicable contemplated Fundamental Transaction and the Termination Date and (E)&nbsp;a zero cost of borrow. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such other
consideration) within the later of (i)&nbsp;five Business Days of the Holder&#146;s election and (ii)&nbsp;the date of consummation of the Fundamental Transaction. The Company shall cause any successor entity in a Fundamental Transaction in which
the Company is not the survivor (the &#147;Successor Entity&#148;) to assume in writing all of the obligations of the Company under this Warrant and the other Transaction Documents in accordance with the provisions of this Section&nbsp;3(d) pursuant
to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder (without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange
for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or
its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise price
which applies the exercise price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number
of shares of capital stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and
substance to the Holder. Upon the occurrence of any such Fundamental Transaction, the Successor Entity shall be added to the term &#147;Company&#148; under this Warrant (so that from and after the occurrence or consummation of such Fundamental
Transaction, each and every provision of this Warrant and the other Transaction Documents referring to the &#147;Company&#148; shall refer instead to each of the Company and the Successor Entity or Successor Entities, jointly and severally), and the
Successor Entity or Successor Entities, jointly and severally with the Company, may exercise every right and power of the Company prior thereto and the Successor Entity or Successor Entities shall assume all of the obligations of the Company prior
thereto under this Warrant and the other Transaction Documents with the same effect as if the Company and such Successor Entity or Successor Entities, jointly and severally, had been named as the Company herein. For the avoidance of doubt, the
Holder shall be entitled to the benefits of the provisions of this Section&nbsp;3(d) regardless of (i)&nbsp;whether the Company has sufficient authorized shares of Common Stock for the issuance of Warrant Shares and/or (ii)&nbsp;whether a
Fundamental Transaction occurs prior to the Initial Exercise Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Calculations</U>. All calculations under this
Section&nbsp;3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum
of the number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <U>Notice to Holder</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i. <U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this
Section&nbsp;3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts
requiring such adjustment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ii. <U>Notice to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a
dividend (or any other distribution in whatever form) on the Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the Company shall authorize the granting to all
holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email
to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days prior to the applicable record or effective date hereinafter specified, a notice (unless such information is filed with
the Commission, in which case a notice shall not be required) stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date on which such reclassification, consolidation, merger, sale, transfer or
share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property
deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action
required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company or any of the Subsidiaries, the
Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of
such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;4</U>. <U>Transfer of Warrant</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in
Section&nbsp;4(d) hereof and to the provisions of Section&nbsp;4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of
this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to
pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the
denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three
(3)&nbsp;Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant
Shares without having a new Warrant issued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>New Warrants</U>. This Warrant may be divided or combined with other
Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to
compliance with Section&nbsp;4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that
purpose (the &#147;<U>Warrant Register</U>&#148;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or
any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Transfer Restrictions</U>. If, at the time of the surrender of this
Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i)&nbsp;registered pursuant to an effective registration statement under the Securities Act and under applicable state securities or blue sky
laws or (ii)&nbsp;eligible for resale without volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions or current public information requirements pursuant to Rule 144, the Company may
require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section&nbsp;5.7 of the Purchase Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this
Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of the Securities
Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;5</U>. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any
voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive Warrant
Shares on a &#147;cashless exercise&#148; pursuant to Section&nbsp;2(c) or to receive cash payments pursuant to Section&nbsp;2(d)(i) and Section&nbsp;2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this
Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the
Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably
satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock
certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised
on the next succeeding Trading Day. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Authorized Shares</U>. The Company covenants that, during the period the Warrant
is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants
that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such
reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed.
The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in
accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring
contemporaneously with such issue). Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization,
transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist
in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order
that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public
regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant. Before taking any action which would result in an adjustment in the number of Warrant Shares for which this
Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant
shall be determined in accordance with the provisions of the Purchase Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <U>Restrictions</U>. The Holder
acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <U>Nonwaiver and Expenses</U>. No course of dealing or any delay or
failure to exercise any right hereunder on the part of Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#146;s rights, powers or remedies, notwithstanding the fact that the right to exercise this Warrant terminates on
the Termination Date. Without limiting any other provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the
Holder such amounts as shall be sufficient to cover any costs and expenses including, but not limited to, reasonable attorneys&#146; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto
or in otherwise enforcing any of its rights, powers or remedies hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <U>Notices</U>. Any notice, request or other
document required or permitted to be given or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this
Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such
liability is asserted by the Company or by creditors of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">j) <U>Remedies</U>. The Holder, in addition to being
entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">k) <U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced
hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from
time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">l) <U>Amendment</U>. This
Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">m) <U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be
effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the
remainder of such provisions or the remaining provisions of this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">n) <U>Headings</U>. The headings used in this
Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">********************
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Page Follows) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer
thereunto duly authorized as of the date first above indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MAIA BIOTECHNOLOGY, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXERCISE </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">TO:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>MAIA BIOTECHNOLOGY, INC.</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) The undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if
exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2)
Payment shall take the form of (check applicable box): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">[&#8195;] in lawful money of the United States; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">[&#8195;] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in
subsection 2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">______________________________________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrant Shares shall be delivered to the following DWAC Account Number: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">______________________________________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">______________________________________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">______________________________________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(4) <U>Accredited Investor</U>. The undersigned is an &#147;accredited investor&#148; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[SIGNATURE OF HOLDER] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name&nbsp;of&nbsp;Investing&nbsp;Entity:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8201;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Signature&nbsp;of&nbsp;Authorized&nbsp;Signatory&nbsp;of&nbsp;Investing&nbsp;Entity:</I>
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name&nbsp;of&nbsp;Authorized&nbsp;Signatory:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title&nbsp;of&nbsp;Authorized&nbsp;Signatory:
&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;&#8195;
</U></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ASSIGNMENT FORM </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.) </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(Please Print)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(Please Print)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Phone Number:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> <U>&#8195;</U>, <U>&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder&#146;s Signature: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8199;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder&#146;s Address: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Exhibit <FONT STYLE="white-space:nowrap">A-2</FONT> </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form of Warrant (Director Purchasers) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>See attached </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH
THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;SECURITIES ACT&#148;), AND, ACCORDINGLY, MAY NOT BE OFFERED OR
SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH
APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMMON STOCK PURCHASE WARRANT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MAIA BIOTECHNOLOGY, INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Warrant Shares: _______</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Issue Date:______, 2024</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Initial Exercise Date: _______, 2024<SUP STYLE="font-size:75%; vertical-align:top">1</SUP></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">THIS COMMON STOCK PURCHASE WARRANT (the &#147;<U>Warrant</U>&#148;) certifies that, for value received,
_____________ or its assigns (the &#147;<U>Holder</U>&#148;) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above (the &#147;<U>Initial
Exercise Date</U>&#148;) and on or prior to 5:00 p.m. (New York City time) on ______________<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> (the &#147;<U>Termination Date</U>&#148;) but not thereafter, to subscribe for and purchase from MAIA
Biotechnology, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), up to ______ shares (as subject to adjustment hereunder, the &#147;<U>Warrant Shares</U>&#148;) of the Company&#146;s Common Stock. The purchase price of one share of
Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section&nbsp;2(b). This Warrant shall be deemed an Award of Option (as such terms are defined in the Plan) under the Company&#146;s 2021 Equity Incentive Plan (the
&#147;Plan&#147;) and shall be deemed granted thereunder and any Warrant Shares issued hereunder shall be deemed issued under the Plan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;1</U>. <U>Definitions</U>. Capitalized terms used and not otherwise defined herein shall have the meanings set
forth in that certain Securities Purchase Agreement (the &#147;<U>Purchase Agreement</U>&#148;), dated _______, 2024, among the Company and the purchasers signatory thereto. </P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">1</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Insert the date that is the six (6)&nbsp;months anniversary of the Issue Date </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><SUP STYLE="font-size:75%; vertical-align:top">2</SUP>&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Insert the date that is the 5.5 year anniversary of the Issue Date, provided that, if such date is not a
Trading Day, insert the immediately following Trading Day. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;2</U>. <U>Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Exercise of Warrant</U>. Subject to Section&nbsp;2(e) herein, exercise of the purchase rights represented by this Warrant
may be made, in whole or in part, at any time or times on or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed PDF copy submitted by <FONT STYLE="white-space:nowrap">e-mail</FONT> (or
<FONT STYLE="white-space:nowrap">e-mail</FONT> attachment) of the Notice of Exercise in the form annexed hereto (the &#147;<U>Notice of Exercise</U>&#148;). Within the earlier of (i)&nbsp;two (2)&nbsp;Trading Days and (ii)&nbsp;the number of Trading
Days comprising the Standard Settlement Period (as defined in Section&nbsp;2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the Warrant Shares specified in the applicable Notice
of Exercise by wire transfer or cashier&#146;s check drawn on a United States bank unless the cashless exercise procedure specified in Section&nbsp;2(c) below is specified in the applicable Notice of Exercise.<B> </B>No <FONT
STYLE="white-space:nowrap">ink-original</FONT> Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of Exercise be required. Notwithstanding anything herein to the
contrary, the Holder shall not be required to physically surrender this Warrant to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full, in which case, the Holder shall
surrender this Warrant to the Company for cancellation within three (3)&nbsp;Trading Days of the date on which the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the effect of lowering the outstanding number of Warrant Shares purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company
shall maintain records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any Notice of Exercise within one (1)&nbsp;Trading Day of receipt of such notice. <B>The Holder and any
assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase hereunder at
any given time may be less than the amount stated on the face hereof.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Exercise Price</U>. The exercise price per share of Common Stock under
this Warrant shall be <B>$</B>_____, subject to adjustment hereunder (the &#147;<U>Exercise Price</U>&#148;). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c)
<U>Cashless Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained therein is not available for the resale of the Warrant Shares by the Holder, then this Warrant may also
be exercised, in whole or in part, at such time by means of a &#147;cashless exercise&#148; in which the Holder shall be entitled to receive a number of Warrant Shares equal to the quotient obtained by dividing
<FONT STYLE="white-space:nowrap">[(A-B)</FONT> (X)] by (A), where: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(A)&#8201;=</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">as applicable: (i)&nbsp;the Fair Market Value on the Trading Day immediately preceding the date of the
applicable Notice of Exercise if such Notice of Exercise is (1)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a) hereof on a day that is not a Trading Day or (2)&nbsp;both executed and delivered pursuant to Section&nbsp;2(a) hereof on
a Trading Day prior to the opening of &#147;regular trading hours&#148; (as defined in Rule 600(b) of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii)&nbsp;the Fair Market Value on the Trading Day immediately
preceding the date of the applicable Notice of Exercise if such Notice of Exercise is executed during &#147;regular trading hours&#148; on a Trading Day and is delivered within two (2)&nbsp;hours thereafter (including until two (2)&nbsp;hours after
the close of &#147;regular trading hours&#148; on a Trading Day) pursuant to Section&nbsp;2(a) hereof or (iii)&nbsp;the Fair Market Value on the date of the applicable Notice of Exercise if the date of such Notice of Exercise is a Trading Day and
such Notice of Exercise is both executed and delivered pursuant to Section&nbsp;2(a) hereof after the close of &#147;regular trading hours&#148; on such Trading Day; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(B)&#8201;=</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the Exercise Price of this Warrant, as adjusted hereunder; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(X)&#8201;=</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">the number of Warrant Shares that would be issuable upon exercise of this Warrant in accordance with the terms
of this Warrant if such exercise were by means of a cash exercise rather than a cashless exercise. </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Bid Price</U>&#148; means, for any date, the price determined by the first of the following clauses that applies:
(a)&nbsp;if the Common Stock is then listed or quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading Market on which the Common Stock is then listed or quoted as
reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b)&nbsp;if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common Stock for such date (or the
nearest preceding date) on OTCQB or OTCQX as applicable, or (c)&nbsp;in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith by the Purchasers of a majority in interest of
the Securities then outstanding and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Fair Market Value</U>&#148; means, for any date, the price determined by the first of the following clauses that
applies: (a)&nbsp;s listed on any established stock exchange or a national market system, the per share closing sales price for shares of Stock (or the closing bid, if no sales were reported) as quoted on such exchange or system on the day of
determination, as reported in The Wall Street Journal or such other source as the Committee deems reliable; (b)&nbsp;if the Common Stock is regularly quoted by a recognized securities dealer but selling prices are not reported, the Fair Market Value
of a share of Common Stock will be the mean between the high bid and low asked per share prices for the Stock on the day of determination, as reported in The Wall Street Journal or such other source as the Committee deems reliable; (c)&nbsp;in the
absence of an established market for the Stock, the Fair Market Value will be determined in good faith by the Committee (acting on the advice of an Independent Third Party, should the Committee elect in its sole discretion to utilize an Independent
Third Party for this purpose). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">If Warrant Shares are issued in such a cashless exercise, the parties acknowledge and agree
that in accordance with Section&nbsp;3(a)(9) of the Securities Act, the holding period of the Warrant Shares being issued may be tacked on to the holding period of this Warrant.&nbsp;The Company agrees not to take any position contrary to this
Section&nbsp;2(c). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Mechanics of Exercise</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i. <U>Delivery of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be
transmitted by the Transfer Agent to the Holder by crediting the account of the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company through its Deposit or Withdrawal at Custodian system (&#147;<U>DWAC</U>&#148;) if
the Company is then a participant in such system and either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or resale of the Warrant Shares by the Holder or (B)&nbsp;the Warrant Shares are
eligible for resale by the Holder without volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by
physical delivery of a certificate, registered in the Company&#146;s share register in the name of the Holder or its designee, for the number of Warrant Shares to which the Holder is entitled pursuant to such exercise to the address specified by the
Holder in the Notice of Exercise by the date that is the earliest of (i)&nbsp;two (2)&nbsp;Trading Days after the delivery to the Company of the Notice of Exercise, (ii)&nbsp;one (1)&nbsp;Trading Day after delivery of the aggregate Exercise Price to
the Company and (iii)&nbsp;the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the Notice of Exercise (such date, the &#147;<U>Warrant Share Delivery Date</U>&#148;). Upon delivery of the Notice
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
of Exercise, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of
the date of delivery of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is received by the Warrant Share Delivery Date.[ If the Company fails for any reason to deliver to the
Holder the Warrant Shares subject to a Notice of Exercise by the Warrant Share Delivery Date, the Company shall pay to the Holder, in cash, as liquidated damages and not as a penalty, for each $1,000 of Warrant Shares subject to such exercise (based
on the VWAP of the Common Stock on the date of the applicable Notice of Exercise), $10 per Trading Day (increasing to $20 per Trading Day on the third (3<SUP STYLE="font-size:75%; vertical-align:top">rd</SUP>) Trading Day after the Warrant Share
Delivery Date) for each Trading Day after such Warrant Share Delivery Date until such Warrant Shares are delivered or Holder rescinds such exercise. The Company agrees to maintain a transfer agent that is a participant in the FAST program so long as
this Warrant remains outstanding and exercisable. As used herein, &#147;<U>Standard Settlement Period</U>&#148; means the standard settlement period, expressed in a number of Trading Days, on the Company&#146;s primary Trading Market with respect to
the Common Stock as in effect on the date of delivery of the Notice of Exercise. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ii. <U>Delivery of New Warrants Upon
Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant
evidencing the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical with this Warrant. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">iii. <U>Rescission Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares
pursuant to Section&nbsp;2(d)(i) by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">iv. <U>Compensation for <FONT STYLE="white-space:nowrap">Buy-In</FONT> on Failure to Timely Deliver Warrant Shares Upon
Exercise</U>. In addition to any other rights available to the Holder, if the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section&nbsp;2(d)(i) above pursuant to an
exercise on or before the Warrant Share Delivery Date (other than any such failure that is solely due to any action or inaction by the Holder with respect to such exercise), and if after such date the Holder is required by its broker to purchase (in
an open market transaction or otherwise) or the Holder&#146;s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such
exercise (a &#147;<U><FONT STYLE="white-space:nowrap">Buy-In</FONT></U>&#148;), then the Company shall (A)&nbsp;pay in cash to the Holder the amount, if any, by which (x)&nbsp;the Holder&#146;s total purchase price (including brokerage commissions,
if any) for the shares of Common Stock so purchased exceeds (y)&nbsp;the amount obtained by multiplying (1)&nbsp;the number of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times
(2)&nbsp;the price at which the sell order giving rise to such purchase obligation was executed, and (B)&nbsp;at the option of the Holder, either reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise
was not honored (in which case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely complied with its exercise and delivery obligations hereunder.
For example, if the Holder purchases Common Stock having a total purchase price of $11,000 to cover a <FONT STYLE="white-space:nowrap">Buy-In</FONT> with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving
rise to such purchase obligation of $10,000, under clause (A)&nbsp;of the immediately preceding sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to
the Holder in respect of the <FONT STYLE="white-space:nowrap">Buy-In</FONT> and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&#146;s right to pursue any other remedies available to it
hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as required
pursuant to the terms hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">v. <U>No Fractional Shares or Scrip</U>. No fractional shares or scrip representing
fractional shares shall be issued upon the exercise of this Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall, at its election, either pay a cash adjustment in
respect of such final fraction in an amount equal to such fraction multiplied by the Exercise Price or round up to the next whole share. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">vi. <U>Charges, Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or
transfer tax or other incidental expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant Shares shall be issued in the name of the Holder or in such name or names as
may be directed by the Holder; <U>provided</U>, <U>however</U>, that in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for exercise shall be accompanied by the Assignment
Form attached hereto duly executed by the Holder and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:13%; font-size:10pt; font-family:Times New Roman">
Company may require, as a condition thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent fees required for <FONT
STYLE="white-space:nowrap">same-day</FONT> processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing corporation performing similar functions) required for
<FONT STYLE="white-space:nowrap">same-day</FONT> electronic delivery of the Warrant Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">vii. <U>Closing of Books</U>.
The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant, pursuant to the terms hereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Reserved</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;3</U>. <U>Certain Adjustments</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Stock Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i)&nbsp;pays a stock
dividend or otherwise makes a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common
Stock issued by the Company upon exercise of this Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii)&nbsp;combines (including by way of reverse stock split) outstanding shares of Common Stock into a
smaller number of shares, or (iv)&nbsp;issues by reclassification of shares of the Common Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the numerator shall be the
number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant shall remain unchanged. Any adjustment made pursuant to this Section&nbsp;3(a) shall become effective immediately
after the record date for the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective date in the case of a subdivision, combination or
<FONT STYLE="white-space:nowrap">re-classification.</FONT> </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Reserved</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Pro Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any
dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities,
property or options by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a &#147;<U>Distribution</U>&#148;), at any time after the issuance of this Warrant, then, in each
such case, the Holder shall not be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the number of shares of Common Stock acquirable upon complete exercise of this
Warrant.. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">D) <U>Fundamental Transaction</U>. If, at any time while this Warrant is outstanding, (i)&nbsp;the Company,
directly or indirectly, in one or more related transactions effects any merger or consolidation of the Company with or into another Person, (ii)&nbsp;the Company, directly or indirectly, effects any sale, lease, license, assignment, transfer,
conveyance or other disposition of all or substantially all of its assets in one or a series of related transactions, (iii)&nbsp;any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or another Person) is
completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock , (iv) the Company,
directly or indirectly, in one or more related transactions effects any reclassification, reorganization or recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or
exchanged for other securities, cash or property, or (v)&nbsp;the Company, directly or indirectly, in one or more related transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a
reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person or group of Persons whereby such other Person or group acquires more than 50% of the outstanding shares of Common Stock
(not including any shares of Common Stock held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to, such stock or share purchase agreement or other business combination)
(each a &#147;<U>Fundamental Transaction</U>&#148;), then, upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have been issuable upon such exercise immediately prior to the
occurrence of such Fundamental Transaction, at the option of the Holder (without regard to any limitation in Section&nbsp;2&#128;&nbsp;on the exercise of this Warrant), the number of shares of&nbsp;Common Stock of the successor or acquiring
corporation or of the Company, if it is the surviving corporation, and any additional consideration (the &#147;<U>Alternate Consideration</U>&#148;) receivable by holders of Common Stock as a result of such Fundamental Transaction for each Common
Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction, unless otherwise determined by the Company&#146;s board of directors (and as permitted by the Plan). For purposes of any such exercise, the determination
of the Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction and as further described
in the Plan, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given
any choice as to the securities, cash or property to be received in a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction.
Unless otherwise determined by the Company (and as permitted by the Plan), the Company shall cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &#147;<U>Successor Entity</U>&#148;) to assume in
writing all of the obligations of the Company under this Warrant in accordance with the provisions of this Section&nbsp;3(d) pursuant to written agreements in form and substance reasonably satisfactory to the Holder and approved by the Holder
(without unreasonable delay) prior to such Fundamental Transaction and shall, at the option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument substantially similar
in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this
Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction (rounded down to the nearest whole share), and with an exercise price (rounded up to the nearest penny) which applies the exercise
price hereunder to such shares of capital stock (but taking into account the relative value of the shares of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital stock
and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the
occurrence of any such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental Transaction, the provisions of this Warrant referring to the &#147;Company&#148; shall
refer instead to the Successor Entity), and may exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same effect as if such Successor Entity had been named as the Company
herein.. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Calculations</U>. All calculations under this Section&nbsp;3 shall be made to the nearest cent or the
nearest 1/100th of a share, as the case may be. For purposes of this Section&nbsp;3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the number of shares of Common Stock (excluding
treasury shares, if any) issued and outstanding. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <U>Notice to Holder</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i. <U>Adjustment to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this
Section&nbsp;3, the Company shall promptly deliver to the Holder by email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment to the number of Warrant Shares and setting forth a brief statement of the facts
requiring such adjustment. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">ii. <U>Notice to Allow Exercise by Holder</U>. If (A)&nbsp;the Company shall declare a
dividend (or any other distribution in whatever form) on the Common Stock, (B)&nbsp;the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C)&nbsp;the Company shall authorize the granting to all
holders of the Common Stock rights or warrants to subscribe for or purchase any shares of capital stock of any class or of any rights, (D)&nbsp;the approval of any stockholders of the Company shall be required in connection with any reclassification
of the Common Stock, any consolidation or merger to which the Company (or any of its Subsidiaries) is a party, any sale or transfer of all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted
into other securities, cash or property, or (E)&nbsp;the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up of the affairs of the Company, then, in each case, the Company shall cause to be delivered by email
to the Holder at its last email address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days prior to the applicable record or effective date hereinafter specified, a notice (unless such information is filed with
the Commission, in which case a notice shall not be required) stating (x)&nbsp;the date on which a record is to be taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants are to be determined or (y)&nbsp;the date on which such reclassification, consolidation, merger, sale, transfer or
share exchange is expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be entitled to exchange their shares of the Common Stock for securities, cash or other property
deliverable upon such reclassification, consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or in the delivery thereof shall not affect the validity of the corporate action
required to be specified in such notice. To the extent that any notice provided in this Warrant constitutes, or contains, material, <FONT STYLE="white-space:nowrap">non-public</FONT> information regarding the Company or any of the Subsidiaries, the
Company shall simultaneously file such notice with the Commission pursuant to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K.</FONT> The Holder shall remain entitled to exercise this Warrant during the period commencing on the date of
such notice to the effective date of the event triggering such notice except as may otherwise be expressly set forth herein. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;4</U>. <U>Transfer of Warrant</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>Transferability</U>. Subject to compliance with any applicable securities laws and the conditions set forth in
Section&nbsp;4(d) hereof and to the provisions of Section&nbsp;4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights) are transferable, in whole or in part, upon surrender of
this Warrant at the principal office of the Company or its designated agent, together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent or attorney and funds sufficient to
pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required, such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable, and in the
denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything
herein to the contrary, the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full, in which case, the Holder shall surrender this Warrant to the Company within three
(3)&nbsp;Trading Days of the date on which the Holder delivers an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised by a new holder for the purchase of Warrant
Shares without having a new Warrant issued. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>New Warrants</U>. This Warrant may be divided or combined with other
Warrants upon presentation hereof at the aforesaid office of the Company, together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or its agent or attorney. Subject to
compliance with Section&nbsp;4(a), as to any transfer which may be involved in such division or combination, the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in
accordance with such notice. All Warrants issued on transfers or exchanges shall be dated the Issue Date of this Warrant and shall be identical with this Warrant except as to the number of Warrant Shares issuable pursuant thereto. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c) <U>Warrant Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that
purpose (the &#147;<U>Warrant Register</U>&#148;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or
any distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Transfer
Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this Warrant shall not be either (i)&nbsp;registered pursuant to an effective registration statement under the
Securities Act and under applicable state securities or blue sky laws or (ii)&nbsp;eligible for resale without volume or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions or current public
information requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of this Warrant, as the case may be, comply with the provisions of Section&nbsp;5.7 of the Purchase
Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Representation by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it
is acquiring this Warrant and, upon any exercise hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or reselling such Warrant Shares or any part thereof in violation of
the Securities Act or any applicable state securities law, except pursuant to sales registered or exempted under the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><U>Section</U><U></U><U>&nbsp;5</U>. <U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">a) <U>No Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any
voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section&nbsp;2(d)(i), except as expressly set forth in Section&nbsp;3. Without limiting any rights of a Holder to receive Warrant
Shares on a &#147;cashless exercise&#148; pursuant to Section&nbsp;2(c) or to receive cash payments pursuant to Section&nbsp;2(d)(i) and Section&nbsp;2(d)(iv) herein, in no event shall the Company be required to net cash settle an exercise of this
Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">b) <U>Loss, Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the
Company of evidence reasonably satisfactory to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case of loss, theft or destruction, of indemnity or security reasonably
satisfactory to it (which, in the case of the Warrant, shall not include the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make and deliver a new Warrant or stock
certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">c)
<U>Saturdays, Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted herein shall not be a Trading Day, then, such action may be taken or such right may be exercised
on the next succeeding Trading Day. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">d) <U>Authorized Shares</U>. The Company covenants that, during the period the Warrant
is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further covenants
that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such
reasonable action as may be necessary to assure that </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of the Trading Market upon which the Common Stock may be listed.
The Company covenants that all Warrant Shares which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented by this Warrant and payment for such Warrant Shares in
accordance herewith, be duly authorized, validly issued, fully paid and nonassessable and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any transfer occurring
contemporaneously with such issue). Except and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate of incorporation or through any reorganization,
transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist
in the carrying out of all such terms and in the taking of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the
Company will (i)&nbsp;not increase the par value of any Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (ii)&nbsp;take all such action as may be necessary or appropriate in order
that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise of this Warrant and (iii)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public
regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this Warrant. Before taking any action which would result in an adjustment in the number of Warrant Shares for which this
Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">e) <U>Jurisdiction</U>. All questions concerning the construction, validity, enforcement and interpretation of this Warrant
shall be determined in accordance with the provisions of the Purchase Agreement. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">f) <U>Restrictions</U>. The Holder
acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">g) <U>Nonwaiver and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of
Holder shall operate as a waiver of such right or otherwise prejudice the Holder&#146;s rights, powers or remedies, notwithstanding the fact that the right to exercise this Warrant terminates on the Termination Date. Without limiting any other
provision of this Warrant, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to
cover any costs and expenses including, but not limited to, reasonable attorneys&#146; fees, including those of appellate proceedings, incurred by the Holder in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights,
powers or remedies hereunder. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">h) <U>Notices</U>. Any notice, request or other document required or permitted to be given
or delivered to the Holder by the Company shall be delivered in accordance with the notice provisions of the Purchase Agreement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">i) <U>Limitation of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this
Warrant to purchase Warrant Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase price of any Common Stock or as a stockholder of the Company, whether such
liability is asserted by the Company or by creditors of the Company. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">j) <U>Remedies</U>. The Holder, in addition to being
entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any action for specific performance that a remedy at law would be adequate. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">k) <U>Successors and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced
hereby shall inure to the benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder. The provisions of this Warrant are intended to be for the benefit of any Holder from
time to time of this Warrant and shall be enforceable by the Holder or holder of Warrant Shares. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">l) <U>Amendment</U>. This
Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company, on the one hand, and the Holder of this Warrant, on the other hand. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">m) <U>Severability</U>. Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be
effective and valid under applicable law, but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the extent of such prohibition or invalidity, without invalidating the
remainder of such provisions or the remaining provisions of this Warrant. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">n) <U>Headings</U>. The headings used in this
Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">********************
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>(Signature Page Follows) </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be executed by its officer
thereunto duly authorized as of the date first above indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>MAIA BIOTECHNOLOGY, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title:</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NOTICE OF EXERCISE </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TO: <B>MAIA BIOTECHNOLOGY, INC.</B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(1) The
undersigned hereby elects to purchase ________ Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer
taxes, if any. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(2) Payment shall take the form of (check applicable box): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">[ ] in lawful money of the United States; or </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:18%; font-size:10pt; font-family:Times New Roman">[ ] if permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection
2(c), to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure set forth in subsection 2(c). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(3) Please issue said Warrant Shares in the name of the undersigned or in such other name as is specified below: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">____________________________________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Warrant Shares shall be delivered to the following DWAC Account Number: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">____________________________________________ </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">____________________________________________ </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:18%; font-size:10pt; font-family:Times New Roman">____________________________________________ </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(4) <U>Accredited Investor</U>. The undersigned is an &#147;accredited investor&#148; as defined in Regulation D promulgated under the
Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">[SIGNATURE OF HOLDER] </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name&nbsp;of&nbsp;Investing&nbsp;Entity:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8201;&#8195;&#8195;&#8195;&#8195;&#8195;</U>
</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><I>Signature&nbsp;of&nbsp;Authorized&nbsp;Signatory&nbsp;of&nbsp;Investing&nbsp;Entity:</I>
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name&nbsp;of&nbsp;Authorized&nbsp;Signatory:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title&nbsp;of&nbsp;Authorized&nbsp;Signatory:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;&#8195;&#8195;&#8195;&#8195;</U></P></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Date:
<U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8194;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;
</U></P></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ASSIGNMENT FORM </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>(To assign the foregoing
Warrant, execute this form and supply required information. Do not use this form to exercise the Warrant to purchase shares.) </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">FOR
VALUE RECEIVED, the foregoing Warrant and all rights evidenced thereby are hereby assigned to </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="49%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="47%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(Please Print)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">(Please Print)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Phone Number:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Email Address:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U> <U>&#8195;</U>, <U>&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder&#146;s Signature: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8199;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Holder&#146;s Address: <U>&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>d776139dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MAIA Biotechnology Announces $1.33 Million Private Placement </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">CHICAGO, IL &#150; March&nbsp;26, 2024 - MAIA Biotechnology, Inc., (NYSE American: MAIA) (&#147;MAIA&#148;, the &#147;Company&#148;), a clinical-stage
biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 578,643 shares of common stock at a purchase price of $2.295 per
share, in a private placement to accredited investors. Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $2.55 per share, which price represents the greater of the book
or market value of the stock on the date the definitive agreements were executed (subject to customary adjustments as set forth in the warrants). The warrants are exercisable commencing six months following issuance and have a term of five years
from the initial exercise date. The private placement is expected to close on or about March&nbsp;28, 2024, subject to the satisfaction of customary closing conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The gross proceeds from the offering are expected to be approximately $1.33&nbsp;million, prior to offering expenses payable by the Company. The Company
intends to use the net proceeds from the offering for to fund research and development activities, such as to fund the first third of the pivotal accelerated approval Part C of the <FONT STYLE="white-space:nowrap">THIO-101</FONT> trial in <FONT
STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities described above are being offered in a private placement under
Section&nbsp;4(a)(2) of the Securities Act of 1933, as amended (the &#147;Securities Act&#148;), and/or Regulation D promulgated thereunder and, along with the shares of common stock underlying the warrants, have not been registered under the
Securities Act, or applicable state securities laws. Accordingly, the warrants and underlying shares of common stock may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption
from the registration requirements of the Securities Act and such applicable state securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to
sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification
under the securities laws of any such state or other jurisdiction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-1- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About MAIA Biotechnology, Inc. </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">first-in-class</FONT></FONT> drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information,
please visit <U>www.maiabiotech.com</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking
statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry&#146;s actual results, levels or activity, performance or achievements to be materially different from those anticipated by such
statements. The use of words such as &#147;may,&#148; &#147;might,&#148; &#147;will,&#148; &#147;should,&#148; &#147;could,&#148; &#147;expect,&#148; &#147;plan,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148;
&#147;project,&#148; &#147;intend,&#148; &#147;future,&#148; &#147;potential,&#148; or &#147;continue,&#148; and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that
statements are not forward-looking. For example, all statements we make regarding (i)&nbsp;the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii)&nbsp;our ability to
advance product candidates into, and successfully complete, clinical studies, (iii)&nbsp;the timing or likelihood of regulatory filings and approvals, (iv)&nbsp;our ability to develop, manufacture and commercialize our product candidates and to
improve the manufacturing process, (v)&nbsp;the rate and degree of market acceptance of our product candidates, (vi)&nbsp;the size and growth potential of the markets for our product candidates and our ability to serve those markets, and
(vii)&nbsp;our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by
our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-2- </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may
cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any
forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, &#147;MAIA,&#148; &#147;Company,&#148; &#147;we,&#148; &#147;our,&#148;
and &#147;us&#148; refers to MAIA Biotechnology, Inc. and its subsidiaries. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Relations Contact </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>+1 (872) <FONT STYLE="white-space:nowrap">270-3518</FONT> </U></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ir@maiabiotech.com </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">-3- </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>maia-20240325.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 3/26/2024 10:48:45 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:maia="http://www.maiabiotechnology.com/20240325"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://www.maiabiotechnology.com/20240325"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="maia-20240325_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="maia-20240325_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>maia-20240325_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 3/26/2024 10:48:45 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>maia-20240325_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 3/26/2024 10:48:45 PM Eastern Time -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="maia-20240325.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.1</span><table class="report" border="0" cellspacing="2" id="idm140070983184096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Mar. 25, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001878313<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Mar. 25,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MAIA Biotechnology, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41455<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">83-1495913<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">444 West Lake Street<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 1700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Chicago<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">IL<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">60606<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(312)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">416-8592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MAIA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSEAMER<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>10
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( )!\>E@'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " "0?'I8I.@D<N\    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)OIW^D8.CFLN))07!!\18FL[O!I@W)2+MO;UIWNX@^@,?,_/+-
M-S M>HE#H.<P> IL*=Y,KNNC1+\11V8O 2(>R>F8IT2?FOLA.,WI&0[@-7[H
M T%5% TX8FTT:YB!F5^)0K4&)0;2/(0SWN"*]Y^A6V &@3IRU'.$,B]!J'FB
M/TU="U? #&,*+GX7R*S$I?HG=NF .">G:-?4.([Y6"^YM$,);T^/+\NZF>TC
MZQXI_8I6\LG31EPFO];;^]V#4%51W69%G57-KKR3=2/K\GUV_>%W%7:#L7O[
MCXTO@JJ%7W>AO@!02P,$%     @ D'QZ6)E<G",0!@  G"<  !,   !X;"]T
M:&5M92]T:&5M93$N>&UL[5I;<]HX%'[OK]!X9_9M"\8V@;:T$W-I=MNTF83M
M3A^%$5B-;'EDD81_OT<V$,N6#>V23;J;/ 0LZ?O.14?GZ#AY\^XN8NB&B)3R
M>&#9+]O6N[<OWN!7,B0103 9IZ_PP JE3%ZU6FD PSA]R1,2P]R"BPA+>!3+
MUES@6QHO(];JM-O=5H1I;*$81V1@?5XL:$#05%%:;U\@M.4?,_@5RU2-9:,!
M$U=!)KF(M/+Y;,7\VMX^9<_I.ATR@6XP&U@@?\YOI^1.6HCA5,+$P&IG/U9K
MQ]'22(""R7V4!;I)]J/3%0@R#3LZG5C.=GSVQ.V?C,K:=#1M&N#C\7@XMLO2
MBW <!.!1NY["G?1LOZ1!";2C:=!DV/;:KI&FJHU33]/W?=_KFVB<"HU;3]-K
M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MJ#(9BBJ6<%H@XLD@;6E6?;!/3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%
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M?^:+X3]>?P%02P$"% ,4    " "0?'I8!T%-8H$   "Q    $
M    @ $     9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( )!\>EBDZ"1R
M[P   "L"   1              "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+
M 0(4 Q0    ( )!\>EB97)PC$ 8  )PG   3              "  <T!  !X
M;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%     @ D'QZ6">UT%-N!   LA$
M !@              ("!#@@  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+
M 0(4 Q0    ( )!\>EB?H!OPL0(  .(,   -              "  ;(,  !X
M;"]S='EL97,N>&UL4$L! A0#%     @ D'QZ6)>*NQS     $P(   L
M         ( !C@\  %]R96QS+RYR96QS4$L! A0#%     @ D'QZ6!PX9>H_
M 0  / (   \              ( !=Q   'AL+W=O<FMB;V]K+GAM;%!+ 0(4
M Q0    ( )!\>E@D'INBK0   /@!   :              "  >,1  !X;"]?
M<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4 Q0    ( )!\>EAED'F2&0$
M ,\#   3              "  <@2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%
3!@     )  D /@(  !(4      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d776139d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d776139d8k.htm">d776139d8k.htm</File>
    <File>maia-20240325.xsd</File>
    <File>maia-20240325_lab.xml</File>
    <File>maia-20240325_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>16
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d776139d8k.htm": {
   "nsprefix": "maia",
   "nsuri": "http://www.maiabiotechnology.com/20240325",
   "dts": {
    "inline": {
     "local": [
      "d776139d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "maia-20240325.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "maia-20240325_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "maia-20240325_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2024-03-25_to_2024-03-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d776139d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2024-03-25_to_2024-03-25",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d776139d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.maiabiotechnology.com//20240325/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>17
<FILENAME>0001193125-24-077564-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-24-077564-xbrl.zip
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MP,11[KP] OX<BI>21+LEU_(& @>N:Q]>#,LQJ,C+5=38N^5*YGN=#QTCZ$9
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M;O!+Q&6<=GE:.6UQ5?4ER-J4.#12.CG,5?P6^?@@2\%NH4&8EUGWV8AZ@^3
M2N<?XPXFJPQC]'1 FY&0L#%W]TEF?'^]VUKC1&XK)71J:@7?+B]47TX+&=%8
ME1F:%R];7P=[>JYHW;6RXZ,T5[201-B/PYSQVVL;,T"FC*][?==I_W)U?7G]
M\W^+I'O5+C_^XJ\GA!;(.FMB"]WT=007N?.?IJU7W\C82AIK0V'N,Z6]HBKD
M/QYUR7]X*)P]7T1:A6>\5[(S3&=W^J:[U#>E=K;-]HBS 5BLY,5UU_K%=7)%
MB)D4;7^+/EM]C<]V6C&_3%+_GLGS_P=02P,$%     @ D'QZ6*G6P9(Q#@$
M$PT% !$   !D-S<V,3,Y9&5X,3 Q+FAT;>R];7/;1I8&^EU5^@^H[.P6505K
M+-N92>)LJF1;3G37L;62,MFYWT 2E!"3  < )7-^_3VOW:<;35*.G4BYE:VI
MC46"C7X]?5Z>\YQO?[C\\<UWW_YP<OSJN_V];R]/+]^<?'?R?X^.'A\>??M7
M_A,^_ZL\D'W[XMVK?V8OOG_Y[LV[\__^XN<?3B]/OL@N+O_YYN2_OYA7=?GH
MNJRNKOMOWC;MHIA_\5VVOP>_?UG6?=E^]^VKTW_HP[?5M+_^YJO#+ZOZBZR8
M5U<U-%#.^B_H-6?ZV*)HKZKZ4=\LOWF\[)]G\O>XZ?MFP1_-FKI_U%7_+K\Y
M\G_/BD4U7W]S62W*+GM;WF;GS:* -QV_.?W^[7]_T6(GO_CNVQ??G7RXKL95
MG^&(LV__^N*[;_]ZAD-.]>#)L\_8A0G-"?7AXN3E3^>GEZ<G%]G93^<O?SB^
M.,F.OS\_.?GQY.WEKDX=/=G0J;[\T#^JZBF\YYMG__EQG?SN\KKJLHMRLFJK
MOH*OSE;MY+KHRNSXJBW+!;29C7I\YK_^X^C9WY]_^]-W[HMO__K3=_CI5\\/
M,GA@6O3E-"NZK)EE/Q;0RG_5XV[Y_,F7>?;D\9-G>38N^]NRK+,?CT^/LQ=5
MTY>3Z[J9-U?K/#NM)X=Y5NSOO2KGQ6W1EMFD:9=-6_154V,/2M^!E\UB6=1K
M\WKX93W-RF)RG2VE_VU6X814LPHZ!4U@"QULOJ)?0>/+X@K&>EVV9=]D(_QA
MGE7U9+Z:5O555O5=UJTFD[+KFK:CMHL.?]S!BWP_=*I:WQ-Z=M+,Y^6DKV[*
M^3H+>NY^T9G.'V:_^Z+__,/)^<GQ10ZC'/\"7<U@%K"CL$\7G8RAGE8X]S 3
M90^MM?TUS%!&6\%O#7P49KQ;%34U4M19^:%<+&G59FVSH&;;\JKJ>EG+MOS7
MJFKIY[A5]O<N<*Z:FG?+E[A[\#=F2QY#!Z$_?0%B9XJ="'[Q;%0<C)X<X(_:
M$GX,7?IKTV;GY=5JSF]\E2VA)ZOY%6U0>FX%$]?F]"+93=FT[*!;'8ZBZKI5
M26/KROD</YF4+;X^^_;U.SBH*MFNJ[Y\U"V+2?E-W=RVQ?*+[^JF?E3,9M6\
MPI=]^U=\_KO,K[O9J=P6C/]7MP;K5]Z4;3&'?8;-UDV?_=)4=3^'$V7&HV?"
MKX@,&AMPTRP3K_,!!WG1P%&9K;!Y:&W25F.>_W 3W.?^K7 _39JKFO:J#F%9
M=+WNXKZJ5]#KV8K./4S:307G&G?$#0B(:39>9XMR,8:EB28 3^??GG?9N"G:
M*7XWA>F<] VNH7EL?\].-)P?N&)>R9-FW;,1S.>TG-$6'I?SYO: ?E"T?36I
MEK"\/+%P!MNB[HH)GST< !RG.>U<NW$;ODKI%Q7>+V5'QPGEUG6R [<5G.#^
MNH%MD!YHUS>3]]?-?.JV:>(H7)?[>V;/;-D6^&OJC)LW%K3X=MCK\ ]XNO ]
M],,["$1*HJ=PG1QE)R!&^C5>'"CF;\KL;%X$-P7^/;P?IH.I4?FODGTX>=S*
M_EXLW',CW1-3[E[^R:>4+J\_Y$E]^^[G/+O$X_KZW?D)W/-OLY?OWEZ<OCHY
M/[X\??=6Q[* \UG,879ORKK FR$0^.$P>#7A2LH:%.;95=-,Z:.;8KXJQG/4
M'>H.3K?<.+1I877*:LEBH9C"'51,UGXKHL*!^P^D03%Y#^)W7DZORFEX0[@]
MY+=.@7W"!9C!MFANNV]HAM-J[6^E5!Z?7YZ^?'.2G1[NTB _IV*M'7AU\OKT
M[2DNY<66L?\VF^OH\ A&^M-WKU"NLK:">M4A" 588]9?0M5&)7 Y[\I;7/#4
M[L*=!:<5#^02Q*6<M_ 9;)+7'!5&;ORZ "E$F[DL:O@XI3H%J@OT_YMM1_)O
M&R9-/D(KBB;MDR;1Z_435,QP.&<@O)K::+7=-<Y'/#[8]R)I5-3C/ P5M,,O
MMPJ>WWN4V+//-;:GAT>C7[9K\+_S\%1;-"/$(:%6OY:%A7$6L(7Y)H0; [8[
MO%?_ZJ_;9G4%UW1=XC=TLY"&L2BG5='"_9.3<&Z;>4<_[?;WY.\YZU/T8497
M.3RY6, ;Y0%60@KM1]'YJ>U(!J\Z%OBBO('1@,H;-W6^ LG^[/&7\N?02'A
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M-..2,K+3G=>RS'Y93:^4=C#V>BZ*]\B^V>_O58LE,^,INRJ\;7HCT"KK'8P
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MMA%=VWB"D1"& B(*^S;*?NZPUS1(_ <<FL5J?J4,M0Q'5EP9ZTP>UY.6T7*
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MVGK/U1 12!=3Y_85\BUPY2+<B31F^33["&)OI/AA/ZFZG>VK?58)%NMRZ)*
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MXP+;<CC1$\1_G=8XS^4TQ=4RB%CFPG5TIY+7UY0L[2II'R(ZD0^D45<BWT'
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M$Z_>K-NB=1$=H;:PG&@;EU30U1H4)J2@KU-836%/)7T)!["5%JM:##R+L'<
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M*"?<-* RY&&M%E3'2/-#=Z%B-- U5K1(SX^]]8C.VR8;/9$_E&+K%1SSB.(
M?U^O%F/^>? @$9%7/E0I9,;0T;YGCF0$AB >:V1LAG$),W%@9@1_ZY)?P_.5
M\JBZU%5S-> !FWCM*81?;=KQ@]Q365C1(S7-"8^@ZE0N2SRB!60/>Z8^=\Q>
M#XAH5"TF;.2JTZ)U/DPEZ!@+$[8#,@$UMX<D;J.&&VU'LD!Q0]K.FVS,U#:E
M*M<81V2L)?TACM%:(/&89TH3>,60<XR[^:K3B;N:.E76<ZQ4I_*)^T.PJ=JK
MYE8A36[S0',QMI<LB5[E'A3GSBF]8X'HO8%:D#FM(%0IX#&V>@TC(.6*Q4P)
MKLIWBR>9;72?#?RJI"+9Z*R^;%=@J.A<"Y$MG@:"+:52C*D(*>P18>M"'@/Q
MX6T\7V*8(Q%:I]*-'^W\HPR-S$T!)S08-ISM?$-H&,=;T+ L)U\2LA;4^:&\
M6%7!;-$?#(>:Q'<P"S_Z'.\\M_?OK)\>8%A*L=1;L' "4N*$99-O')K=O,6U
M3J]51] BABO:(/<+1N6A?C^OX%*A$D8P]XM"75I$=T09\V5=S#&BC*8,I4S]
MY2A__/@Q9==LFOS1N.@\"=H_?CX^BZR:0:$G\?1$A<3A:,M938J4 R,L9Y0E
M&*CP"6$M82:5%ZG;$\;W&,^%W?JD7Z"O01+(__)D^ CRFY;9Z&GR]G3EQL-+
M87\/;X4#/[>VP4T_8AX4$$"5)!/:PU%U9DX4*%G8X8^L*6LW$-9.)=D]*O0!
MML2,"V>TZ;(ZB':="M=4U[>=YTBWZYKP/K3]'?(P_(IKCZ=D[&=D^ZQ'+_2P
M]1$Y6C!OH]8"9P8204 GI^H>&-+OX#ST;K3DMM7XIC,72)U/DGND#8Q034N_
ME$N?>I*PG3_P%=WN\%(XUAO>FL+<(Q"(B!R)0P^1]Q1!C+'U;EO7Z\09SUE;
MQVR3!5W3004Z),'HMH"TF3G=(:"YF)VQ+OA61_ZNB;,/#/M+]NWK=V\OP9A5
MZ_6ZZLM'W;*8E-_4S6U;++_XCA_9\@",[5$S>[2$>2K[;_^*CW\G_U&/JW/X
M'3@TT8;5ZCR>>_KQ ]DYC*TC_;B!A$S^.]__8K5^=%IK<V>X4):>TEG!6E<2
M[9QC.>>T]GZC;[S'!AE-F'^L9AC5#-+S.M35MPA 2I0@JD9\:O3"6%5@_J 3
M>R*45W0L>1-NN$"Q5_;6V)KW$BE9L9$5B]/(SA(_@K',-RL 4AR4$D;8B7!@
M,U.BCK )I3TA.[U8DX*ZS=2=/H0Z*3"NF!JMPV(GQ.:CFA26&.XUBP,''M&D
M$=R<' ,#_M:4G*0("Y()P&($I(Z!O]N030?>HMWN%)-M$;,D:)KAJO/K91O,
ME5WL0[E8^C@4IW-RA@[>T;.!IH<>IKLP(9!X)^IZ-NCHAPE0&$?VBH@0P^;:
M<,^XLMHTD8&;< HG-$JZG28V2!/:)P%4>Z=A>T1$^VAM3N@6I$(T?:($I*-I
MEB>J+DS%^_W1S<^87? UD\1*INT@[_G>SRO"$4AUCGQ@%'9VR8#.4JH;JVAA
M"9@H<3ATBKEH(F6<P1V'%T4>K" Y:&MZ"+8YJM*;"J9Q0FRGP 'X<H:1-]3!
M)1N7^'T[Q=PZ6]NP*-(O#"^Z.<I7+5RG<DD<B*;,B=_.T<A*/K8QJ$KL]63+
ML&%/, WZY /,70U:!GIID14UBZP.\0.+AS4HU;*]6(AM^?Z-^?$!!LQ)8,-W
M^WM;KV&GT7;5AVST-]D_<*T3++5&J2KY\8,)-G>HW@M^UZ8!'M:'KZHS3Z^;
M5*=$FH(/XR3/C+K_P5(>'1V$M(=<3P2;-YX]O ]\HEXR()O'>\*=/O9IH&'*
M?-VUG@_2M\@^XETI9=RT.G%8A-@/,PQA8'@]B# 3B[<O5%8+07V"J1Q_72E3
M.>4K$55O9WX49!YMJCE&0S-C$58#<0D%UX5][Y.#@/;\C$=MA&WV&AJ&]UJ-
M&(\8.8-BE]/0"OH(CQ/FU6UQ.?T:3]/8K;)D-*EZ6*PY(X$*.P:\HDKDIR1+
MPP"Z]^\[PU Z:0S$V\;4U3I\C(6U>&>Z6II<(Q5V RLWQPOU!*<GTN+)5>5=
M*^![TZ(Y@B(N&7E=(18)-L'HZ>/^^H!:V&D=C4!1>T1\KFHAX0%B4216+LH0
M"MM)2*CB<LSK[H!O$);P*[TL]_=LQ*@PE][4>$8VCHEK+4K=">=PB008 Y"&
M9S@=!IO%T7^^*M5%2&+P8X A' (1RZ/SY*&%\<GZ2 +QY^+%&-YY0YWN"5X.
M!0',!4@.#TI6#VQ\/L5;9NY,.G0H'OT_+"3ARS\A"9\7DG"'3>/W*]49:+;$
M?M'[@-F:(J'8?)^7&#/*6#<1I89/Q:X#[WJ 6Q_LR54KIQ_3F>U+N1K\Z&D+
M6N@+I<@*'>"N>O9,&K]BUV K9,LL!79W1840)03YAI->< I]WJG16O :<XR;
MUK4A6HE_O+^W<7V*UF-VU?@4[\C1X9?_2>$&7@44[<S432)=;E?ZKCL0>4V+
M#1U#/FU*2+S66C@NE9"4LET)H23;,.))E;/UVO:"=]/LY!)I">)9\F(RC6A\
M\5O(!%$N7:=\<)X\S D2,G)RE-3>V<$)42"KA0 R4O2^FA@Z(/G=:J;^5M;S
M4[2>3ZFD]8::NA[:B3I.SI16IHZ6*P["WS"7W&H=<D?6Y573$YK76(RJ9PD\
M$TYHB.<.;K0G::>1U#AA6/18JW,705$B[K'K<"I[J) S9%LSJ6MW+(NG]$#;
MZ]^%'R'-D&H+GSZ4&9,E8=ZB,UFW5KV/HN>L&0D37#@-Y.G'BLD,DV*T><#O
MH^YCU4LEE]$$I+A6@H1GXK:P9-58TH^E,&6J5<S70PQ<'<2Z[L/S]"SCNHHZ
M^52R\I4CW'@NDLH52KBT_A@^5DZC%3^'_W5V*4R$#$LEH 0*BA)]V\+JX=@9
MM3SJ1] VC==YJ!3/&%_]4FQ:IN/#J_LU9DKN5/V_>O0_N2K] =Y[$[L_U:X2
M>L">"0'SP!$MX2'K1R*=/0;8ABZ9UQ2 1=>JN\==94B7;& G,[0N3<608;DI
M/1CF1F&S8>Z*3Z&R@>:I+DF^>^;JIG[$S?CY\U=;$(@VV8^F6Y&/3%D*AE60
M<_,=_*)J#68TS6-DF&E,^61LY8K][D'>@Y1VW;[YMA6T.+38E-R"]<4C_5%K
MN3UC2I)CA-\@Y,[Q# /#(F4.3\EQ 2FL!D,/V=ERD&'];5D&V*5\T\I\_H61
M^4)VV6LF.JVG&_9/_&[;8&T"1]P.;WZN*T>N"6R8*CRBM3SCI)^,JB@0JR*M
M8:A26 YXX<V<52BY&*P7!+9LSM!\;:)XCMK"N;8]KHM$3\0-L9&T+X+*HJLS
MU0-BY9@+P R?$&P%MHV[TM&>TX?!MNR2J+2[R>=Z6_76J(N*G%DGC@;]R"MD
M#F)IG1\>T6T]MGS'X_ 9X!H ?8?4'EQATKY95 WCJ&O:K6^(%N".[PA[Q<66
MI$FOPQKN3_)/8\O7Y9R2]\C75TY=L4;%CGL.K?V]*&F=6/$'M9WL_<QY9 *3
MTS011WG@SA8_1N/DV:A=?;KT"C41E=).UJVA&Y@YGJ+[BYZKBX4NF[&D&+Q?
M,[U+]%A4EZ:FJ)$CYXQN=.=4)W44L:E<9QR_"!72/+%/5-":_3*H5,,+Z+2K
M(ERU-&''QKM,1@+OP835^89R2*F!!@J6PP)1=<QH9\5L"&)U1NJY4>!3VRX"
M99I-9J3]QCVVOV>ZLT3Y3AA(@X68S F$YT84,6Y,&B805H*4$#[@J;ZBH=^'
MZOXEUT0W9L@Y5_8YFQ=:-KO!\58+1\!/]'EXHW&)H$%LLFF-_FHVY_#^[SU1
M9>ZUD; "BRF*>^R*C,3U<(U*0G5]FCF;:4QYW(D:I53.6%EL,<9;FSY>-A5&
M.Y8XO%$(O0B@"_(.K7WD=)^#H(86*$^/>KA4" '%$(@VJ,-A0-=MYCW]Q;19
M]H/)S)TY',[,1(UC8?4FSWMU=>515UK/R 1Q,+]WT!\*^-Q4;;^B ^"!?\:@
M\X9^^L@WK5D B5ZY!/J$^N?"<?XXWHO3YV_97:!N;\$N.0OLD@&NXH3E;$J[
MB6S2)#VZ\.)\M)F@U[M3#;WQ9<,B443D67@'>D!$;!JHRE7UOF9V0*GL6:JI
MU!$S59.84)D;[MJ&*_X(MR<&;C7QU)6B&3":>\ZU+M>$4V^D&A5F7I4WS&/G
MGW>3_VG&9RX.&W7SL)4>"W9C#8O48_>=%,1UH PZ8DM_7P><];H$P2^'L+0F
M>U^6R^'OK07WT&R-0%^&S@5J0(SUW&@A?KSMKI:@,Q6Q!6/;B6>!^=<_F[\"
MM7/K?5?]+>WREPT3GDSAZ]Y\0),;$+59VH3,P\[D#;%E'Q-V?:[)WM_;;9#C
M'4K]NF,G/K]/@"!/%*N>EKJUQT6'CM>91(_</H KZ1-EARG!+GL\7K*V7'!U
M!TMC$M0<3!P6R0M$Q=6](:X/D&3OC"6J,%48<9G?!4B_??N'A+:12R[<8D.-
M'92IU1Q$5=FL.HO;M6EI#"+G\9/+UGZ0LD%">.M6]^[6<7_UZ'\.=<0/2\"&
MSIP_+%#A;W\"%3ZOFOMW*A?*SJ&SMIF =M$%>FN C8:=B":A%"G*X.=$4EKT
M?8&?91JBZ(=1G)6Z3:"QI;S(P"W3H3J?)HQ!N]NF?<^L!LM*<H$XB$<1;>^^
MZDKU[?%KOO%.#I>2$V=P#3.E(ECWM!SWV<A2CTH>!#Y.EP5\@$*YHS)RY+4:
MEOU,-!S4'F,E<MEBSR8E4LL@1$E[W993Q>Y+G\.<DS;\^P3LVQO$B>"]-IK$
M4^!SC:4Q4$&<8PPT 5?EN,U&4U<X-ZS?^/KEV3$^\.[U\4O47IWKY3X<%E]Q
MG#ZLYXO[VEF26N$K #.'!G$*)_95@D9+ZP:O&3B#'I)8D&M)*:-^>)W$A'?Q
M=BTQXZGSE;FM2LJJ'=E%(Q>A,+:65NO,9@26P.I/6,7'K7[6-II"*,89OM>P
M6_1S)EP-7*,%:!>3]^XZI:<"=F_0V?$SV*,\;F[Z]KI1/TL7*Z$C$Z;$['?Q
M& :S??3E!B(1''F(=GB< IP?>$#O'>9=M;[!_),3RZU ..V@NM_GO/-'!^X)
MF6WROVJ9UA$N">)L#!)95^$,W>@6?@PSLB 3EA-S3=!O3F7"0,_5VO"L]_MX
M7\[^/_QO0VDUB*/'9P20A)]W8IV8O,*@ -XOJ^F5N"P8_MLYD)274=32JNU-
M>R8? RZ@IJW+M98@G^FQX:<;5RWNRG@/7&0GFAJ"Y6.I-EQI]N:OVKB< T&=
M?=UR[T7'].>6#H1*54U0"BCV<\.OGQLSKC'NL;#0D4O+2+'X5S8&N=$19YS2
MRCOO6"4Q*"_UZNGV#B=%(4#H$RI Y:V$R=X/<"$.F- &L_59Q@RB[_!N$H=R
M>".2[)"LDYB&.[50Z9C73F3'-J_9_MY(W#E,;SE1D','1QE=292L2Y'VPGN0
M_(*GNKFA3H/= 6QJZ1ZX@TLU"+![)ZNOW[QQ8Y/Y[UQJ[/H-EH0;=[=\ET@_
M/5/>1^9W1_1GFMY=6T.O)F;Z;FI*:OQR]444HDH5A4&WDN/H[,DV919F;;&:
MYME5B[5&Z_(*A!(7E^4TS-EJGH%])Z\6DKZ)TV/0OSB@G=](&Q_N4[:IA4-;
M3K<R ,2X@13$+6)"X3KI8("B**.]M8-Q<*LZ$BDA<E+4P8BP4P2RBK? A[#&
MZ\BQD.MUX 5#XFIP\M\)_."J8/D[V@$'W2')#Z+K@]AI&+6,1728T@K;',AE
M!#0;D0=W2[M2PMWRB@)W]$FPTN9@HX405C\1IM1T_JOL#4W#E<U/+/J8@1=\
M(]*4RL"H%.]6L )"%R=^9/_D$A&P"S8H?%,LA>,Y0%7<7TXD%6U<60;O/QL.
M.DHTI$%.N5><Z&,K?S)2@HP*G8S./3N**Q0.)FDX;%?6<$Y 9,6\5RV(0"Y$
MH%*2)0=\"^>@1/ !7ID'S)!5=?.RX%TGP>X@O(Q!OYXK642?>P=JO#^HOXTG
M96A+N1+D?J#3F_9U)07?C'-R4\& +6PJ_%MAAIK3#MO?$P.;\Z:#Y+E GML-
MX#^,P[3IW/-8U]8=GJIE[]0#A-;RL53CD+O)Z[>1&?E42F;Q%\XG-FZ;%6X)
M(Y)B764=X:?E<F$!*;<@95U20X,<H6./6TM.>P130:_B;*"AR5)N2BX< NV)
MLE& ,>5,:NQR8BE=3H:%F@HJWN(%=MTP?F9K18^H_X?9<1!WLX,:=HM-(%\6
M5+LA,LDJ2<P-T2I/C)[@:#1\Z,B=J3JZ"G9CT$@=$UUT<8W+@Z"4IQ6MY"GG
MPSSZ8-):>%!>WD!SKIBV9B,P2<0*[JJV^O<0QV"7>+0V;;OX##2("2NE@FP+
M>\M)XC$>,^&?E_67?$J>,BG S=WU\5 \V__V_AB[!KTPDCKY:=XY+!236ZF/
M+FFX_7ME+G%?,&#.1NJ)+6_H*7-[W7Z?UMMWP7+(^=V!+.V0JQFT%J=FN>$D
MMT\-5Q%CXA'+4)?*;1WNWC#X2>J3D,6C[B(E[1.'Q*!\O/$U.C)^-4[5<'ZU
MB!U3-BDY[,LPXWO(V]<8N*R+ -J0OG0Y .LED'K/:;\\2>&K-EV 8AZ3BB<*
MGNIWG#.N.;V(P>D9!+-EWIRC\RYF,0SZ(^SBI!3XE08R[XHJ<A_NJK[SE=^Q
MVBD^W)C0I)EDFJK,*<DJ<SP1 9UMXR$.G16TEC-F\R^D-A]R,L BS#M)7Y5:
MV*0+^IR^8$A]8#%NJ&+'U (V#9U-_I7H;HXX0#%-K2IHJ0-C' HVS$>+T+'?
M%#\R%L/_Q]Z[-[>-7.G#_[.*WP&53%+D6[!&\F5F;$]<+R718R6VI-5E/%.I
MU!9$@A+&%*  I&3FT__ZW+I/-P"2LFS+WCBU.Y8H$&CTY5R?\QSO4E'4+ERK
ME37F/C]_D/DI=6LS+WEM \PZZDXAYH%==$41X;EMW<X%(B[A1NP#UN4@!=7F
M*76 Q$OQ2@1XN#H\)I@ 75+%ENGX"A;[BHKG$)8&\A[B6D9#PZE822<G4I?S
M+ @Z!CD39FXM,WQ#!7=P$G'-EQ1\P^W:N*J_XK3EC]_2EA^Y9^(F',/7Q@OG
M'$+]"&H=SV@9P<?4R7W 86YB]Y$&TNR,5M*/\]]SR[K<SIX: ),+,7JR&9<[
M \I@NL#[IEQ]8DZ\^X.#*A!0O@D/04WH01YFU4R&EGJ$,]S](A^'\2= <*,*
M#4;*=.SDX%"S%W\")NO>/VJXO;\T4@Q#:U,CG,&8%*V9]4Y\9D[(O;JV=Z+?
M/7P\U&EFQ#V2"S@?L[1D.U/8BYR8-5Z+%HIN"'$/5<<IKA#6LWL1$E*A:\T:
M15QH4]@%'=O);'I%)'.1!8.?C>4&EG/=TD6@74X#Q^TS8C/'VI#^L*T"4LN/
MNHJ?S_YHC?NP:4OAE"%M$1IIS  +;GJ=74\%S8EI*I82 T>$6:\[@QN<+23R
M3$6] J-=M@F=8/ ./#6+R:17?&WO(3DP]-HLB]S8>XK?!*,4^(56<G%T%^A%
MC+&72"OOT31-2@+Y&*U;<H1T10#U;"$T!PJ5,*%7(FCELF&H;;5J)$T]G/#K
M#=-P'];9UA86+1RQ605#X":ZGWD<#R,UC)4$>Y]L&$A=,$06I1-SQF>R-T)(
MQ#YE5C+(XN#*!L4.V+5<02I\LZ[OO <LOB>YA4E<LNDD8XZ_2N-S*?] S-U-
M(AT7PD?9A$O5^&R!7V/T&6JM_/< %W5:%79<0HY,IYF;R=4-U0V _('K6[JQ
M"-PHIFO=F!1H$AO]<;0!C>YN!QL TI.#U$S(VX>5C,P!,;;WF6($.*SVHYP1
M\A_D8\6XI&SR&2QXF(_"-+9YKRI$37%$[X9\+GRE$I-35>T6!#<D20#\FBC*
MX+[G1NQ=<5?$H-1!F(YC;AF=B2-Y78A)H1FY5!GFO8@1I"V !F^@"DYT*AEF
M;<='3#->+O$H53Z0;%914/IE%K;*PJ7%&TLLB-S"<ZB\U# ]7"PBUPQPH2C3
MF3O#0VIXW>5U"*=&@*KR $NY%NTLT"":3_=25L4U\OS^S4K  YNI<"6=24Y-
MAT*R,(B#9$C?X]?0(OL*<PZB"1D6T&S03Q^%>3C8#*JQ@'0D^I 9:*!C""31
MTJG W&)M+AJ:G3^N)5!PRWD65HU58,([ JQ?)@+2C!WF9317BD1-/$8ZLN_'
M$O)3="$"7*T\(">V=Y&90$JCBCO<65-3-?1)(*!2]7F95]03\UK[^*Y\09Q/
M7EXY6"=ABP%HES'%?<?/)?Z6LC<T,^5"JK9BK(,.O5HXRD*#4:BIS1F378O4
M@.V;YN<0#UZ*0*=P> L*79&/?#$GNJG-YN,84ZF1-XLZ38%\JFSRE 6RM:3,
M/NVF!G7RK:8'+AA!*R='\:H &B'09E*G=+GEK$+OQ4\WK37A$#%%<^,F5>G(
M995*$!F'/WDU.WSLVR<V*"VB&/1G8(*)6^AV/GP.UQ-"(?["S3.XAMQ'FCH?
M/##V3W)N>TCC7KA.+\P&P):'* FL?0N.^:289N TP[?*BG_P+Q%@=7-QFS%$
M4\9S4NJP=D_<!69WT#Q'5N#YR1(<ZC@=,9!; R?K]P24B/D)C2?4 ^N.,V:I
MS.4WKC B.3.?\;;%A!J%Y9J*?G6;27IYF?2V\=(AQE=J>6'.C5!GE)F/W,"N
MDWAW6&[?R;D'R_H)6M9<P;&#4!+V01WY.V1N%RE6S-<HMSD4BNTZV@@[T."E
M$!=H;K@#H12+\@;;K%'_%2-,9X1,08<H<'"#6,]:'!N!IR1P;TBS_U%P]W='
M)NE' K5%$LF@]4CEK$I*TI[L\\(8UI,$W2Y!2WHOLEW 6YM?=IVL:@UNKQO/
MOI?=@U7Y0TX0&6\+*GR,DR%;Z(0D'\+M]BUQAUQ?,PTMXZ#7>8(YF)TU>F6?
M$NF>[,%B(RQN3,U9; K+SU_M%S:UFDS]+LIQ)$1)SI+%M+5JWBA&!^SIUF$$
M3\]*]?RW.G1H'3/('A-"#1(^@*W#IJ0K2UNS_-T#LZG/ ;(K18\-DU[K9T^$
M 9R]@-A2.C8_P@N?SQ,,EG G!3H0BZL4"\3='XF5Q>CH_^ \]<4?;7@X;@;U
M['56Z:0F4RX*&+%<;@T*NWU<)$6:#H5 W[HMAQL-')M8<SZ@'@2[3?C S<Y$
M^(LT)FDEA;N'PXBU@U@:N_L\VIY" OC=(GJ)87H^D(#B4RU;/?/?QMQU"XV$
M:FUWFZ-( 8R:8C%-R&I-9L2M!1S\<%>059:)PBS!%2I?2M/;5 K".;F;= WD
MT+137$+(I8+J.DIE6RRZW<L8863![E-N*>+U[ID41#5E_@S1705!7&^"\/N(
M6:]3. K; FO:6M?GR@O44861+#]S[E *AJE>9V0&TV^G.;I'QS,J"G%'AQ>C
MVTGA'TU?*%[+NLORU<($?OH&$_B(T_GS]HO!T<G>SNMA]"MLBNT72S(PGV(
M;_:.=X:O7P_VAP>GQY]=0#_9H%S8B;,'429S$U0_CL)0*\M8.99J+9URJ):T
M)5&I6 ?N)D\H5^U.<\$_&G<RF54%]G01 DUUCV7$4/4XJ1FK&.-$\H - -VU
MG.9QX *6;(# (A@EF_'SR\N$<^U%J0F6)]D$^-V?_'Q\:E?0K<:/3\SB7$.G
ML5$R?8 ;_IE9V#^]F%W\_+WYQHN^UP@PZ*7N &+/0:$*80<L5@P?7!0W,$WT
M.V4%>!FTJ4_)_80F%^[K(?.(.A&7+[4->QB0R2NM.19[A9VT_N<W+9YPOS)!
M^ X9X1OR$M@X:+<3M&]KJYRKA55Q CSZR804:2.\& FJQM>91.<%14U=QZTI
MR*ET\\5R9KMHQK9RROT9[VL;, B>]8I1K",,=<F8)3,(OD*W8UX<0RSH.=C\
M21QT:E2$^K7,2I/U B\/_P9]UW$N5M5P(98GU2X2;+.53@2D;!^,DX4X$.AK
M54)F3G%0ZP)U.]-T!B$T1_C<D$/U,(1,^N)]047 ^C&8)Y=7QG![G^K5<[^/
MYQ1E-69).F["/^ AUDW1<Z_Q8\V^N@<DP!/J83#,9\!2;_> <YI;*.1FQ3DR
M-^M<'=.1H^%F\RDSJ=OBI 9=2X_STX_"]26I]Z80F2!^C3"&U58-UF;JYVH.
MU>[IF(!,%)-1"&>XQ"^*C9%T.G*AFWH!L? [S?"$V^(R.UJ5<*' )*J.R[2D
MH*G<8>RF4$^8D5,R8_<A53&I34XRR]*!*NBDD^)R[SYU;L4E!;#+,R\04JHB
M4H*N6<HI:PE@-P,++Y<Z-V?[.[+*\^PZI;R>(S8O=&L<M/B?^6VNT&,F'I:\
MXN*\V%(3"X-K\$9^0_;K+(F :6O*9#:4!N&Z(_I\/,;@?$B(@QO6:/QDAIRP
MU#V-"7$H?09I^!FEA[@3Q)-GCS:CJXW+C:@'*_1[4;Z+=I![S;Q)WP?0&8LA
M5@2YJ K>SUKZT7\Y,P'=Y_141%+0"N\V3B2CR-7^WNM C4DRDV#H&G.5+X+9
M&JG9,MYJ :FFA[>TW?+QFK:;F6Z8%LJU0%]U+OTYW3C>B,@ZX_ZAH^(\QVHR
M",GG:)]!X0?T>P*@&*^-)=LAF@%J\"/$D)(C$'ONYJ*X]!8WJS4)Q2-%8EY6
M;B*H/SGT!#WVSKNKOEN]X8WAZ2_S?;'2?69..I%K 2G=Q^:<6Y-Q[A[,"LSF
M#*2&O7H>O44<GT,5+D/NL=.)T+]QS, _^,D5A'--TR6!W(1S'D2(.'QD'L*U
M9C',KE1Y$5=Q[LKLXR:+43-_H\J77-H8FUNET'OMR>;&UE^6I&^H#)R/AZ1S
M&SI2:O^X!T$XKSU0(]"_WFZACT3:&3>@=IE=0E'&OI20*BP4%4S,K6F_<*/2
M(JCE0LX3J) .22JSB4]<$ >(S5*PG #T*PM.=Q*0$6V-,::V  -N7@^PW[I&
M$CQ/@A%Z*-6^9%YMJBV9@3?0NC+"GQZ.@)Z9CM=XI*0H #ZJ4@BXK06N2G,Q
M3B>);7M1:\' ,ZKB_)1T=,UOZT<C-(M(DB=(6@* ?,3/T1B\;K;$H.J/3C6#
MDH$V7"4M.5:/5J+D?A:'FL J=H1:Z,'Z9 @^0NWG\0!0R1]V&(-5RKC!H$WV
MZ>V*7R?[%5<8CZJFTN"7PQU;WP9.<=0V)450*A="8:]0!:=JU8Y$MG&=NOC"
M)7CGV)^W]19-H2R;'[!=U<#57];0(1RXWMELW]MIL97'C>FHL+85A+NC7<C(
M>R-VFCK-G>-S"IJP*SEV+WXO)HQ?$0V(2A)?\">VVVM)83$SO<98RBC]D,-&
M&1=HH2K>H02W= M6U:O-=H<7(R7()L81.E4"K?@'Z6C=AV^(N;SC^0B"+P45
MYT:#"A2JG;5F >7M#$2EYU@N1B?A+,W3";ZY#[CGK9&A&:J?Z7S)A)[NQZG
M9*"VU/#'< &$<83.7%&VA*77@G($FUP#1L\6Y/&7_9!, X;'0R/ST1C&4TO:
MP>-JI!&0TGE;)N$,>W72:$HP[\<ANBH(-X7:FN+$?'&:2M;59YN!932VR;@>
M#YD)<I#[(^L'B9$1T&>V-K,C'T#*%>&KTF#91L:^]C[*3[\E\#ZN6/J)0E8@
M?<KQ V(5V$:9,B)WK%$X-17&L"2R>U0DD01HK$!2(,]5LDFJ<$ BU9]#%A**
M!*^$B4.8V*C<=LEIZGJ3VDR'ZTGF)3IJ7!3T%G5-_M.]Z%ZD2OB%8AU&T+Q.
M;CCJ:$0BYNX%BSSB*\3$EWA_'%V;S3=&LDGMN)":,9OVRJR=AW1K(76TVNH<
M1R/IS;&N<\)"$UZ/%KP./A.A6PK><#SC()!$IUQ^A((*CF<8<CI77$ C?#OX
M"W2RFHGR'[J<E->,<2J0,>;I1OLEF#U_5K#G0C!O0BY4K$636;-OO"+K!B'?
MXUZ/=:(N?B7%:S>K]&%+%%7H&LR]CBC9<O?J)AY&\2*UKRI-Y-(CBB-,YY5Y
MZ'1AX>*XBO"&0F6)=+/&(C<GGLO=T)9E7* LMK=<C)#.C*J\+D:([S'.UV7F
M,H_VR=$?1H]6XVRD=^^'#B*.M@NJ.(;LRILDOX!P7&YE4C)&/DVOI!*<HCEG
MGCE;'[*Q"1D;,6HR0Z8NOVEHR(AI@JP:S:O*<<NH8M(F Z,A)K'L.#/#<WVR
M@3L(BG-B70K#M0$ M2YME>/ \MBXLT02F-J92;4+RW9B549GL?*YP\-5M XJ
M+IQF$FQZ)"JJ2_!->?JQIYF9+/%" 'V?<\:>;$'[7;WQ;)6.WGDT%W;L+L(\
MD22KE8"2&Y?/SU*"@R(SC:9Z:WP),(<3KLWW@'282B"N3*D)AG)1#/+A5]!$
MMZ%PFT/M4?M0!0.3/_5MCH[EXXR2B1+7=OW3)D5I@]M8T]5L=C=VS9&9<CU-
MV?-#H#6E'BV+3LNT<N#7"O7](BSZ"GF7 F=1%^2Z@ F\/BP+A 7H89DFON#P
MB<?J"CQ)?_WS3UM/GSS?TQ$9>3L2BK#Q&E<7 C=T/GTSIEIZ1C%<A[P%'IE4
M"/,)*G-HB1K)]Q'R<,W;3! 22S:E0AUGEV= KF6Q NME"NS3+#*!"#NMXEI-
M/BYIU)  W4$^E&6A&+_ A[/P#NH=#(2IJDBV];WO(W1 7#S'<W,.K@$)+C&6
M@-J-@&".\KKE)%1X'XY]"5#+,OHKF,7,*W.YEQ??XFH$6IA&5X1S'%QG394'
M-P7Q')3$2 @66X)((8H5&#6&28@;(6K)'0Y#&3/$<H YA]1.$#(@) T1J;/4
MG/14)=7Q[OKQ"L] >11+.\"R%HU'U6B=V/P<:@QY=DAU,.X"Q*4M0!2'*X<&
M=J!5.8)#@R9Z2QX+MCA'R^#:2QZZK*.7L3;C7'FFTP>@<.0L.U7CTUPH%A/W
M+%= 10!F2.N*?38\-@XU4>%.HH>;FYLQ )RQZF#H[N41" B3;K>CKCB6I]$Q
M.4K!^:B$8Y?)A0)Z[G3C?,/X&C<W&P W@?%NF#7NNR]H$("QDHU/,N:2;/=R
M#>K'[8/QG,/CZ(8A6EWFW.VL$=!,0%04+\(_2$S0B7I-N&',%4:LF4NPT .[
MAE2I4!@$0\PJ>WSZ3F+B3A>])&@19%[B&U!P:>-J/.&HDI^S1KKH"%N>4@F+
MT]7WX"H37\PQD@00X9"KGP"CVRCTV$_.< DBYF:H!+DYR9I!B&/*N#=JH8'>
MY^55BIEYSX+%6" 4'^!:F@,]18_3^.%%-J8N VP,N'H.:E"GNCEP58NS%#21
M 37NL /6T )/#7#;._-_P%C?L-!V_V4 ^A7>$DF"Q)Q"(JN3WR>Q+&M:'DG#
M3KB99='.2H\>+FIFAYMD.0<.B"89$LU3#!&@B(46-WB=$930@-3M6S3GSP"8
M-J/[V[]PAY&$[='0([>PWW5V@]D^O/Y4N#O+KN9T)Y+E0&\CN46RHS%J%I[7
M3(SC&;*L8W=AE!%6J;EM@!;CK=9?8B6^(!8;ARM?<6U=/V0[]#4WZOT<Z4=,
M 352C<ZA F]<)C=&W& S;<%)M%!$!'AEGS*BIY'UMJ2/]"22LZ*3X*SUOO:L
ME\1P8K0-$)GOISE= 1PWNHY)83+R^#(A7J>"X [2$KL1T1/2G8X+<=69QHR@
MRVQJTZ;5CH-J)"65<C.2'_S28SCJX(.$.1383"4L"@WVAA<$715X&A#Y8P3#
M2 4LM,(6=<S2C?]BILNO-VAL5PI5_-=P*ND:/44R;42$71!!?I938E&6U%C/
M&+9)A92$4_R:B8A22L^QT&.-PH$:%4#IMB<!933Y:B)%8R3HE?W12(3A0&=F
MZN8EAPV:J65U.U.;TZ=5P?B<C]YN)L6DIV"I1[#&O,>3\W.(P,X<B !BL( ^
M8V8RO0-MB*5RQ(ST%&/'EHGG>=7*7QR-_X@R]_I.&NC5_'6IS=,8>\T0 >MD
M= "'R-B',A8S!5-&^(84+;&-)FC8*>^0>RGB(!*M(S5R#Q[@&3CZ56S9,X$6
MW(LAX$[A"XQJNS16Y)3TNG$5H67#S)PFYLPV]R@6+ >"2@?B*X: %/)R4@Z4
MV_% $$F:7%"PYXP"0%QW2<AR$ (C6*"I;FIAWC#L=\)#A$+EF(_Y-$OGD46Q
MJ[OC/; T,S%^THV>%FY%)O.BN-NY&M(V#K>!,U5F:OM=%F5(@&)W-=&]F[],
M9G;^YFQ(G+CSGU-PK3; 8-U(_%,LU.O;HE!55Q+;<M;5#!-]Y'%BY 1:^%C3
MP+@Y9G>")K2DYGT([18CXLQS\11U>O@\N&U8BQI\A:GFAYO?4LT?65P](7%E
MO& GG?SP)04WP$*>33D&8C%MX+,0OL,K?P"#!/&%1 ))\5C-JP>H< EIV1Y:
MTBAA%A1F!U83DG&=I=Z(I(&)5_VUHJ,<G6^+S0'?D2WO(D]G<-QX9!9_ Z[6
MV&A\ZJIQ"7'-1,G'!0H3<"1=;1L=<DF2N&80VJP+*-':ROA4^H<'RXA,";VW
M9GQ0RS?-D,[=J+ %!1VE@PUVQ0 4Y'B!P.#DAMTA-1WWXVL@S.V0N7^/C4L]
M@.@@1R3K2'R]B9@0SC$'EZYQ1:VAQQ*X?K=CK7M4#\IO($^,>JI:'T(AHF8V
M"<F$ )3AJ8]'&A)(_VB1[EX&L51&;&D3'E8_)VB>"206,\ J.N![Q=1C<#Z5
M<1CEG);$/Q9CY"*!:8Z!IT*BA. O(,GI>5$RJ5-1<I<.KRS#W M>>0SM[] @
MU:2GSGZK>1;1#/B;TS26MA^V9Z-&CXC[E:/ 6:MZ\RS)WY7SJ]F(952MN2-^
M.B(S'FX*679X)VK^$C0)Z;/[Y7>6\3"\RK+V$T,1EQ_;-9,8':X6 WMH%LFP
M@82B\D2N,VFI(?SEXR61)!<RE"UWD8Q=73CR;K%SX,,IX,-T5DPF]@O%2!JO
MW(.Y_:.TO[Y*\2;1/D4[/50[YZ@.E-#%@#,>1)>[\9-TYK5]-*3;7,W>/1PQ
M(CRU$AGI3A79:1U/'8"AA3VSA751FD/I/*EM6*(%^QI%R)CP<]^1+(&4JJX>
MZXH)69+^+4H_@]OT=3L3TN4+<T(A08.3S0YB,Y.RW(8PO\IKAV9&!94& K"Y
MR*YBC&RRF4WR@M<3\C-2=F#?X1W&5B9DEE"?8)LD@)3@G#ELK"K2SRZ]%5V'
M:[I6O^NM5[D.S"EM5F05@RP:=J VN3)WYJ:8(9])A%HRYTK7K1#$,U5VX'?U
MK&.=[1]6A/,0+C?SH>FNRP-;;,9,#?8T"5A89Z(!3W+-7F9S\+@)7>+=QE&8
M+KTVA;;5GLT/TRIP6T-''DE@-]5QD(*!UYF1>IHK?17\+V@% \014ZJ#@.8(
ME@/*S(VN _/R3,1 # ]M-DA%\'CE _7F>#3WI"B!2S?QZZB9T8@VU=ALYL)R
M<X2N@(3V'16P2KE:4 MG7RF)*Z%@JB%J(QXF:*7.[39*^*R=HB71(IS:HL;J
M[=MY7=3LCXKIE/+4TT7MN_@08X.<U^;D/BSOGZ@1D5E%M""C7?*4:CV(FIAR
M9BX$@LX7V%CN3N)SN00P%Q!2_;'UZ=KP]DCKJNK%ZME8O0)..E@2("8<A\_G
M.9JH2T;I "\R3)='QN^&/-@P &PU;-6 BAZA:851&I^-G!L@HBEVFRD#M3*>
MD]UGIIQHS!S),!$ 833OGHPWQ$H?@\$V3A9&9A^;Y<4?7A7@F\!/Z6RT =NJ
MV]FCY9LFU/$IN;H"98SO[XP@8R4H%A77N8^L\:NL]."@%,'6TDA"%EY:5GS_
M:'MN=!/@S[#@WB5:^#G")X66BF@$>H9#Q*"/9FMFD=4 $?>D2/03[N5H/T1<
MTX["H[M#W1 K43$;9.+^GN;:KR@0;8:[CG09>RK@0@ :X0KJ%.?8KA$S*==8
M^[@T%A+;N#&GY',P9*?<>7GB0>JM/R9$40RM22[/LO,YU^V5J?51C0!'7TIU
M<AR7R63F8'C>QF (MHW?W *E+S:DK5>L\+6)34 %XC@ZAN85!L[8*:<\&>9<
M*,UC>3F;$E"9I8VH*S=KY.DLU?B/.9,N3U!5$S\O8K7KK,)5S+^-,PS&C^T'
MQGT^8\HN+3-MQM8S5)NX>''%T,]4M!_"0W'?_,[FT&Q%/V^_,.?F[6#OU^%1
M=/ R^OOIT>_1R='>X#6<'^3AVW[!A'QXZ=Y^MS/8_ST:[)SL'>P;V7>Z=Q)'
M!T?1X='!SG"XN[?_2[2W'\$EYEY[Q[M[>&&T?71P^LNKDVC[=_S;X>#HQ/ST
MRV!O__@$/SDX>66&@)_'D?D9?]P;'D?#P<ZKZ!_[!V_-K5_#MW?- TZ&^W#;
MP>O7</4!?N&7H^'@9&AN-_P-_AP=#H_>[)V<#'?QH8>'K_=V!MNOA]'KP5LC
MJH='0_AX^_C@]>G)$&YSNK]SL+^[Y^Z[=W0T_/4 OH2/[7:&OQT>#8^/S:\X
M8\?1RP-SA1DVSA@\!N:/&EG!E'W(FMZ)17'O1<^BTZ)#5*\OD02E;X:R]^*K
M3:!L?4N@?,RC;P[HV[V3?;.5H[=P$ Y>QDTP*U1\Z &Y2C7)YXHI[Y?% C8)
M@8@6;D0NNZ]85:MVPOD52%.5^'UXJ:<%H!-'A(,"VOZ:F%3O_=!MX-;][.U?
MLT8G*!& ^?/X<+!C),S?_K3Y)_S]<+"[*[][:[U]<+0[/,+/>0STR0.S05X/
M#H^'S^2'I:L0+EEMT\,>PB$>O> ?=F4@C_YBSOKW)[ON#[_RE^E-W8CE0O_[
MCW^\XPT>WG4 3^1S\Y\C]:HRI>J$9@B>?I8@6NQV4_HB&!QP145F=<Q:[\/1
M!IWV9K WB+;W#DZ&.Z_VS1'_!03__HZ0T+JA!V]H-U+]"J2D6OW553<X?3%0
M%%#$!?>,5(M,G#]IZNW5R[\:[AG%:Y;B!W]0ZG,W)P\_\C4-H_QT2_MB>_'L
M#BNVM@#>@H_.D/+;??0>XB?F-?Z\B?^[I41V4NE>M]RJX/OPP9LDFS[CH/L]
MK/ =9F??."MWV1YWG]VO:KI.(&3^A<P76'VHJ3^E,?WB+9;-<E5D =71&0$#
MV65621C".O:?+0MU_/ QQG1\D5Y=@</Z9CZ=&C_XR S)6 <\?\GEU?/HE?GO
MS+B<QF19XF]\#+/\Q:--\]/HG?'AIU,@"CV<)O])/O5#7>&T\1*W-K>@_.+3
M/G$PF^7/<*IAYE\:XW1L/H^C8?7OC6ZG5R83_NC_KWAY+G%UJ*3G,_M\_SP:
M&A-F?Y?\]\/!+T/?/8Y>#U\:M_OU8/\?RW;KIW#;H-YJ<')Z-*1AO80HP>G1
MSJO!L1GL2V,D'[P]_M?7B^I[^,TI_9C[V&T-?]\<0WP'K?3CX<[IT1X&A>3B
M:/#+T7#XQKSBOSY_V+G-C:;T'M5E?H@/'=W&A28FS6\^]&U]:!S(/?F@:(MZ
M6)]GT?]^T/\^S!7\Z5Z,41>9-&\^<#&@8]Z_B]O.R-?T\K+B3>]]Z\7_FEX<
M_8C6-_^:WF2(-"@2DVE[H_^3B_@)C6UI<QGB'/[ZYZ<_/G[\//I=.I?1K_M%
MJ_+2#E?[\+3V6M\6WKJ]$U&+W8%R=^+-QGH^HX>KQ[2KZ#EL<T0]PJB738C[
M(:'^]9J0?AT'^..,N8&6^UGT7>TT?6JWZP51AS_K=C[_H_UV@$W:PO$L3J.#
M&T:"1MM3<-;=V7F\\?3I7_1A>HH?]"8 #E\+>&M[TO8UC_VG?/>A,;+WYT :
MUZPE/_T&=)*GI?![&42OUL3*&/.CBW3TCE!5 ,TKWIN3IGI@-' NH=G^@#T*
MU3Z:L":JQ6/06BL<"O1[L6SY5"RM)"ZC:_7#' /#$B8HY+E"-B#DXPJ;*?GW
MLWB->6Y)RQEYS@1>TE[5?%THA5PSW7%6$5$CW*N7Z7GS+R;4!;^2;2N2C]?I
M$-( LS2/DF=A":SE6U>C7,'(V#O#.G%N($#E:>IU<&=,$6YJMP-.71]A)*J/
ML"7$";HC"(&@WBR"*)-1Q%Y9:E 1BCBU[!W^;#N44Q5V#^2_K2GOVZAH-"UR
MZ'I^1HU9958TXT<U2Q.JNLJ#16\'.18,EO3>)1P# &^YA2_!V3[V2UJ,^LQU
MVV, G.YL_F& MSO%2L((R8Z1Q7O[I\.O.)KVZ%LT[6,B@8#K#)N9K:ZH&3S8
M<MK\=%GCU4^RF5]R#WBQ<E:.MP>6B&6@'5O./]4-Y'._P\][+X[3U/7/^JK!
M5H^_G<0[Y:N&>PAE/'FU=RPAZ]^C_8,C!"FJ&#;D0]Z^VMMY%5QJ?A[^-CS:
MV3O&P.JKP:_#:'LXW(^.AK_L'9MW'D(0\^15MQ/<$*"1P]]V7@WV?QD:E?#F
MS=[Q,6 OZX_6?WR)\,OCD\$)9([,0U[O#?9WAM'IX0'@.&$L;PX1P_GRZ. -
M#^)H@)^<8MXI',;."=QUZ^FC1W$T,+^_&9K+=J,>7$=,;_[5Q/G6C^$%S']V
M=@Z.=A'L&4=O!C!U)^;]S2U?XJL?''4[QP>O\56'AR>0"C@^'1B1<7* PS67
M[9SLF3GS1HKO!WF")6,^"N\U^'6P]QH7P9\$!+P"RC4RM]\_)BPLCO/X=/OO
MYO'F^P1B]<9P-/R?T[TC',4QS%##& C=RG. RT KK>"KM%+J>Z\';X\W@CT$
M]PEN;];[%&^ "\L[;$CCT%^%*3?3??AZN/O+$$=CK(O](;TCC,:\]O;!_B!Z
MN;<[-%<?_<(#/MW'.20@[^L#,W]X3\+?'I^:?>Y&L]1F>OCX4XCH[1>PZW$K
M'.S\PV60W@Z.CF#)5S0=_S1Z8R7^[%NBYLG67<&&/]U?HJ<E='-7;(Q,'U;I
M_.G%'C(D@2_"X><X>KCY\/'=(LRUC^\;W?>Q)XW[_@V%@ +G3U:(9_!V;4BW
MJ OI1PCKZKSTUJ/;)J91H"^7=CWP8DD90P$(;5,P_UD96_9WXI.,,>I[G4SG
MJ5!9C.,@%BI](J3ABO^(5]@,0C\!2F*Y,CLF8JS9A2[?#>C[7>5U!5ZXZE W
MEAB;A(ZH#(Y*;FQ(+(ZX?(KZ[F*I6U"5X\)G&'@(WH W3+?C[1C]1E@CE ?=
M@S=7=,0-LD*WVW$/:<<%(SWAJE"LE K&"%$HK!RU%)TQ!3HPS'Z61L*:9H,C
M&"@$-=7M;&=0+W^1%]/B?&'T5#[: 'Z!W72:W"1(OUQ>"4V(/R2.[*B1P)K#
MDWGS<.T7Q&":2[D4[TS3WF41JU_5#RI)4:^NT.("03\,!!PF><K5:< KX=5T
MJ=8$\F1'-/!O:/_+^]7NDL,2&243H,&>2)S8(\Y_V#OKWT/9)+(8VV+)G\'U
MQW]H4%M406E^WX5AT]&BSW:2*W,4IYCYI/.*^!8I_G;,./+"7ETJ0F)@AH!S
M%QOCF'/7[:BX-9#IFLV>T#PM@<OX>ZQ^@;?=J.S8D^^Q*DX/2]Q=/,%6J2R$
MI*.^6%/SG@\N4E MQN7<7&6=P7JN0I"3_[H%5DV3'?=Q[3%EZ(4&86@P>@ :
MUO[HMD=_B]KT_Y]"F\S8EDVZF?SS#U.[=>VO;]J:T Y2QM%=C?SG4? V>SF2
MFUDM(\W4,3.1O8]Z/W"XWVS%V07HOAS[,B>N=X(S\"(_;VS-BV_;HDTW?HW;
M OJY+M*D7+X7@OZ1L>7&POMQ/Z0$*2<DXX6I$7EL=@G\B=1KV67"U-4;;;OM
MBU%2#ZV2$G7+']P>E\\?P>+@*.\TZJ2OQZ3"VS2\8V?A!(: L0E)6<8>O;-6
M2,(Y%'#R:).DVV'F!B!$BYN8JP-KN,1_JYI9W.@D*3N7(KI$%! 8G3 FFZJL
MT]@F <KU</<EE5Y0%[;9!_4*Z:V%9/"_0T%[L!:LQ<AX'?.;?6_IW W)"FC<
M])ZM&B@4\8R0^G>5$;*!I/)\+W.^IQDQ8#L P(VYWT/^19W$2K+0*N&=(RP"
MOLX7=CMX)7!\,AT57'8,@ 4H9#A.9\;70KOI$'G8T=ANMTG'?3,LWHW]EE2Y
M\\+,"&$K5$G&),[D\+'-)XG:F4?U[9O(D;"A^!:]<( ZH@I%;DZSC2V+[<W.
M@&RU=+UPB3JZNL@<B3=",( <XR:'C9Q (QC8<=@?LD)V16/H3P'M-"-ZZ O\
M17&3%Z-TC$U9].B"&1P9=RLULP:R>/5;Z#VS\3.R!VQ#/U7:S]W.DAV=Y>\>
M".^B[.N&35PC@ \;PQM]8'Z$$WP^3Y!3)J6N+Y@!GRVN\'[N;X0$2\KL/T2:
M+7B#AF>KIRYIHL". HD+8K\BW$QM1S&)B2;JO+I85& $8.L_H*"O>6J!&"+.
M)'5K(!QS"!EN!]VP)1/H-X9+YUHRBM\@EUKN-,>>P[R6+)"AN@R(Q^LOU^VL
M-W[L@JYYS6VK!6"ZZ3UJDB.Z/*"08:!HP\8Z3:*O\GM)J1%L1(=,[.2X8@5
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M<'_H= !U.;?=5SD$C?U-@W9NY#@P5WWZ'AHI4B)#,P6><<MBOSCW_A$)5MB
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M>F><4CY>/CY+IG@:Y+OHN<'[[*:XL0 5?P)=;AT?S$59S,\O\&Y\$=P<D&^
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MN=3-GGY7R3RCQ Q5Q!NWXZ$:#$T5P)_LMD'N<Z1R@6(N&'[)X3ZO_$ZS7<-
M!1Q*!]+&@OF5BBM=A"9BD0/:8$)CH)K$5G/!&IK@9BZNS4$PO[;.(JPE)_^T
MH.AV8)#@+EX4>0$3VO.*5@-7, Q7L6),QWCRVWUE-ZRV<^ZP9LZ^Y,391>)5
M4>*"31<8%IQFC&Q&Z>5QA3G;4%':VUS+1K?S$CRY]XFY26HU$0_9E:]Z@S0C
M0Z^G^6"95_INBYQK4&$%UEO>5A6'4AV4Q@SHYF?IV(NPM\PC?A^^9.,J*"%I
MA+1ONYV5&Q=?91->)68PO5#6B[#B7=B,A4>R"M"Y=6D7EG(GGNBFV(170DM?
MXQB2+P9*2)'E7'@JW<]L#@Q%#Y2#+MCR("_$20>998F9WFZAS!9C-COEUZCA
MQ>)8N&#(I23E<-ZG155AA;PNB*>WQ>R+=9)$FEMK%.V25)M9<!:S-#"T,N-W
MJ3I6<[ZFR0V7=L$2(/Z 54%L4TPN\P.,;^-T!%ES&#/E,4;@A0,[!B4+\_'W
M>,,_YKEDV<R1G+2YT]H1GSB+DP^T9?EOWMH-N%,E!IU*Z':TX8;N(G*7<2'M
MO;M-9+/O%]'+DBP9(TI82)NY/(8F.&16FTLF[I+*7H)]<APM#![I^H7VO+$4
MM<R+;=!=C-ZP]2FWT]B8F@5%XEKE]?RJ/BM8K$T5(#5J<0(2XE-2V58-@HQ@
M%+ J 0:K5)U@LJJ1VL".O;FBGZZ4:]@<<?FY&I#>'"]S@S&S&*(R,ZO/A9(X
M,U^ (WA-GOB.&<XY6-,GR7N.! \9_,.>FDIOA^%?V2_ )63%P0CO&&ATB9*3
M_524#%D -VV6O+<> 8@7#& @;P0.HT'NZHQ[0V@T%GH.WG[VQ2RJ:1F8*78%
M/&VOZW!%L_;D,>]?^FN)_U8(-F90SQ@;)KE-1%]]#FLBZ0]8@!@^N"ANTFNB
M2(TCP2/AP;RVD=H&_!/U]7&C37@TSKML'G_LA]-NP NQT3:.5-7M.W"<80;5
MP1@@@P-%;K&9@VV#P 1)3>U,6Y@P$ S% IMJ4W2O';J?P+ELOL@(HOFE^?\)
M=,#B:(#1FI=G1MR;F9G9?>GM1K4)9\+J>%*S2U#(F'^#> -BZ*S!LEX#+>BC
M]F"<+&S#"N 0JBHN>VPAW)#&2)/4=51J1=[T\#UIY8WE811^5L$ZC*9I4E*+
M(L?/ROH:[3*CVZ&D;(+:VMC#_;N^&PKKLLB-7; \%OL5$S#\^"TG_8EU%RLO
M[K5D]L]V4;RKZI ZC,Z"KTJEDF M5& :$@RBVSF#KQ% BWAU,@JY$=2)-8BQ
MFD#.5C:10$*KT22*HT]I2MX91)GVS4H+Y;;8U5:DO'88KC9T(LPEI[3@P_9I
M0/%4)^:J1\J5"[[P0Q9ML^H'8+UP8BRS;B;)JD8,:'8['(/AT8M=9XT)"GMJ
MVCI'^EVL0<SF@71ZL^(\16EKPTC^G ^D2U$5"^,1*^;#M*P@\ #F)B55D^C<
M&)1@3#;?,V(EU@3>[';<DQBPQ ]0J=;!;%9F9W.<^4,"0ZLX))!<<$F?M)(T
M!Z"X07,9@GB537XU-IMTN\JKST?^NSZ#E5\2%Q+!EFP%29F>%SHZ$%(K-;M]
MYE0' VVT+4 6J+F!CQKFP:;;P.U-UXM,K5GWV RLH;@[5Q#0K&4""R?.3N!I
MIU&9R9=1=3LKAT7W;ZG.M.C T%VF)#XZ_'F1N_QMRTFM;9+:W+O-&JR ^4/3
M OCTEFYX)9(  @6NBG'.U0B1@C"G:V;^B-UI4S0/?C1&1;U;0AWV'MXL#VUD
MU=A*'L+'?3DBR+T=NQ8[QA\MSHNY->G4MRS9#T5IS.G[V)/-IW'X'LI$?!'(
M'D<]9!<+D9DZO/4* L@ON='B6$DZ6/]AE$Q'<VJ1N;+:8NM1;VQK+<QHC2]C
M7,[!:&:]AG(^Y;U36M:/RJ/\F*E(5S;C$Z9*0,*IK"45N+))1U5J<6RA0I*7
MX^.,F0:(1;L\8^O[0>JTX05=1HXS@2!)S#M:6#CJ;'"V<"9T"!5:.633VCSC
MA,!8-O[ZYY^VGCYY?E)7I6T[TG:5K9,6<\4?5^EY@@U]])3=45WC7=E<&DJH
M'L8 >/H 4%\[N@U;W]>6,!NKI3TWZI#009N,RRJ-85*! 3HCL"#0P'5D7,>&
M7(VL(-(95R*]DD;&VC![0JM7-R?6G=?H"Y[6;L<?'\(6$3C':26OZ<L*4R.N
MQ0\4%"DO=.K"W-!(XFR"O$9F1V/&&<T]Z!2<C!8VSN3-LIP2!66@^+=>B<3&
M1\F$@^3<'.) 7D]@;F>K5]M6$#9 $CZA*-R(ZI98LS#/<CO*.@^I1OPU6R,Q
M5(3REJ+(SM2"-&]S'PKC3UPAI:[I"1,(ET4UP\R]A09F(U*1.81ZJ1Z79:.U
ML7=LHCLFA".CBBF.%ZL$K;E_F=K[S\T.&\&MB[E9.8Q(23V':F;<VVG\=I"I
M:N[G'$2> /<($T7Z>BU+5<TOJ_Y3B?G+","[*G%R:EB\AIC\,AI8)"&W!PQN
M.F72J1R?UJ0_U\H#^S6O_")[Y,@[&N5;[:JFDT@.8LV+Q W1;,P!?UNK@1F[
M7%K@Z]9,N/4,Y2J3!"K"=A)=O8NAZ-M,P(VJ3Z<X@.,D:9"\W8X3O0J=:Z?Q
MGX\WGC[]R_=/X;__DHEH6EHY<4U;U,L=+UD-+S]P%Q=-IY4Y=<L'4FC([5I>
M(A0'4>@I 1OXYW7<X@9.X@:)ZU=%K'/?#,;+20)!V^ 2?.@*&!7]T99@N7-\
MD4[;$@+KS);4TA9@EC-$SMBABXUHD*N%8H-MU3Q"%-$XV,0K[^I#'4G\#UNW
M+"BH9MR>;>S7 @@R81FQ^DGS'%@6:^52%=CMGGD9,\"M7%)7$,P&<9#3I6,Q
M)P29*R-<1C/TKS$1,%L$M$Q+)AZ!+&6)>\$?5H^=$C'_*"3:9Q$E:;%49A>3
M:/ &4*HIX1+<6^!WPCE8M6SL)#LGA1KO74+Y.]E)E!R?7_'$&+<C3R&>A4UU
M2JS^+ 4<8:;<V Q3(N8.HXC.)Z+UT=6P=2<I7"K<FA0D,'># 9B'NTJ].H;[
M"VH&]\CVV=GAQFP#FW*OOJ26.R1U=C/$V(S)(#XVKFDS]MSO@F.VZ#2M^5)*
M,"HBV"NLI*4T0[<SYN=Y46K<@G#1&.K+18_#AE._8\L=)SO!!O#%<JE"4(S.
M*>Q/"N"G+!"!-F5YFU3NX6EDUA_@M1,I/B[F9[-81?(E),JVGW>S;L>IV33,
ML"^7_'VJ) 9WC^:N6L=<,3(!0VP /2AK:BW69<.CXO+,G,;*@[4"1)1[%( A
ME]+R117LC_[Z S#FWB54<S0- 7E)KX5J!B:FHNX$HRET.L!Z%?:*ERAC?[9'
MU&Z11QO:EV@9>S[TK(Y6<2 .#]>2>( >!^0Q[Y66T/'0?7&]Z'./@M5H[8+R
MG9<+.S6"'FZS]1@W3X @M&:\> (%EO("O>Y@9+?R@1H,3/=,%U&PM^1N!=6Z
M$7^'.S&ZA+0@/TMX-HDW7>R[UE+7YAM3J-Z8):3<QF3L* 04XG3\_&2HPX''
MQHX3J\:=O:-FI]MQQ8]<2(Y.A^"_:_$HE76M&IG<*<"BI*4G&Q&3LW)4JB+3
M_9U:WH7EP"Q>R*TGD<!C70?44*8/_%.[(?"&KQ:S\-,WS,*G;X1R/#^K((YB
M3A^5O44'9I\" *=JK8MRY[?R<:KU<XM11!*GRGC1JO<<*S?CB/5/@21DTPHO
M;DMC(3R"1JLQFA6%\6ZX&C3V L>"YR.C>090[P*(6!/Q9EAHB$3@G!P>JB99
M+09%2UM?5T-8KYW1=7H!WC09,9PL[#'N\OQBX >/B@/Y'/RYCGP=N4(%?NHX
MJ"" F@7T>IM53"WNB7=Q2@?S24;JMFN?GF0Q8<SE6/976_=T<L]TE*HI"[J&
M^]QOTN4V3%5([4@B>P*X:XQ]G&/C9[SPG.)B+JA01D*GU+PX!54*YKQXP8UC
M]W0=)&O>EFW3;_&5*D+8,-Z5@XUZ(>(3$3IUR&<#L*6>!W*(?ZG9)^5GRPC]
MIS,:@!JQB9+D_4@!(XGMKTRWA.?-.0HAR-L?F3<JK@96Q8GXLCVLG6Q('LN<
MMN<&$GFYYND/GM1WX-^EUSE+#D\L3/!9NL"]*7N IT$1.( PQFT)"XNY!/#I
M<,6PT 01L;0@E%>^ZZ+T[QUN1JV2#HWL/P+9OZO=6U1XW<XN]:MP#8-"%@G?
MT:Y5 %?<K<ZHCA(/VZ6P&]9<[\#=)I_:*)P43J&GY%A$JPLPL+52+,2>)SF;
ME[GVTG0(@$A+5N%+P@$3B4LE_G^8L(V=OH6_7I%0=T-*[)R8FUQ!FF8RB6L>
M:*RHI(P!!ZMPCN&Q&/$$A!97'ZN1,%I8%?OVHY[M^@1<$NJ%/'6M#19GQ?O<
M>CI' N+&)8@98]'&E+5*_.A1B9P%W'*+L-55A^IVJ@<7 S>6:O96H?75*_9N
M1VA.6C2[(_'5,W_O:MNM)2=/ZIOC\RIK[]%?AJHV CLX+*&BYJ&UZ>NF<.$2
M=;WD:7V7$7* DOJ75JMJ&FI ?EK3W%CD7E?=T?]-S3TFH/C+>3Y.+JD6YL1)
M=8F8WS)*'OOMTFR@DFJAI@O*^<AO*-X!2 !*G; 1! ]4ZJ7B0$_%3:HQ_$LP
MGJJ8 LV9 F"YH@" =)<<L\TU[#H&O=PP1IN\ @\^,R*O7/3;QZW'!+9_'$U3
M5$[&JX0*--A!4AD5V]JCF& $"W%QK,UB:9KA^""E (2O8%)GA/Q4[:C9G G>
MV$UD8LR%DL$(/)]<B\<3ZL7*U>KH=XQU9UP<^4R8F+BK>BI )/JD)W"T.I#%
MGW\DY1.-YW.FDK17(KXFV)F8EV07Q#7<N-2(S-,RJ1@F%[-N1F'I:*'"%R!I
M+,LAL:B[O(8:TY/-O]CMRFN@X\MA J?A\NL"@3!7T*-:/AO1UR3)$X3Y75;A
M%H>JVUG[5-7M0V,_E.=)SKW=N7R&C%S[61.0@(X0+.]\6A62 '!+4U_NVCVR
MRH5VD=%!T-UXF-4ZDUJO+6VW$ZXM968^8 J7RR600//+2X)%.I.=WM@>'R3B
M\XWHLWD%Z:G*BTJO=!:"-8EK*Q(S74&WLZQ8SS@%#\ ID'"VDZB-IG]?4*#Z
M#,/5A'8T%TLU"[9)/6.[IOEJ=KHJFE3$(N#YJ!^CMDQ.V?Q5.E+=SMIG*NJA
M5Z%(?);H02_BR*%$LN!LK+>]2JIFA34QB6&"1/%Q^MQ1K3PHUH7H=GQ*%I^"
M(RLL_4H!@-<RU:75+2]N>?6:Z&A6.R1P@NK0D15L _WURG\B@<T[* 4('MQ<
M8:5K4=:D:09A >'/KN;E-<&;U+=<P9:$ZA-$&D$O.+ZO'Z8>3(VK 9D^\Q1U
ME6:RIT7&%6NR@EM6@1*U&BBR3B;6\?HL X<W;I*E@_E$JUZ')%O_R".' #;4
M(.FX+-T-;5@*\V)! E: 8O9M6Q8O\AAN'5%+V^7V0/IT!J!&JL8^,N)^MA]
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MA9WB^&8TOK$_ODMO?#[71NF0.M$(>@%BTE5*8ESQ@"_?;2!7>M:HQW-O.AE
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MK3VJ9N9?%\PS8YI;\'@>:+C>8,H+TSF@O@,=VYIP*"(D4S%]A^("/X!Y*<Y
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M[Z(@S#/;"2]\-YYV@!?:S9$C*HW""_#+*VA-%ZH_E]EE#?K)6M/J24K9$'D
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M;=S=;]=#<OVJJ.R*6FGKA!"2%&1X3X_YGQV:3/>R$Q 3P2F9MERZR0-8IF0
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M3_)B&J4/]H)N!^X_B+,J+O9>'1Z]5Q??)./J:O?YUK,D>Q!$:7*9P0/B2?6
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MBN6\$(+TRZ^!F&-1_\D$!/'HBI\'CT*E$74[@R(:)]DEW ,*(#&O3:;3>)S
MM>D"1IZF^0U>95V]U<9M?]Q,>GI;,PG4A0A>U!/PE_S@9=W!OV"8[_8.45"S
M:4&?=3L'T0QLD13>,Q:#95["KZC_D3 YJM,;E/9*QK-%(KKA*KJ.B4K3.,J
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M#VH(,Y@9 >,]3SFGY"H"(_QS'I>,$),OLA@9J[+,)ISOIF]E\1O=H/5Z X^
MQXH8(WM,L/TTSY&[+X/CK;.M8&-(T=.:L42XMQ>[3[:#J!7.!TK\Z>[VXW;
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M E*:D$A#5$-"'RLM+VI:T8:NX7JV-4VOS'6T[1(38@8&J)(8]J7P_:_ -2T
MDCC.2@YM3-:)#NS/%P^/,N7MPUVO874P;0"3Q;>D"T6IIJB7L6]EI3-T=Q.[
MHD1XF7>3@2_[ILR79)$V*();,=+(.MPBQN:PR!)W]8K8)3SFN#0D%9&')HK<
MHI?+/$6:C^>Q(F#$!3J$Q);?ZS$A6V4YO"DQEV1BVR824+#C&;JH#IZ-$9)A
MD7_T!-X&)EIA[ C=5'D36@,S0AW:T4DE-^3(3\5,T"0IIE8D2%<LA:HKC)^
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M]8A=J+J869NW7D" Z24S6AHK2P?M/HRB=(3=.<1565ILL?-D8ZQ++6"TX,J
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MF=5,=\&M@ P,F4YQ"=WV$!3Z6S9YUR!'+T>)SCZ& Q8-=9O?;*+[V?=$]XK
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M)WC YHIKW#1%O&N%443'NF4KQ?6SB.*6O%$V[>(Y!0=;"=9B&TV%\;N=Y95
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MW1S&$%W0B'Q<Q3,BFDU,.:_3\3 8X.;C[N _UL*E7*M#)H\$-':_!GJMFL8
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M^PI-9.8W\% F?XP1"_B6#)AHMW%1WG&EMO1?%\IWT>QO[*@]_P-02P,$%
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M4@A)5>+"X=L]>,5OPJ9%-*,*XX7)%"<]IQXKF9469].;+#4J50JJ'<1Q#6>
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M-TZD6**O/,(2SX[?_[!=<AGMU>4.#]A'F==G[#_[8"X>^1M02P$"% ,4
M" "0?'I87P/4!YL3  #0=0  #@              @ $     9#<W-C$S.60X
M:RYH=&U02P$"% ,4    " "0?'I8J=;!DC$. 0 3#04 $0
M@ ''$P  9#<W-C$S.61E>#$P,2YH=&U02P$"% ,4    " "0?'I8UACI)?1#
M  !(2P$ $               @ $G(@$ 9#<W-C$S.61E>#0Q+FAT;5!+ 0(4
M Q0    ( )!\>EASJCV@E L   4C   1              "  4EF 0!D-S<V
M,3,Y9&5X.3DQ+FAT;5!+ 0(4 Q0    ( )!\>EAM510A0P,  &@+   1
M          "  0QR 0!M86EA+3(P,C0P,S(U+GAS9%!+ 0(4 Q0    ( )!\
M>EA-<SLFK 8  *5)   5              "  7YU 0!M86EA+3(P,C0P,S(U
M7VQA8BYX;6Q02P$"% ,4    " "0?'I85&F=I^,$   2+@  %0
M    @ %=? $ ;6%I82TR,#(T,#,R-5]P<F4N>&UL4$L%!@     '  < O0$
' '.! 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>d776139d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="maia-20240325.xsd" xlink:type="simple"/>
    <context id="duration_2024-03-25_to_2024-03-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001878313</identifier>
        </entity>
        <period>
            <startDate>2024-03-25</startDate>
            <endDate>2024-03-25</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-278">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2024-03-25_to_2024-03-25"
      id="Hidden_dei_EntityCentralIndexKey">0001878313</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-289">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-290">2024-03-25</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-291">MAIA Biotechnology, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-292">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-293">001-41455</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-294">83-1495913</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-295">444 West Lake Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-296">Suite 1700</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-297">Chicago</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-298">IL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-299">60606</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-300">(312)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-301">416-8592</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-302">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-303">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-304">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-305">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-306">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-307">MAIA</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-308">NYSEAMER</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-309">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2024-03-25_to_2024-03-25" id="ixv-310">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
